

# AUTHOR INDEX

*Arthritis & Rheumatism*. Volume 48, Numbers 1-12, 2003

- A**
- Abba A, 1343  
 Abraham DJ, 1979  
 Abrahamian D, 3253  
 Abukhalaf I, 3272  
 Accardo-Palumbo A, 728  
 Ackerman H, 90  
 Acott PD, 2294  
 ACR Audiovisual Aids Subcommittee, 2737  
 Adarichev VA, 1708  
 Adeyi OA, 2541  
 Aeschlimann A, 3291  
 Aganna E, 2632, 2995  
 Agostini C, 2390  
 Aguilera S, 2573  
 Ahmad RC, 2375  
 Ahmad T, 807  
 Ahmed M, 2036  
 Aicher WK, 348  
 Aigner T, 430, 860, 1166, 3395  
 Akahoshi T, 231, 2931  
 Akaogi J, 2990  
 Akbarali Y, 1249  
 Åkesson A, 2593  
 Akey JM, 2011  
 Akikusa B, 486  
 Akizuki S, 1647  
 Akkerman A, 495  
 Aksentijevich I, 2645  
 Alarcón GS, 864  
 Alarcón-Riquelme ME, 174  
 Alarcón-Segovia D, 442, 471  
 Albani S, 906  
 Albert VR, 3253  
 Aldea A, 2632, 2995  
 Alegre J, 866  
 Alexander D, 348  
 Al-Fayez F, 709  
 Aliabadi P, 1034  
 Alizadeh AA, 2132  
 Allain F, 2197  
 Allaire SH, 3212  
 Allanore Y, 2019, 3503  
 Allen NB, 2942  
 Allende C, 2573  
 Alloza I, 2773  
 Alm GV, 2524  
 Alten R, 2224  
 Alvarez L, 824  
 Amara I, 625  
 Amengual O, 886  
 Amft N, 2472  
 Amiel D, 3382  
 Amin MA, 3568  
 Amos CI, 906  
 Amoura Z, 3207, 3487  
 Amselem S, 2324  
 Anderson JJ, 3031  
 Anderson P, 541  
 Anderson RJ, 944  
 Andersson U, 876, 1693, 2052
- Andreaskos E, 1901  
 Andresen J, 1468  
 Andriamanalijaona R, 1569  
 Anolik JH, 455  
 Anthony KK, 1390  
 Antoni C, 1504  
 Aoki H, 2819  
 Aparicio AG, 1764  
 Apras S, 2256  
 Arackal S, 993  
 Arai Y, 1562  
 Arakaki R, 3603  
 Arenas J, 700  
 Arkachaisri T, 460  
 Arkfeld DG, 982  
 Armuzzi A, 807  
 Arnett FC, 2585, 3295  
 Arnold EL, 2078  
 Arntz OJ, 1750, 2949  
 Arostegui JJ, 2632, 2995  
 Arp PP, 1913  
 Arregchini M, 2695  
 Artlett CM, 2567  
 Asano T, 2682  
 Asherson RA, 3320  
 Askanae AD, 2699  
 Askling J, 963  
 Astin P, 64  
 Atamas SP, 2083, 2262  
 Atayan K, 2324  
 Atkins KM, 1493  
 Atley LM, 3130  
 Atsumi T, 886  
 Attwood J, 746  
 Auger I, 1223  
 Aust G, 134  
 Authier FJ, 569  
 Aveberger AC, 2052  
 Avorn J, 2207  
 Aweh GN, 3055  
 Ayadi H, 3297  
 Ayoub G, 581  
 Ayoub N, 581
- B**
- Bäckdahl L, 551  
 Backhaus M, 3338  
 Bader-Meunier B, 1093  
 Bae WC, 3382  
 Baecklund E, 963, 1543  
 Baggott JE, 2979  
 Bagin RG, 442  
 Baigent C, 12  
 Baik JH, 2025  
 Baildham EM, 3518  
 Bajocchi GL, 3219  
 Baker KP, 3253, 3475  
 Baker N, 2632, 2995  
 Bal BS, 134  
 Balandraud N, 1223, 1849  
 Baldassare AR, 3328  
 Balding J, 1408
- Ballesta AM, 824  
 Ballhorn W, 97  
 Balow JE, 719  
 Balsa A, 638  
 Bambara LM, 1170  
 Bañares A, 1158  
 Banares M, 737  
 Bang D, 2025  
 Bankhurst AD, 1493  
 Bannwarth B, 2075  
 Baragi V, 1742  
 Baraliakos X, 1126  
 Barbero A, 1315  
 Barbieri A, 3168  
 Bárdos T, 1708, 2959  
 Barker MD, 709  
 Baron JA, 560  
 Barr W, 2697  
 Barrera P, 339, 360, 1002, 1853  
 Barrett J, 560  
 Barry FP, 3464  
 Barton A, 3615  
 Barton IP, 3224  
 Bartscher M, 660  
 Barwick T, 3085  
 Batliwalla FM, 876  
 Baumgartner E, 1420  
 Baxter-Lowe LA, 534  
 Bayry J, 3497  
 Bazzi A, 862  
 Becker MA, 2036  
 Bednarski JJ, 757  
 Beebe-Dimmer J, 2246  
 Belch JFF, 854  
 Bell A, 2773  
 Bell M, 829  
 Bellone M, 1109  
 Beluffi G, 3509  
 Benjamin M, 896, 3610  
 Bennett R, 927  
 Bennink MB, 1750, 2949  
 Benoehr P, 1858  
 Benoist C, 944  
 Bensen W, 829  
 Benson MD, 1430  
 Bentaberry F, 2019  
 Bentham G, 814  
 Benton N, 1814  
 Benz K, 418  
 Beppu M, 2819  
 Berden JHM, 1355  
 Berenbaum F, 2019  
 Bergink AP, 1913  
 Berglin E, 2741  
 Bergmeister H, 2042  
 Berlo SE, 2959  
 Beroukas D, 1167  
 Bertrand C, 370, 3300  
 Besette L, 829  
 Best J, 81  
 Bettosini F, 1385  
 Beyer TD, 6
- Bezemer PD, 284  
 BG9588 Lupus Nephritis Trial Group, 719  
 Bianchi DW, 3237  
 Biasi D, 1170  
 Biberfeld P, 1543  
 Bidwell JL, 2632, 2995  
 Bierwirth J, 3542  
 Biesczat D, 1708  
 Biggs J, 1464  
 Bijl M, 248, 1930  
 Bijlsma JWI, 396, 1229, 1797, 2693  
 Bijzet J, 248  
 Billiau A, 2983  
 Billinghurst RC, 3085  
 BIOBADASER Group, 2122  
 Biondi ML, 2695  
 Birbara CA, 35, 855  
 Bird P, 614  
 Bitti PP, 1385  
 Black A, 278  
 Black CM, 1979  
 Blake SM, 1292  
 Blanchette C, 829  
 Blanco FJ, 700  
 Blaschke S, 1858  
 Blaschke V, 1858  
 Bläsing F, 2779  
 Bliddal H, 2434  
 Block JA, 1466, 1556  
 Block MM, 2739  
 Block SR, 2739  
 Blom AB, 255, 1002  
 Blomberg S, 2524  
 Boback K, 2501  
 Bodman-Smith M, 2146  
 Boerman OC, 2059  
 Boers M, 272, 507, 1481, 1771  
 Bohnsack JF, 2989  
 Boiardi L, 3219  
 Boiocchi M, 3181  
 Boissier B, 2324  
 Bokarewa M, 1693  
 Bollow M, 1126, 1374, 3338  
 Bolognese JA, 3031  
 Bolon B, 2042  
 Bolstad AI, 174  
 Bona CA, 2275  
 Bonass EA, 2865  
 Bonavita G, 2627  
 Bonilla G, 1764  
 Bootsma H, 248  
 Borderie D, 3503  
 Borgeat P, 1137  
 Boross P, 255  
 Borton MA, 2763, 3328  
 Borzi RM, 278  
 Bost M, 1093  
 Botsios C, 2390  
 Boumediene K, 1569  
 Boumpas DT, 719



- Bourdeaut F, 1093  
Boyle DL, 2450  
Bradbury L, 2234, 2898  
Bradfield PF, 2472  
Brand MD, 1438  
Brandt J, 780, 1126, 1667, 2224  
Brandt KD, 378, 385  
Brandt L, 963  
Brandtzaeg P, 3266  
Braschi A, 2999  
Brasseur JL, 523  
Braun J, 780, 1126, 1374, 1667, 2224, 3230  
Braun MM, 319  
Brebant M, 523  
Breedveld FC, 271, 1513, 1841, 2132, 2415  
Breit S, 418  
Brennan FM, 1901  
Brenner M, 944  
Bresnihan B, 1408, 1676  
Bridges SL Jr., 906  
Brik R, 1149  
British Paediatric Rheumatology Study Group, 1398  
Britti D, 3544  
Brodsky I, 1463  
Brodsky RA, 166  
Brokstad KA, 3187  
Brook R, 1992  
Brookes S, 2865  
Brooks P, 1464  
Brophy S, 2234  
Brown AK, 285, 1214, 2898  
Brown MA, 90, 2234  
Brucato A, 266  
Bruce IN, 3159  
Brunet J, 1582  
Brunner HI, 1469  
Brunner J, 6  
Bruns A, 1332  
Brush M, 2697  
Bruyn GAW, 1164  
Bucala R, 103, 291, 1171, 1881  
Buckland-Wright C, 370, 3300  
Buckley CD, 2472  
Bucknall RC, 2796  
Buckwalter KA, 385  
Buenviaje H, 2011  
Bugbee WD, 110  
Bukhari MAS, 46  
Bulpitt KJ, 1493  
Bunce M, 807  
Burastero SE, 1109  
Burge DJ, 218, 1493  
Burgkart R, 2829  
Burke JR, 2652  
Burmester GR, 475, 927, 1332, 1438, 2224  
Burns CM, 2541  
Burt R, 2697  
Busso N, 651  
Busson M, 2240  
Buttgereit F, 1438  
Buyon JP, 281, 2080, 2699  
Buzás EI, 2163, 2959  
Bybee A, 2632, 2995  
Bykerk V, 829
- C**
- Cabanes L, 3503  
Cabiedes J, 471  
Cabral AR, 471  
Cahill MM, 2660  
Cahue S, 3359  
Calabrese F, 2390  
Calguneri M, 2256  
Caliez A, 2197  
Calin A, 2234  
Cáliz R, 638  
Callahan LF, 906  
Cambridge G, 2146  
Campbell D, 455  
Campbell IK, 1177  
Campistol JM, 2632, 2995  
Cantagrel A, 1163  
Cantini F, 1467  
Caporali R, 2999  
Caputi AP, 3544  
Caramaschi P, 1170  
Carcassi C, 1385  
Cardiel MH, 442  
Cardon L, 2234  
Carette S, 829  
Carlee JR, 2979  
Carletto A, 1170  
Carlson E, 1165  
Carmen S, 3253  
Carmona L, 2122  
Carr A, 1461  
Carson DA, 642  
Carter JD, 1770  
Carter RH, 882, 3242  
Cartman A, 2903  
Casali B, 3219  
Case JP, 1556  
Caspi D, 3299  
Cassatella MA, 2796  
Castañer JL, 2632, 2995  
Castelli A, 728  
Catanoso MG, 3219  
Cattrina AI, 1543  
Cauli A, 1385  
Cavill D, 3293, 3597  
Cawston TE, 1057, 3404  
Cazaneuve C, 2324  
Cedraschi C, 1420  
Cerdeño V, 1764  
Cerinic MM, 3023  
Cervera R, 1466, 3320  
Ceuppens JL, 2807  
Cha DH, 3237  
Chabaud-Riou M, 2450  
Chae YM, 268  
Chaisson CE, 2836  
Chakrabarti A, 1992  
Chakraborty P, 3297  
Chakraborty R, 2585, 3295  
Chambers MG, 3452  
Champey J, 569  
Chan AWK, 2888  
Chan EKL, 2080  
Chan RWY, 1326  
Chandrasekaran R, 1708  
Chandrashekar S, 2080  
Chang S, 2343  
Chapman K, 1461  
Charron D, 2240  
Chartash EK, 35, 855  
Cheema GS, 3475  
Chehal A, 1468  
Chen CT, 1047  
Chen D, 906  
Chen J, 1721, 2461  
Chen JF, 240  
Chen PP, 737, 1622  
Chen Q, 275, 3219  
Chen SJ, 1964  
Chen WV, 906  
Chen Y, 2461  
Cheng EY, 791  
Childhood Myositis Heterogeneity Collaborative Study Group, 2567  
Chin M, 334  
Chizzolini C, 2593  
Cho JY, 1249  
Cho TJ, 2845  
Choi GH, 3253  
Choi HK, 1530, 2750  
Choi J, 2262  
Choquette D, 370, 3300  
Chow KM, 1326  
Choy BK, 1249  
Christgau S, 2855  
Christianson TJH, 3522, 3532  
Christodoulou A, 776  
Chrubasik, 278  
Chubinskaya S, 2188  
Chukwuocha RU, 737  
Chung HS, 2025  
Chwiecko J, 1639  
Ciancio G, 867, 1467  
Ciboddo G, 3299  
Ciccio F, 728  
Cicutini FM, 682  
Cimaz R, 266  
Cimmino MA, 1207  
Ciarli C, 2903  
Clancy RM, 2080, 2699  
Clauw DJ, 277, 2916  
Clayton AR, 2362  
Clegg DO, 906, 3230  
Clemens L, 81  
Clements KM, 3452  
Club Rhumatismes et Inflammation, 2019  
Çobankara V, 2256  
Coblyn JS, 944  
Cody T, 1742  
Cohen P, 1420  
Cohen S, 625, 3224  
Cohen-Solal J, 2240  
Cole AA, 1292  
Colomina J, 3296  
Combadiere C, 3487  
Combe B, 2019  
Conaghan PG, 64, 1214, 3039  
Conrozier T, 378  
Constantin A, 1163  
Conte PM, 2923  
Cook JL, 134  
Cook MN, 1292  
Cooper B, 2246  
Cooper C, 1030, 3224, 3359  
Cooper GS, 3242  
Copel JA, 281  
Coquet M, 569  
Costedoat-Chalumeau N, 3207  
Court-Payen M, 955  
Coutts RD, 3382  
Cox V, 1030  
Crabbe J, 1814  
Craft J, 2992  
Crawford B, 625  
Crawshaw J, 807  
Creighton-Achermann L, 2873  
Cremonesi L, 1109  
Criswell LA, 906  
Crofford LJ, 277  
Cronstein BN, 240  
Cross A, 2796  
Crow MK, 2396  
Crowson CS, 54  
Cryer BL, 2074  
Cuchacovich R, 583  
Cunningham S, 2773  
Cupps TR, 2916  
Curiel DT, 2949  
Cush J, 3230  
Cutolo M, 2713, 3023  
Cuzzocrea S, 3544  
Czachur M, 1102
- D**
- D'Agati VD, 460  
D'Agostino MA, 523  
Daifotis AG, 1102  
Dale K, 2214  
D'Alecy LG, 1992  
Dambach DM, 2652  
Damle A, 906  
Danda D, 3293  
Danneskiold-Samsøe B, 2434  
Darke C, 90  
Darque A, 1849  
Davee SM, 1721  
David JR, 1881  
Davidson A, 495  
Davies KA, 1930  
Davis JC Jr., 1067, 3230  
Dayer JM, 2593  
Dayer P, 1420  
Dayton T, 3557  
D'Cruz D, 1466  
Dean JA, 2645  
de Andres MC, 700  
de Benedetti F, 1398  
Debré M, 1093  
Debre P, 3487  
DeBusk LM, 2461  
De Ceuninck F, 2197  
de Hooze ASK, 1750  
Deighton C, 1513  
de Jager W, 2001  
de Jong BAW, 2741  
de Jong EMGJ, 1355  
de Jong Z, 2415

De Keyser F, 1015  
 de Kleer IM, 2001  
 De Klerck B, 2983  
 de Koning MHMT, 2996  
 Delaney N, 1948  
 Delano D, 240  
 Del Carlo M Jr., 3419  
 del Hoyo P, 700  
 Delignat S, 3497  
 Delmas PD, 1102  
 del Rincón I, 1833, 2425  
 De Luca C, 2593  
 De Maio M, 3544  
 De Marchi G, 3181  
 de Martin R, 1901  
 de Médicis R, 2310  
 Deng C, 746  
 Denjoy I, 3207  
 Denton CP, 1979  
 De Re V, 3181  
 Derese I, 2807  
 Derksen RHW, 1355  
 De Ryck L, 1015  
 Desai A, 240  
 Desmeules JA, 1420  
 Devalaraja R, 1742  
 De Vita S, 3181  
 de Vries N, 1162, 1762  
 de Vries RRP, 1452  
 Diamond B, 2710  
 Dieppe P, 1461  
 Dietmaier W, 97  
 Dietrich H, 2605  
 Dieudé M, 2082  
 Dijkmans BAC, 269, 284, 507, 2415, 2996  
 Dijkstra PF, 507  
 DiMicco MA, 1292  
 Di Paola R, 3544  
 Distler O, 861, 1639  
 Dmitriev IP, 2949  
 Dobson CL, 3253  
 Doherty M, 1041, 2627  
 Doherty S, 1041  
 Doney A, 854  
 Donn R, 1398  
 Doran MF, 54  
 Dorner BG, 1858  
 Dörner T, 1332, 2697  
 Dorsch S, 1939  
 Dougados M, 523, 2019, 3230  
 Downey KJ, 1721  
 Downie-Doyle S, 3293  
 Doyle DV, 3112  
 Dragicevic G, 81  
 Dragomir AD, 675  
 Drayson MT, 2362  
 Drewe E, 1768  
 Drogou I, 569  
 Drouin EE, 534  
 Duclos B, 944  
 Du Clos TW, 1475  
 Dugo L, 3544  
 Duhaut P, 3207  
 Dumond H, 3118  
 Dunkley P, 767  
 Dunlop D, 3359

Dunstan C, 2042  
 Dupuy A, 3237  
 Durbach A, 2019  
 Dutch Juvenile Idiopathic  
 Arthritis Study Group, 507  
 Dutch Working Party on  
 Systemic Lupus  
 Erythematosus, 1355

## E

Easterbrook M, 863  
 Ebling FM, 475  
 Eckert M, 2541  
 Eckstein F, 2829, 3377  
 Edberg JC, 3242  
 Edgar C, 2845  
 Edmonds J, 614  
 Edwards BM, 3253  
 Edwards ET, 319  
 Edwards JCW, 2146  
 Edwards SW, 2796  
 Egan PJ, 1177  
 Egeland T, 2214  
 Ehrenstein MR, 2146  
 Ehresmann GR, 982  
 Ehrlich GE, 276  
 Eibel H, 348  
 Eiken HG, 174  
 Einhorn TA, 2845  
 Ekbohm A, 963, 1543  
 Ekindjian OG, 3503  
 Ekström K, 963  
 Elewaut D, 1281  
 El-Gabalawy H, 944  
 Elkayam O, 3299  
 Ellerin T, 3013  
 Elliott K, 146  
 Elliott SF, 1057  
 Ellman JA, 757  
 Eloranta ML, 2524  
 Embry JJ, 3431  
 Emery P, 64, 271, 285, 896, 1162, 1214, 1513, 3039, 3085, 3610  
 Emkey R, 1102  
 Emoto M, 3061  
 Enbrel Ankylosing Spondylitis  
 Study Group, 3230  
 Endo H, 2931  
 Englmeier KH, 2829  
 Englund M, 2178  
 Enokida M, 1732  
 Epstein M, 2321  
 Epstein WV, 573  
 Erkan D, 2769, 3320, 3611  
 Erlacher L, 2501  
 Erlandsson-Harris H, 1693, 2052  
 Ernst M, 1177  
 Ertenli I, 2256  
 Escalante A, 1833, 2425  
 Eslick J, 3096  
 Espinola G, 3272  
 Espinosa LR, 583  
 Esser S, 3096  
 Estrach C, 3611  
 Etzel C, 906

Euro-Lupus Nephritis Trial  
 Group, 1466  
 Evans LA, 1979  
 Eviatar T, 410  
 Ewerbeck V, 418  
 Exley AE, 2472  
 Eyre DR, 3130

## F

Faciszewski T, 1414  
 Falk B, 534  
 Falus A, 2163  
 Fang Y, 1913  
 Farkas C, 2163  
 Farkas E, 2163  
 Farley D, 1302  
 Farnetti E, 3219  
 Faure S, 3487  
 Fautrel B, 2019  
 Fava RA, 1471  
 Favret H, 378  
 Fearon U, 3085  
 Feghali-Bostwick C, 1956  
 Fei GZ, 2533  
 Feingold J, 2324  
 Feist E, 2697  
 Feldmann M, 839, 1901  
 Feletar M, 2067  
 Felgar RE, 455  
 Felisaz N, 1569  
 Felson DT, 625, 1034, 1781, 2836, 3031  
 Feltelius N, 1543  
 Feng A, 1493  
 Fenlon D, 283  
 Fenner H, 579  
 Fernandes JC, 1582  
 Fernández J, 2573  
 Fernandez-Gutierrez B, 1158  
 Fernández-Sueiro JL, 700  
 Fero M, 2132  
 Ferraccioli G, 3181  
 Ferrante A, 728  
 Ferrara DE, 3272  
 Ferrara GB, 867  
 Ferrari A, 1109  
 Ferrari M, 1109  
 Ferrer MA, 638  
 Ferrero E, 1109  
 Fertig N, 203, 1363  
 Fesstová V, 266  
 Fife MS, 3202  
 Figdor CG, 360  
 Filella X, 824  
 Finck BK, 218  
 Finckh A, 1420, 2393  
 Finger DR, 3000  
 Finger F, 3395  
 Fink DJ, 3464  
 Fink JS, 240  
 Finnegan A, 1708  
 Fiorillo MT, 1385  
 Firestein GS, 862, 2450  
 Fischer T, 3338  
 Fischkoff SA, 35, 855  
 Fiselier TJW, 507, 1750  
 Fishbein KW, 1047

Fisher CU, 1948  
 Fisher IB, 1979  
 Fisher SA, 1200, 3202  
 Fiskerstrand CE, 146  
 FitzGerald J, 737  
 FitzGerald O, 1408, 1676  
 Flahiff CM, 2509  
 Flatø B, 2214  
 Fleischmann RM, 927, 1493, 3230

Flemming D, 906  
 Flory C, 1582  
 Foell D, 2622  
 Forbes A, 682  
 Førre Ø, 2214  
 Fort JG, 3102  
 Fortune F, 807  
 Fossati-Jimack L, 1612  
 Fossel AH, 560  
 Foster HE, 767  
 Foxwell BM, 1901  
 François RJ, 1374  
 Franssen MJAM, 507, 1750  
 Fraser AM, 2989, 3085  
 Freeman GL, 1833  
 Frémont P, 829  
 Frenkel J, 2632, 2995  
 Friedman DM, 281  
 Fries JF, 2694  
 Frischbutter S, 2779  
 Frosch M, 1676, 2622  
 Frostegård J, 2533  
 Fujii K, 1239  
 Fujii N, 1271, 1762  
 Fujii T, 1766  
 Fujita S, 2555  
 Fukuda A, 2682  
 Fukuda K, 3151  
 Funk JL, 1721  
 Furie RA, 442, 719  
 Furst DE, 35, 855, 3328  
 Furumitsu Y, 3061  
 Fuseler J, 3557

## G

Gabriel SE, 54  
 Gaip US, 6  
 Galbiati S, 1109  
 Galdo F, 700  
 Gale DR, 2836  
 Gale ME, 2836  
 Gandon-Laloum S, 1093  
 Ganesan A, 2173  
 García-Pavía P, 2036  
 García-Puig J, 2036  
 Garlaschi G, 1207  
 Gasparotto D, 3181  
 Gay RE, 642, 1639, 1873, 2069, 2163, 2788, 3291  
 Gay S, 97, 348, 642, 859, 861, 1639, 1873, 2069, 2163, 2788, 3291  
 Gebhard P, 3395  
 Gedalia A, 218  
 Gefeller O, 1530  
 Géher P, 2163  
 Gehi A, 1067

Geiler T, 2396  
 Geneviève D, 2324  
 Genovese T, 3544  
 Gentiletti J, 1471  
 Gerhold K, 2697  
 Gerrard L, 146  
 Gershon SK, 319  
 Gershoni-Baruch R, 1149  
 Gershwin ME, 2605  
 Gerstenfeld LC, 2845  
 Gherardi RK, 569  
 Ghillani P, 3487  
 Giannini EH, 218  
 Giarratano A, 728  
 Gibbon WW, 64, 271  
 Gibofsky A, 576, 869, 3102  
 Giesecke T, 2916  
 Gil JT, 866  
 Gil KM, 1390  
 Gilbert C, 1137  
 Giles IP, 2111  
 Gill SE, 2173  
 Gillespie BW, 2246  
 Gillet P, 1594  
 Gillooly KM, 2652  
 Girodon-Boulandet E, 2324  
 Gladman DD, 2067, 3159  
 Gladstone DE, 1463  
 Glant TT, 1708, 2163, 2959  
 Glaser C, 2829  
 Glass DN, 3202  
 Glick GD, 757  
 Gloghini A, 3181  
 Glück T, 1765  
 Goemaere S, 1102  
 Goggins JP, 1034  
 Goicovich E, 2573  
 Goldbach-Mansky R, 585, 944  
 Golder W, 1126, 2224  
 Goldman BI, 2974  
 Goldring MB, 1249, 3395  
 Goldring SR, 1249  
 Golse K, 430  
 Gómez-Reino JJ, 2122  
 Gömör B, 2163  
 González MJ, 2573  
 González-Rojas J, 2353  
 Goodman MP, 2078  
 Goodson NJ, 1462  
 Goodson T, 2979  
 Gordon G, 2001  
 Gordon TP, 1167, 3597  
 Gore-Hyer E, 798  
 Goris A, 2773  
 Gorochoy G, 3487  
 Görtz B, 2042  
 Goto H, 3061, 3538  
 Goto M, 971  
 Gottenberg JE, 2019, 2240  
 Goulene K, 266  
 Gracely RH, 2916  
 Graff RD, 2722  
 Graham C, 2773  
 Grall F, 1249  
 Graninger WB, 2501  
 Grassi W, 3023  
 Grassnickel L, 1667

Grava C, 2390  
 Gravalles EM, 873, 1249  
 Gray L, 3557  
 Green DJ, 72  
 Green MJ, 64, 3039  
 Gregersen PK, 876, 906, 1171  
 Greidinger EL, 582  
 Griffiths ID, 767  
 Grifka J, 97  
 Grisham M, 3557  
 Grodstein F, 3055  
 Grodzinsky AJ, 1292  
 Gromnica-Ihle E, 2224  
 Grond J, 1164  
 Grootcholten C, 1355  
 Gross WL, 1168  
 Grossman JM, 737, 1622  
 Grotendorst G, 798  
 Gruber R, 2501  
 Gu X, 1249  
 Guadagnoli E, 560  
 Guadiano C, 867  
 Gualillo O, 404  
 Gualiabens N, 824  
 Guerrero A, 3296  
 Gulcher J, 391  
 Gunnarsson I, 2533  
 Gursel M, 1701

## H

Ha MK, 2025  
 Haas C, 348  
 Habros JS, 2763  
 Hachicha J, 3297  
 Hacquard-Bouder C, 523  
 Häfner R, 2001  
 Hagihara K, 1521  
 Hagino H, 1732  
 Hahn BH, 475, 737, 1622  
 Haibel H, 1667  
 Haines GK, 3568  
 Häkkinen A, 59  
 Hall FC, 2375  
 Halliwell B, 3140  
 Hallmans G, 2741  
 Halma C, 1164  
 Halpern M, 846  
 Halpern WG, 3253  
 Hamanishi C, 3151  
 Hamasaki Y, 1117  
 Hamersma J, 2234  
 Hamilton CD, 2085  
 Hamm B, 1374, 3338  
 Hammaker D, 2450  
 Hammer J, 534  
 Hammond L, 2632, 2995  
 Handel ML, 927  
 Hannonen P, 59, 1808  
 Hansen M, 2128  
 Hanyecz A, 2959  
 Hara F, 3151  
 Hara M, 186, 193  
 Haraoui B, 370, 3300  
 Hardy R, 1030, 3359  
 Harianto H, 81  
 Harigai M, 186  
 Harper L, 2362

Harrington T, 575  
 Harris EN, 3272  
 Harris RE, 2916  
 Harris WH, 560  
 Harrison BJ, 46  
 Hart DJ, 1024, 3112  
 Haruta Y, 3280  
 Hasegawa H, 2555  
 Hashiguchi T, 971  
 Hashimoto A, 2931  
 Hassett G, 3112  
 Hata K, 1445  
 Hatachi S, 668  
 Hattori T, 268  
 Hattori Y, 1647  
 Haugen M, 2214  
 Hauner H, 418  
 Hawkins PN, 2632, 2995, 3299  
 Hayashi I, 2931  
 Hayashi Y, 3603  
 Hayer S, 2042, 3308  
 Hayes K, 3359  
 Hayrapetyan H, 2324  
 Hayward NK, 2660  
 Haywood L, 2173  
 Hazes JMW, 856, 2415  
 Haznedaroglu IC, 2256  
 Heberer M, 1315  
 Heggarty S, 2773  
 Heldt C, 2779  
 Helmick CG, 675  
 Helsen MMA, 2489  
 Henklein P, 475  
 Hepburn B, 442  
 Herberth G, 475  
 Herborn G, 579  
 Heremans H, 2983  
 Hermann KGA, 3338  
 Hernández-García C, 1158  
 Herrick AL, 3518  
 Herrmann M, 6  
 Hessian PA, 334  
 Heurkens AHM, 1797  
 Hiepe F, 475  
 Hieshima K, 2555  
 Higaki H, 1923  
 High KP, 2632, 2995  
 Highton J, 334  
 Hilbert DM, 982, 3253, 3475  
 Hildebrandt B, 210  
 Hilger A, 1047  
 Hill CL, 2836  
 Hinterwimmer S, 2829  
 Hirakata M, 1766  
 Hiromatsu K, 495  
 Hiromura K, 2442  
 Hirsch R, 917  
 Hirt A, 2788  
 Hiscock J, 1167  
 Hitchon CA, 944  
 Hitman GA, 2632, 2995  
 Hjalgrim H, 963  
 Hjelmström P, 3187  
 Ho A, 3280  
 Ho M, 854  
 Hoch S, 1463  
 Hochberg MC, 675, 917

Hoeben RC, 1841  
 Hoffman GS, 1160, 2406  
 Hoffman IEA, 1015  
 Hoffman RW, 582  
 Hofman A, 1913  
 Hofman DM, 1797  
 Holers VM, 2701  
 Hollander AP, 709  
 Holmberg J, 2332  
 Holmdahl R, 2332, 3584  
 Holthuisen AEM, 255, 1002  
 Hooiveld MJJ, 396  
 Horst G, 248  
 Horton WE Jr., 1047  
 Horvath L, 2697  
 Hosono O, 1890  
 Hou A, 2845  
 Houssiau FA, 1466  
 Hovannesian Z, 2324  
 Hu PQ, 1363  
 Hu SI, 1302  
 Hu X, 2092  
 Huang W, 495  
 Hübscher O, 2077  
 Hudelmaier M, 2829  
 Hüffmeier U, 2386  
 Hughes AE, 2627  
 Hui W, 3404  
 Huizinga TWJ, 858, 1841, 2132  
 Hull KM, 1769  
 Hülsemann JL, 270, 1468  
 Hummel KM, 1858, 1873  
 Hunder GG, 873, 3522, 3532  
 Hunziker EB, 3464  
 Huang DLT, 3207  
 Hurme M, 3068  
 Hurwitz DE, 1556  
 Husby G, 3266  
 Hutchinson P, 1881  
 Hwang KK, 737, 1622

## I

Ibañez D, 2067, 3159  
 Ichikawa N, 186  
 Ida A, 1612  
 Idone C, 3299  
 Ihn H, 1652  
 Ijiri K, 971  
 Ikeda E, 1890  
 Ikeda T, 1562  
 Ikeuchi H, 2442  
 Illei GG, 719  
 Ilowite NT, 218  
 Imanishi J, 1562  
 Imanishi Y, 3538  
 Imperatore EA, 460  
 Inaba M, 3061, 3538  
 Inan MS, 1249  
 Ingvarsson T, 391  
 Inman RD, 791, 3230  
 Innes NJ, 814  
 Innocenti S, 1207  
 Inoue A, 2555  
 Inoue K, 971  
 Inoue M, 2931  
 Inoue R, 2483

INSSYS/GCA Investigators,  
1160  
International Myositis  
Collaborative Study Group,  
2285

Inui K, 3061, 3538  
Ioannidis JPA, 1930  
Ionescu M, 1261, 3085  
Iotti R, 2077  
Isaacs J, 64  
Isenberg DA, 1343, 2111  
Ishii KJ, 1701  
Ishimaru N, 3603  
Ishimura E, 3061  
Isomäki P, 1808  
Ito MR, 1445, 2555  
Ivashkiv LB, 2092  
Iversen M, 2393  
Iwakura Y, 1890  
Iwamoto I, 486  
Iwamoto Y, 1923  
Iwata S, 1890  
Izui S, 1612, 2353

## J

Jabr FI, 1468  
Jackson CG, 1493  
Jacobi AM, 1332  
Jacobs JWG, 1797, 2693  
Jacobs KMG, 1229  
Jacobsen S, 955  
Jacobson MA, 240  
Jaffré B, 1594  
James IE, 1292  
James T, 807  
James WH, 283  
Jansen A, 2415  
Janssens-Korpola PL, 2632,  
2995  
Jarraya F, 3297  
Jasin HE, 580  
Jawaheer D, 906  
Jayson MIV, 612  
Jendro MC, 1468  
Jenkins A, 72, 81  
Jensen KE, 2128  
Jewell DP, 807  
Jibreel I, 227  
Jin L, 2011  
John S, 3615  
Johnson K, 1302  
Johnson KJ, 757  
Johnson KL, 3237  
Johnston V, 2214  
Jones GT, 2615, 3518  
Jones OY, 218  
Jones RJ, 166  
Jonsson H, 391  
Jonsson HH, 391  
Jonsson IM, 1693  
Jonsson MV, 3187  
Jonsson R, 174, 1167, 3187  
Joosten LAB, 339, 1002, 1750,  
1853, 2489, 2949  
Jordan JM, 675  
Joshi VR, 274  
Joshua F, 2321

Jover JA, 1158  
Judex M, 97  
Julkunen H, 280  
Julovi SM, 1271, 1762  
Jury EC, 1343

## K

Kaaja R, 280  
Kaarela K, 3068  
Kabouridis PS, 1343  
Kacem HH, 3297  
Kadono Y, 2682  
Kaeser L, 3291  
Kafienah W, 709  
Kahan A, 3503  
Kainberger F, 325  
Kaine JL, 2763, 3328  
Kalden JR, 6, 1504, 1513, 2386  
Kaldjian E, 1742  
Källberg E, 3266  
Kallenberg CGM, 248, 1930  
Kalsi J, 475  
Kamat SS, 3176  
Kamatani N, 186, 193  
Kameya T, 231  
Kamphuis SM, 2001  
Kan VL, 1156  
Kanbe K, 275  
Kane D, 1408, 1676  
Kanege F, 3280  
Kaneko Y, 2442  
Kannan K, 3557  
Kaplan MJ, 1992  
Karassa FB, 1930  
Karim Z, 64, 3039  
Karkavelas G, 776  
Karlsen EW, 3055  
Karpouzas G, 475  
Karschikus C, 81  
Kasperkovitz PV, 2132  
Kastner DL, 906, 1769, 2645  
Katagiri H, 2682  
Katano K, 2483  
Katayama I, 1117  
Kato T, 602  
Katsumata Y, 1647  
Katz JN, 560  
Katz PP, 935, 3046  
Kauffman H, 410  
Kauppi M, 1808  
Kaveri SV, 3497  
Kawaguchi Y, 186, 193  
Kawahara K, 971  
Kawai S, 2819, 2931  
Kawano M, 2483  
Kawano T, 1923  
Kawasaki H, 1890  
Kawashima M, 631  
Kay GF, 2660  
Kazatchkine MD, 3497  
Kazis L, 2836  
Kean A, 334  
Kearney JF, 1602  
Kees F, 1504  
Kehrer C, 1992  
Keitzer R, 2697  
Kelekis DA, 732  
Kelley RI, 2645  
Kellner H, 2224  
Kenter K, 134  
Kerber RA, 2989  
Kern M, 906  
Kerr GS, 1156  
Keystone EC, 35, 855  
Khamashta MA, 1930  
Khanna D, 2078  
Khariourov A, 1667  
Khosrotehrani K, 3237  
Khy V, 370, 3300  
Kikuchi S, 1612  
Kim HS, 2025  
Kim MY, 281  
Kim SJ, 1569  
Kimberly RP, 3242  
Kimpel D, 3557  
Kimura N, 1766  
Kimura T, 3350  
Kimura Y, 2923  
King-Jones K, 1569  
Kiraz S, 2256  
Kiriakidis S, 1901  
Kirkham J, 2865  
Kishimoto T, 1521  
Kitajima S, 2483  
Kitamura Y, 186  
Kitasato H, 231, 2931  
Kivitz A, 3230  
Klareskog L, 963, 1500, 1543,  
2533  
Klarlund M, 955  
Klinman DM, 590, 1701  
Klinzing S, 2788  
Kluve-Beckerman B, 1430  
Knecht H, 3377  
Knöll A, 1631, 1939  
Knudson W, 3431  
Koarada S, 3280  
Kobayashi H, 1890  
Kobayashi K, 3538  
Kobayashi M, 3603  
Kobayashi S, 1890  
Koch AE, 3568  
Koch G, 625  
Kocsis K, 2163  
Kodera T, 2275  
Kohn M, 2555  
Koike T, 886  
Kojima F, 2819  
Kojima I, 2442  
Kokkola R, 2052  
Kolba KS, 2763  
Köller M, 325  
Kollias G, 2042  
Komiya S, 971  
Kondo H, 231, 2931  
Koné-Paut I, 1093  
Kong PL, 2992  
Koni I, 2483  
Kono S, 2931  
Kontny E, 1551  
Korn JH, 1478  
Koshiba M, 668  
Kostense PJ, 2996  
Kotake S, 186

Kowal K, 1639  
Kowal-Bielecka O, 1639  
Kowalczewski J, 1551  
Koyama H, 3061  
Koziolek M, 1858  
Kraan MC, 271, 1162, 2132,  
2155  
Kraus VB, 675, 2942  
Krause MM, 1438  
Krauss S, 1438  
Kremer JM, 1493, 2763  
Kremers HM, 54  
Kriegel MA, 2386  
Krishnan E, 59, 1808  
Krishnan S, 1948  
Kroccek RA, 1858  
Kroon HM, 2415  
Kruithof E, 1015  
Kubo T, 1562  
Kuchen S, 348, 2069, 2788  
Kuenzler P, 2069  
Kuh D, 1030, 3359  
Kühn K, 2873  
Kuis W, 507, 2001, 2622  
Kullberg BJ, 1853  
Kullmann F, 97  
Kumagai S, 668  
Kumar S, 1292  
Kumeda Y, 3061, 3538  
Kupersmith M, 1159  
Kurasawa K, 486  
Kuroda Y, 2990  
Kuroiwa T, 2442  
Kuroki K, 134  
Kurosaka M, 668  
Kürten B, 1828  
Kurtis MS, 110  
Kusaka H, 668  
Küster RM, 1631  
Kusuhara K, 2632, 2995  
Kuwana M, 1647  
Kwiatkowski D, 90  
Kyburz D, 642, 2788  
Kyogoku C, 273

## L

Laan RF, 3224  
Labrador-Horrillo M, 1169  
Labs K, 3338  
Lacey D, 103, 1881  
Lacey JV Jr., 2246  
Lachmann HJ, 2632, 2995, 3299  
Lacroix-Desmazes S, 3497  
Lafeber FPJG, 396, 1229  
Lai FMM, 1326  
Lai KB, 1326  
Laiho K, 3068  
Laing TJ, 2246  
Lajaunias F, 1612  
Lakatos T, 2163  
Lamb R, 1398  
Lanchbury JS, 1200  
Landais P, 1093  
Landewé RBM, 1, 272, 2694  
Lane SE, 814  
Lang BA, 2294  
Lange M, 218

- Lange U, 1828  
 Langer S, 475  
 Langevitz P, 3298  
 Langnickel D, 475  
 Lanyon PC, 1041, 1768  
 Lappin PB, 3253  
 Lard LR, 1841  
 La Regina M, 2632, 2995  
 Lark MW, 1292  
 Lassere M, 614  
 Latchman DS, 2111  
 Lau CS, 2888  
 Lau J, 3237  
 Lauener R, 642  
 Laugier P, 1594  
 Lauwers-Cancès V, 1163  
 Laval S, 2234  
 LaValley MP, 2207, 3212  
 Law CL, 1612  
 Le ET, 2942  
 Le M, 2275  
 Leandro MJ, 2146  
 LeBideau M, 1093  
 Lechner S, 97  
 Lee DM, 944  
 Lee GM, 2722  
 Lee HS, 146  
 Lee JH, 319  
 Lee KH, 2025  
 Lee S, 2025  
 Leech M, 103, 291, 1881  
 Le Graverand MPH, 378  
 Lehtikoinen P, 3077  
 Lehmann HW, 1631, 1939  
 Lehmann M, 1569  
 Lehmann W, 2845  
 Lemelle I, 1093  
 Lems WF, 269, 2996  
 Leonetti F, 757  
 Lepage V, 2240  
 Lesch C, 1742  
 Lester S, 3293  
 Lew RA, 560  
 Lewis CM, 1200, 3202  
 Leyton C, 2573  
 Leyton L, 2573  
 Li EKM, 1326  
 Li J, 2052  
 Li KW, 689  
 Li PKT, 1326  
 Li W, 3212  
 Li X, 3242  
 Li Y, 2509  
 Liang MH, 2393  
 Liang Z, 2343  
 Liberman UA, 1102  
 Libermann TA, 1249  
 Licata G, 728  
 Lichtenstein JR, 282  
 Lidar M, 1149  
 Lien G, 2214  
 Liepnieks JJ, 1430  
 Lichtenberg G, 1355  
 Liljeström M, 3068  
 Limburg PC, 248  
 Lin PC, 2461  
 Linder R, 1168  
 Lingard EA, 560  
 Linnik MD, 442  
 Lipsky PE, 585, 1332  
 Listing J, 1126, 1667, 2224, 2779  
 Liu FT, 2788  
 Liu H, 3096  
 Liu RQ, 119  
 Liu X, 1080, 3272  
 Livingstone W, 1408  
 Livneh A, 1149, 3298  
 Livrone F, 1207  
 LJP 394 Investigator Consortium, 442  
 Lodder MC, 2996  
 Loesberg WA, 2949  
 Loeser RF, 110, 2188, 3009, 3419  
 Loeuille D, 1594, 3118  
 Lohmander LS, 2178, 3130  
 Loiseau P, 2240  
 Lombardi A, 1102  
 Looney RJ, 455  
 Lopez AM, 2567  
 López-Armada MJ, 700  
 López-Hoyos M, 2353  
 López-Nevot MA, 638  
 Loreck D, 3338  
 Lorentzen JC, 551  
 Lorenz HM, 1504, 2386  
 Lorenzen I, 2128  
 Lories RJU, 2807, 2983  
 Losina E, 560  
 Lotz M, 2873  
 Loughlin J, 1461, 1913  
 Loukopoulou D, 227  
 Lovell DJ, 218  
 Lu LM, 1445  
 Lu P, 2652  
 Lu Q, 746  
 Lu S, 2332  
 Lubberts E, 339  
 Lubeck D, 3046  
 Lucas M, 203  
 Luderschmidt C, 210  
 Lui LY, 1034  
 Lukaszyk AB, 1639  
 Lum RF, 906  
 Lundberg IE, 2533  
 Lunt M, 46, 1398  
 Lupattelli G, 2700  
 Lupoglazoff JM, 3207  
 Lussier A, 2310  
 Luta G, 675  
 Luyten FP, 2807, 2983  
 Luzina IG, 2262  
 Lyles KW, 2097  
  
**M**  
 Ma D, 1464  
 Mabuchi H, 2483  
 Macchioni P, 3219  
 Macfarlane GJ, 1686, 2615, 3518  
 MacGregor AJ, 1024  
 Mackenzie A, 146  
 Madaio MP, 2992  
 Madhok R, 272  
 Maeshima A, 2442  
 Magder L, 582  
 Mageed RA, 1343  
 Maghidman S, 2585  
 Magnaguagno F, 1207  
 Magni-Manzoni S, 3509  
 Magnusson M, 2524  
 Magy N, 1430  
 Mahadevan V, 2645  
 Mahomed NN, 560  
 Main SH, 3253  
 Mainard D, 3118  
 Majka DS, 2701  
 Major G, 2321  
 Mak TW, 3280  
 Makni-Karray K, 3297  
 Maksymowych WP, 584, 2011  
 Malagari K, 732  
 Malfait AM, 3304  
 Mandl LA, 3055  
 Maneiro E, 700  
 Manek NJ, 1024, 3112  
 Manger K, 1930  
 Manna R, 2632, 2995  
 Mannarino E, 2700  
 Manning C, 1249  
 Manolescu A, 391  
 Manolescu I, 391  
 Manzi S, 719  
 Marasini B, 2695  
 Marchesi S, 2700  
 Marchesoni A, 2695  
 Marchionni L, 1109  
 Marcinkiewicz J, 1551  
 Marcus DM, 280  
 Mariette X, 2019, 2240  
 Marion TN, 1602  
 Maritim B, 541  
 Markowitz GS, 460  
 Marmont AM, 2696  
 Marmor MF, 1764  
 Maroudas A, 410  
 Marquina R, 2353  
 Marshall N, 767  
 Marshall SE, 807  
 Martel-Pelletier J, 370, 1582, 2855, 3300, 3301  
 Martens PB, 866  
 Martin I, 1315  
 Martin J, 638  
 Martin MA, 700  
 Martin MU, 2949  
 Martín Mola E, 1764, 2122  
 Martinez-Soria E, 1612  
 Martini A, 1398, 3509  
 Maruyama H, 2555  
 Maruyama I, 971  
 Marzo-Ortega H, 896, 3039, 3610  
 Marzotto A, 3181  
 Masciandaro S, 867  
 Maslinski W, 1551  
 Mason RM, 3452  
 Massarotti M, 2695  
 Masuko-Hongo K, 602  
 Matejicka C, 864  
 Mates M, 571  
 Mateu PL, 866  
 Mathieu A, 866, 1385  
 Mathieu P, 378  
 Mathis D, 944  
 Matsui T, 231  
 Matsukawa M, 3151  
 Matsumoto I, 944  
 Matsumoto K, 486  
 Matsumura R, 486  
 Matsunaga S, 971  
 Matsuno H, 3350  
 Matsuoka Y, 1647  
 Matsushita, 3151  
 Matsuta K, 273  
 Matsuyama T, 1117  
 Matteson EL, 54, 1775, 3522, 3532  
 Matthys P, 2983  
 Mauri C, 839  
 Maurin EC, 1390  
 Maury CPJ, 3068  
 Mawatari T, 1923  
 May W, 2100  
 Mayes MD, 1190, 2246  
 Mazda O, 1562  
 Mazzon E, 3544  
 Mazzuca SA, 378, 385  
 M'Barek KN, 2855  
 McBeth J, 1686  
 McCarty DJ, 2627  
 McClelland RL, 3522, 3532  
 McColl G, 72, 81  
 McColl SR, 2310  
 McConnell HM, 2375  
 McCrory MA, 1602  
 McDermott EM, 2632, 2995  
 McDermott MF, 2632, 2995  
 McEntegart A, 272  
 McGaha TL, 2275  
 McGonagle D, 64, 896, 1214, 3610  
 McIntyre KW, 2652  
 McKay JD, 442  
 McKee SA, 2632, 2995  
 McKenna F, 3102  
 McKiernan F, 1414  
 McLean L, 1814  
 McMurray RW, 2100  
 McQueen FM, 1814  
 McWilliams DF, 2173  
 Meazza C, 1398  
 Medema JP, 858  
 Medhekar S, 580  
 Medsger TA Jr., 203, 516, 1363, 1956  
 Meharra EJ, 2873  
 Meisel C, 1438  
 Mekki QA, 2763, 3328  
 Meliconi R, 278  
 Melief CJM, 1452  
 Mellins ED, 2375  
 Mengle-Gaw LJ, 2763, 3328  
 Menon Y, 583  
 Mentlein R, 660  
 Merino J, 2353  
 Merino R, 2353  
 Merle-Vincent F, 378, 2019  
 Meroni PL, 266, 3272

- Merrill JT, 737  
 Messer J, 2750  
 Metselaar JM, 2059  
 Metyas S, 3475  
 Meune C, 3503  
 Meynard JB, 1223  
 Michaud K, 1530, 2750  
 Michel BA, 1873, 2069, 2788, 3291  
 Michel M, 1930  
 Middel P, 1858  
 Migone TS, 982  
 Mihara M, 495  
 Mijares-Boeckh-Behrens T, 1169  
 Mikecz K, 1708, 2959  
 Milewicz DM, 2585  
 Milicic A, 90  
 Miller FW, 2285, 2567  
 Miller ML, 2737  
 Milliken S, 1464  
 Millward-Sadler SJ, 146  
 Milner JM, 1057  
 Miltenburg AMM, 2375  
 Mimori T, 1766  
 Minden K, 2632, 2995  
 Mineau GP, 2989  
 Minn H, 3077  
 Minter RR, 3253  
 Miossec P, 594, 631  
 Mirakian RM, 2632, 2995  
 Miralles A, 1764  
 Mischung C, 2632, 2995  
 Mitchell JP, 1948  
 Mitchell R, 103  
 Mitri GM, 203  
 Mittal G, 274  
 Miura H, 1923  
 Miyake-Nishijima R, 1890  
 Miyara M, 3487  
 Miyazaki J, 2555  
 Miyazaki T, 1445, 2682  
 Modafferi D, 927  
 Mödder U, 157  
 Modrow S, 1631, 1939  
 Moffet H, 829  
 Mohan C, 1080, 2343  
 Mojoli F, 2999  
 Mok MY, 2888  
 Moldovan F, 1582, 2855  
 Molina C, 2573  
 Moll T, 1612  
 Molloy MG, 2632, 2995  
 Monaco C, 1901  
 Monegal A, 824  
 Monestier M, 2974  
 Montecucco C, 2999  
 Monteiro J, 906  
 Montero MD, 2122  
 Montesinos MC, 240  
 Moore J, 1464  
 Moore TL, 3096, 3176  
 Moorts RJ, 2796  
 Morado IC, 1158  
 Morand EF, 103, 291, 1881  
 Morard C, 651  
 Moreland LW, 35, 855  
 Morgan GJ, 864  
 Morgan ME, 1452  
 Morgan SL, 2979  
 Mori S, 1445  
 Mori Y, 1964  
 Morimoto C, 1890  
 Morin F, 829  
 Morishita H, 2483  
 Morito F, 3280  
 Moro-Oka T, 1923  
 Moroldo M, 3202  
 Moroz C, 846  
 Morrison JF, 3615  
 Möttönen T, 3077  
 Mould AW, 2660  
 Mouthon L, 3497  
 Moutsopoulos HM, 732  
 Mouy R, 1093  
 Mpofo S, 3611  
 Muche B, 1374  
 Mugnier B, 1223, 1849  
 Muir K, 1041  
 Mukherjee D, 1992  
 Mulcahy-Hawes K, 807  
 Mulherin D, 868  
 Müller B, 2779  
 Müller GA, 1858  
 Müller-Ladner U, 97, 861, 1765  
 Munakata H, 3151  
 Munneke M, 2415  
 Muñoz-Fernández S, 1764  
 Muñoz-Gomez J, 824  
 Murakami Y, 231, 2931  
 Muramoto H, 2483  
 Murata N, 268  
 Murota H, 1117  
 Murphy JM, 3464  
 Myers A, 767  
 Mynett-Johnson L, 1408  
 Myoui A, 2670
- N**
- Nabbe KCAM, 255  
 Naccache PH, 1137  
 Nacionales DC, 2990  
 Nagasawa K, 3280  
 Nagata-Sakurai M, 3061  
 Nakagawa T, 1271, 1762  
 Nakahara H, 1521  
 Nakajima T, 971  
 Nakamachi Y, 668  
 Nakamura I, 2682  
 Nakamura K, 2682  
 Nakamura T, 1271, 1762  
 Nakamura Y, 1445  
 Nakanishi Y, 1923  
 Nakashima T, 1117  
 Nakatsuru S, 1445  
 Nakaya H, 268  
 Nakayama J, 3350  
 Nakayama S, 1239  
 Nakazawa T, 668  
 Namai R, 231  
 Nambiar MP, 1948  
 Nanpei A, 2670  
 Naraba H, 2819  
 Nash GB, 2472  
 Navarro-Cano G, 2425
- Neeck G, 1828  
 Neidhart M, 1873, 2069, 2788  
 Nelissen RGHH, 1841  
 Nelson JL, 906  
 Nepom GT, 534  
 Nesher G, 571  
 Nesterovitch AB, 1708, 2959  
 Netea MG, 1853  
 Netter P, 1594, 3118  
 Neumann E, 97, 861  
 Neva MH, 1808  
 Neville M, 807  
 Nevitt MC, 1034  
 Newton J, 90  
 Newton RC, 119  
 Nguyen N, 3096  
 Nguyen P, 1071  
 Niccoli L, 1467  
 Nicoli D, 3219  
 Nicolo D, 2974  
 Niculescu F, 1071  
 Niculescu T, 1071  
 Niederauer GG, 3382  
 Niederegger H, 2605  
 Nijenhuis S, 2489  
 990757 Study Group, 927  
 Nishikawa M, 2670  
 Nishimoto N, 1521  
 Nishimura A, 231  
 Nishioka K, 602  
 Nishishita T, 2461  
 Nishizawa Y, 3061, 3538  
 Niu J, 1034  
 Noelle RJ, 2541  
 Nojima Y, 2442  
 Nolte M, 1067  
 North American Rheumatoid Arthritis Consortium, 906  
 Nose M, 1445, 2555  
 Nossent HC, 1462  
 Nossent JC, 300  
 Nourooz-Zadeh J, 284  
 Nozaki Y, 1445  
 Nueninghoff DM, 3522, 3532  
 Nutt A, 580  
 Nuutila P, 3077  
 Nylen K, 2881
- O**
- Oamar B, 3475  
 O'Brien E, 2989  
 O'Brien L, 2011  
 O'Connor PJ, 64, 271, 285, 1214  
 Oda H, 2682  
 Odendahl M, 1332  
 Oettgen P, 1249  
 O'Fallon WM, 54  
 Offringa R, 1452  
 Ogawa N, 2391  
 Ogawa Y, 3350  
 Ogilvie EM, 3202  
 Oh SH, 2025  
 O'Hanlon TP, 2567  
 Ohashi S, 1562  
 Ohshima S, 2788  
 Ohta A, 3280  
 Ohtsuki M, 3350
- Okada F, 3538  
 Okada K, 2483  
 Okada Y, 1890, 2285  
 Okano T, 1732  
 Okouneff S, 1261  
 Olea N, 2573  
 O'Leary DH, 1833  
 Olivieri I, 867, 1467  
 Oliviero F, 2390  
 Olofsson P, 2332, 3584  
 Olsen BR, 2509  
 Olson JC, 218  
 Omura T, 2483  
 Ong VH, 1979  
 Onji M, 1445  
 Ono M, 1445  
 Onozawa Y, 3350  
 Oostveen JCM, 507  
 Opipari AW Jr., 757  
 Orts J, 3296  
 Orttutay Z, 2163  
 Ostendorf B, 157  
 Østergaard M, 955, 2128  
 Ostuni PA, 2390  
 Ota F, 2442  
 Otero M, 404  
 Oyama Y, 2697  
 Ozbalkan Z, 2256  
 Ozturk MA, 2256
- P**
- Pacione CA, 2188  
 Padula A, 867, 1467  
 Pagenstecher A, 348  
 Paget SA, 1159, 2769  
 Pai YC, 3359  
 Paleolog E, 1901  
 Pállinger E, 2163  
 Palmblad K, 2052  
 Palmer CNA, 854  
 Pannu J, 798  
 Panzeri P, 266  
 Papanikolaou G, 227  
 Papin S, 2324  
 Parel Y, 2593  
 Parizot C, 3487  
 Park J, 430  
 Parkkola R, 3077  
 Parry SL, 2375  
 Parsch D, 418  
 Parsonage G, 2472  
 Pasch LA, 935  
 Pascual M, 638  
 Pascual-Salcedo D, 638  
 Pasquali JL, 944  
 Passiu G, 1385  
 Patel NSA, 3544  
 Paterson AD, 791  
 Patrono C, 12  
 Pattoli MA, 2652  
 Patwari P, 1292  
 Paul WE, 2275  
 Paulose-Ram R, 917  
 Paulus H, 2078  
 Pavletic SZ, 1463  
 Pavlic R, 1992  
 Pay S, 2256

Payne U, 791  
 Peariso S, 2627  
 Pearson CI, 2173  
 Péclat V, 651  
 Pedersen-Zbinden B, 2128  
 Pediatric Rheumatology  
 Collaborative Study Group,  
 218  
 Pelletier JP, 370, 1582, 2855,  
 3300, 3301  
 Peloso PM, 2011  
 Pendleton A, 2627  
 Pepmueller PH, 3176  
 Pérez P, 2573  
 Perino A, 728  
 Peris P, 824  
 Perlman H, 3096  
 Perry D, 1814  
 Perry JW, 982  
 Pesman GJ, 1002  
 Peter HH, 348  
 Petersen W, 660  
 Petri M, 166, 582  
 Pettersson U, 2332  
 Pettit AR, 1249, 2660  
 Pfenninger D, 1992  
 Phillips CB, 560  
 Picher M, 2722  
 Pidoux I, 2903  
 Piecyk M, 541  
 Pierangeli SS, 3272  
 Pieterman EJ, 858, 1841, 2132  
 Pietka TA, 3130  
 Piette JC, 1930, 3207, 3487  
 Pile K, 3293  
 Pillet P, 1093  
 Pincus T, 313, 576, 625, 906,  
 2706, 3613  
 Ping L, 2391  
 Piperno M, 378  
 Pischel KD, 862  
 Pisetsky DS, 862, 873, 906, 1166  
 Pistorio A, 1398, 3509  
 Ploegert S, 1315  
 Ploos van Amstel HK, 2632,  
 2995  
 Ploumis A, 776  
 Pogolian S, 2425  
 Polgár A, 2163  
 Politou M, 227  
 Pollak S, 278  
 Pollard KM, 210  
 Pols HAP, 1913  
 Pongratz G, 1504  
 Pons F, 824  
 Poole AR, 1261, 1271, 1762,  
 2903, 3085, 3452  
 Poole J, 1030, 3359  
 Poortman C, 3253  
 Pope J, 283  
 Pope RM, 906, 3096  
 Portnoff K, 862  
 Poss R, 560  
 Pottier P, 3118  
 Poubelle PE, 1102, 1137, 2310  
 Poulakos J, 927  
 Pouliot M, 1137

Powell RJ, 1768, 2632, 2995  
 Prahallad S, 2989  
 Prakken BJ, 2001  
 Pratta MA, 119  
 Presle N, 3118  
 Prestrud AA, 1463  
 Price JS, 3452  
 Prieto GA, 471  
 Prieur AM, 1093, 3202  
 Prior D, 81  
 Proudman S, 64, 3039  
 Prue RL, 2362  
 Pufe T, 660  
 Pujol JP, 1569  
 Pullerits R, 1693  
 Pulsatelli L, 278  
 Punzi L, 2390

## Q

Qiu L, 1742  
 Qiu Y, 2652  
 Quartier P, 1093  
 Quezada SA, 2541  
 Quinn JP, 146  
 Quinn MA, 64, 3039  
 Quintana F, 846  
 Qvistgaard E, 2434

## R

Radbruch A, 475, 1332  
 Radjenovic A, 271, 1214  
 Radstake TRDJ, 339, 1002,  
 1853  
 Rahman A, 2111  
 Rahme E, 2075  
 Rainger GE, 2472  
 Rajagopalan S, 1992  
 Rajkumar V, 1979  
 Rantapää-Dahlqvist S, 2741  
 Rao T, 746, 757  
 Raphaël D, 3487  
 Rapiti E, 1420  
 Rasch EK, 917  
 Rau R, 579, 2997  
 Raufman JP, 580  
 Ravelli A, 1398, 3509  
 Ray A, 134  
 Ray BK, 134  
 Raymond Y, 2082  
 Raynauld JP, 370, 3300  
 Re R, 2077  
 Reddig J, 2224  
 Redlich K, 2042, 3308  
 Reece RJ, 271, 1162, 3085  
 Reeve JP, 2011  
 Reeves WH, 2990  
 Reginato AJ, 2627  
 Reich K, 1858  
 Reid DM, 3224  
 Reiff A, 218, 2079  
 Reiman RM, 1602  
 Reinhold-Keller E, 1168  
 Reino JGG, 404  
 Reis A, 2386  
 Reiser M, 2829  
 Reiter K, 1332

Rekving OP, 300  
 Ren Y, 2888  
 Renkiewicz R, 1742  
 Renner JB, 675  
 Rethage J, 642  
 Reveille JD, 791, 2011, 2585  
 Reviron D, 1223, 1849  
 Ribbhammar U, 551  
 Riccobene T, 3253  
 Richards CD, 1750, 3404  
 Richards JS, 1156  
 Richardson BC, 746, 757  
 Richter W, 418  
 Rider LG, 2567  
 Ridgway JP, 271  
 Riemekasten G, 475  
 Rifas L, 993  
 Rihošková V, 2069  
 Rijkers GT, 2001  
 Rischmueller M, 3293  
 Rivero M, 2036  
 Roberts JR, 3000  
 Robin V, 283  
 Robinson E, 1814  
 Rodriguez J, 2697  
 Rodríguez Valverde V, 2122  
 Roivainen A, 3077  
 Roldán JF, 2425  
 Romas E, 81  
 Romero-Merino E, 1169  
 Romo R, 2573  
 Rondan KH, 2415  
 Rönnblom L, 2524  
 Rooney M, 2773  
 Roos EM, 2178  
 Roosendaal G, 396  
 Ros I, 824  
 Rosa R, 2697  
 Roschke V, 982, 3253, 3475  
 Rose P, 3140  
 Rosenbaum JT, 1469  
 Rosenblatt J, 455  
 Rosengren LE, 2881  
 Rosenlund B, 174  
 Rosier RN, 1779  
 Rossi F, 1398, 3509  
 Roth J, 255, 1676, 2622  
 Rothfield N, 1165  
 Rothschild B, 2389  
 Roubey RAS, 3004  
 Roudier C, 1223, 1849  
 Roudier J, 1223, 1849  
 Rouphael N, 581  
 Rowan AD, 1057, 3404  
 Rowley K, 81  
 Roy-Beaudry M, 2855  
 Rozman B, 1513  
 Rubin RH, 3013  
 Rudders S, 1249  
 Rudnicka W, 1551  
 Rudwaleit M, 780, 1126, 1667  
 Ruiz ME, 1156  
 Rus H, 1071  
 Rus V, 1071  
 Rush S, 3046  
 Russell AS, 584, 2011  
 Ryan LM, 2627

Ryckman C, 2310

## S

Sabbadini MG, 1109  
 Sadeghi C, 2845  
 Sah RL, 110, 689, 3382  
 Said-Nahal R, 523  
 Saïed A, 1594  
 Saijo S, 1890  
 Saito I, 3603  
 Saito K, 1239  
 Saito T, 486  
 Saito Y, 486  
 Sakellaropoulos N, 227  
 Salden M, 2146  
 Salemi S, 3291  
 Salisbury SR, 2294  
 Salmon JE, 460, 1930  
 Salmon M, 2472  
 Salomonsson S, 3187  
 Saltarelli M, 2942  
 Salter DM, 146  
 Salvarani C, 1467, 3219  
 Salvi R, 651  
 Sampey A, 103  
 Santos L, 103, 1881  
 Sanz I, 455  
 Sarkisian T, 2324  
 Sasaki M, 2555  
 Sasaki Y, 2819  
 Sato EI, 3168  
 Satoh M, 2990  
 Satoh S, 1766  
 Saulsbury FT, 2632, 2995  
 Saura R, 668  
 Sauvat S, 569  
 Savage COS, 2362  
 Savnik A, 2434  
 Sawada Y, 2682  
 Sayer AA, 1030, 3359  
 Schaible TF, 1504  
 Schanberg LE, 1390, 2402  
 Scharstuhl A, 3442  
 Schattenkirchner M, 1513  
 Schechtman J, 927  
 Schedel J, 859  
 Scheidig C, 2386  
 Scheja A, 2593  
 Scherb E, 2386  
 Scherer A, 157  
 Scherle PA, 119  
 Schett G, 2042, 3308  
 Schiffer LE, 495  
 Schink T, 3338  
 Schlegelmilch JG, 864  
 Schmidt KL, 1828  
 Schmidt RE, 3542  
 Schmidt TA, 110  
 Schnarr S, 270  
 Schned AR, 2541  
 Schneider H, 430  
 Schneider M, 157, 2224  
 Schneider R, 218  
 Schneider U, 3338  
 Schnitzer T, 3001  
 Schölmerich J, 97, 1504, 2713  
 Scholtens L, 2001

- Schonkeren JJM, 1841  
Schörle C, 3395  
Schottenfeld D, 2246  
Schrier D, 1582  
Schroeder HW Jr., 906  
Schulz A, 2042  
Schur PH, 944  
Schwartz BD, 2763, 3328  
Schwarz EM, 1779  
Scirè CA, 2999  
Scott CA, 3181  
Scott DGI, 46, 814  
Scott DL, 857  
Scott JK, 737  
Sebbough D, 3207  
Seedhom BB, 2865  
Seeliger S, 2622  
Seemayer CA, 859, 1873, 2069, 2788  
Seibl R, 642  
Seitz M, 863  
Sekut L, 3253  
Seldin MF, 906  
Sella EMC, 3168  
Selva-O'Callaghan A, 1169  
Senécal JL, 2082  
Senshu T, 2489  
Serrano I, 3544  
Seto H, 2682  
Setton LA, 2509  
Sfriso P, 2390  
Sgonc R, 2605  
Shahrara S, 3568  
Shakoor N, 1556  
Shamseddine A, 1468  
Sharma L, 3359  
Sharp JT, 21, 2997  
Shea B, 283  
Sheeran TP, 868  
Shibue T, 273  
Shigeta R, 906  
Shimizu M, 1271, 1762  
Shinawi M, 1149  
Shipkolye F, 2855  
Shi S, 2903  
Shiwen X, 1979  
Shiyama O, 3280  
Shnier R, 614  
Shoji T, 3061  
Shott S, 1556  
Showstack J, 289  
Shulman MJ, 791  
Shuster DJ, 2652  
Siau JL, 3140  
Sibilia J, 1093, 2019, 2240  
Sieper J, 780, 1126, 1374, 1667, 2224  
Sierakowski S, 1639  
Siergiejko Z, 1639  
Silman AJ, 46, 1462, 1686, 2615, 3518, 3615  
Silverman ED, 1469  
Silverman GJ, 1484  
Silvestri E, 1207  
Simkin PA, 3610  
Simmons DL, 2472  
Simms RW, 1478  
Simón AJ, 471  
Singh R, 583  
Skarstein K, 3187  
Skinner K, 2836  
Sletten K, 3266  
Slettjord CN, 1462  
Slifman NR, 319  
Sløetjes AW, 360, 1002  
Smeets RL, 2949  
Smeets TJM, 1162, 2132, 2155  
Smid M, 1109  
Smith C, 1901  
Smith EA, 798  
Smith O, 1408  
Smith R, 3253  
Smith S, 3615  
Smolen JS, 2042, 2501, 3308  
Snijders A, 1452  
Snowden J, 1464  
So A, 651  
Sokka T, 59, 313, 1808, 3613  
Solans-Lagué R, 1169  
Soleiman A, 2501  
Solis P, 2632, 2995  
Solomon DH, 2207  
Somers E, 1992  
Sonderstrup G, 2375  
Song J, 1521, 3359  
Song T, 2332  
Song YW, 1930, 2567  
Sopena-Sisquella JM, 1169  
Sørensen H, 1513, 1667, 2224  
Sorg C, 2622  
Sorrentino R, 866, 1385  
Sørskaar D, 2214  
Souta-Kuribara A, 1890  
Sovran H, 1223  
Sözeri O, 2779  
Spaepen A, 3377  
Specker C, 157  
Spector TD, 1024, 3112  
Spencer RGS, 1047  
Spiera H, 1159  
Spiera RF, 1159  
Spik G, 2197  
Spratt H, 3291  
Squires GR, 1261  
Stabler T, 675, 2942  
Stafford G, 1721  
Stanford MR, 807  
Steck E, 418  
Steen VD, 203, 516  
Steere AC, 534  
Stefansson K, 391  
Stefansson SE, 391  
Stein LD, 218  
Steiner G, 2042, 3159, 3308  
Stenlund H, 2741  
Stern MP, 1833  
Stevenson JT, 3328  
Stewart N, 1814  
Stewart WA, 2294  
Stoeken G, 1841  
Stohl W, 982, 3475  
Stoica C, 2275  
Stoll M, 3542  
Stoltenberg M, 2128  
Stone JH, 1160  
Stone M, 791  
Storm G, 2059  
Stramba-Badiale M, 266  
Strand V, 21, 442, 625, 2997  
Straub RH, 1504, 2713  
Strunk J, 1828  
Sturm B, 3253  
Stüssi E, 3377  
Su K, 3242  
Suarez-Almazor M, 280  
Sugai S, 2391  
Sugimoto M, 1521  
Sugiura H, 1647  
Sulik A, 1639  
Sumida T, 944, 3603  
Sun CK, 334  
Sun G, 927  
Sun X, 1742  
Sundarajan M, 2450  
Sundberg E, 2052  
Sunderkötter C, 2622  
Sundick RS, 2605  
Sundin U, 2741  
Sundström C, 1543  
Sutmoller RPM, 1452  
Suzuki T, 1647  
Svenungsson E, 2533  
Sweep FGJ, 1002  
Symmons DPM, 46, 1462, 3615  
Szalai AJ, 1602  
Szeto CC, 1326  
Szkudlarek M, 955, 2128
- T**
- Tacrolimus-Methotrexate  
Rheumatoid Arthritis Study  
Group, 2763, 3328  
Tada Y, 3780  
Taher A, 1468  
Tak PP, 271, 1162, 1762, 2132, 2155  
Takada K, 2645  
Takagishi K, 275  
Takahashi KA, 1562  
Takahi K, 2670  
Tam LS, 1326  
Tamaki K, 1652  
Tamamura H, 1271, 1762  
Tamayo E, 2353  
Tamura M, 1239  
Tanaka H, 1890  
Tanaka S, 2682  
Tanaka Y, 1239, 2682  
Tan AL, 1214  
Tan FK, 2585, 3295  
Tan L, 1249  
Tan SM, 982, 3475  
Tang J, 2888  
Tanigami A, 268  
Taniguchi N, 971  
Tanner SF, 1214  
Tardif J, 829  
Targoff IN, 2285  
Tarkowski A, 1693, 2881  
Taupin P, 1093  
Tektonidou MG, 732  
Temple MM, 3382  
Temporini F, 3509  
ten Cate R, 507  
Teoh LA, 35, 855  
Terada M, 1445, 2555  
Terauchi R, 1562  
ter Borg, EJ, 1797  
Tercero GM, 3295  
Terkeltaub R, 1302  
Terlain B, 3118  
Terslev L, 2434  
Terzidis I, 776  
Teshima R, 1732  
Tesser J, 927  
Tessier PA, 2310  
Thamrongsak U, 1249  
Thepen T, 1229  
Thiel A, 780  
Thiemermann C, 3544  
Thomas AMC, 2472  
Thomas JW, 2461  
Thomas R, 2660  
Thompson AE, 283  
Thompson KM, 3266  
Thompson RN, 3611  
Thompson SD, 3202  
Thomsen HS, 955  
Thomson GT, 2011  
Thomson W, 1398  
Thorburn CM, 2519  
Thorne C, 829  
Tian TX, 2916  
Tian X, 2916  
Tiitinen S, 3068  
Tijssen H, 1762  
Tillmann B, 660  
Timms AE, 2234, 2898  
Tochimoto A, 186  
Todesco S, 2390  
Toes REM, 858, 1452, 1841  
Toh L, 81  
Tokunaga K, 273  
Tolboom TCA, 858  
Tomita T, 2670  
Tonks ID, 2660  
Torensma R, 360  
Torp-Pedersen S, 2434  
Torres RJ, 2036  
Tortorella MD, 3304  
Torzilli PA, 1047  
Tóthfalusi L, 2163  
Toyoda T, 2865  
Tracey KJ, 876, 2052  
Traub L, 846  
Traynor A, 2697  
Tremblay JL, 370, 3300  
Triolo G, 728  
Trojanowska M, 798  
Trupin L, 3046  
Trysberg E, 2881  
Tsagias I, 776  
Tsao BP, 475, 737  
Tsokos GC, 1948  
Tsoras M, 3202  
Tsuchiya N, 273, 1930  
Tsui FWL, 791  
Tsui HW, 791

Tsuji W, 3230  
 Tumlin JA, 442  
 Turesson C, 54  
 Tweezer-Zaks N, 3298  
 Twine N, 3202  
 Tyndall A, 2593

## U

Ueki K, 2442  
 Uitterlinden AG, 1913  
 Ulbricht KU, 3542  
 Ulloa L, 876  
 Urowitz MB, 2067, 3159  
 Uthman I, 370, 1468, 3300  
 Utrecht Arthritis Cohort Study Group, 1797

## V

Vacca A, 1385  
 Vaiopoulos G, 227  
 Vaishnav A, 719  
 Valet G, 1332  
 van Booma-Frankfort C, 1797  
 van Bruggen MCJ, 1355  
 Vandal K, 2310  
 Van Damme N, 1015  
 van de Loo FAJ, 1002, 1750, 2949  
 van den Berg HM, 396  
 van den Berg WB, 255, 339, 360, 1002, 1750, 2489, 2949, 3442  
 van den Bersselaar LAM, 339  
 Van den Bosch F, 1015  
 Van den Bossche N, 1015  
 Vandenbroeck K, 2773  
 Van den Ende CHM, 2415  
 van den Hoogen FHJ, 857  
 van de Putte LBA, 857, 1762  
 van der Heijde D, 272, 1126, 3230  
 van der Heijden A, 2489  
 van der Horst-Bruinsma IE, 284  
 van der Kraan PM, 3442  
 van der Laken CJ, 269  
 van der Meer JWM, 1853  
 van der Pijl JW, 1355  
 van der Pouw Kraan TCTM, 2132  
 van der Sande JJ, 269  
 van der Veen MJ, 1797  
 van de Stadt RJ, 2996  
 van de Winkel JGJ, 1229  
 van de Zee R, 2001  
 Van Doornum S, 72, 2700  
 van Duijn CM, 1913  
 van Duivenvoorde LM, 1452  
 van Eden W, 1788, 2001  
 van Gaalen FA, 858, 1841, 2132  
 van Ginkel FW, 1602  
 van Ginkel K, 360  
 Vanhoutte PM, 2197  
 van Laar JM, 1463  
 van Leeuwen JPTM, 1913  
 van Lent PLEM, 255, 339, 360, 1002, 1750

van Loon ME, 2155  
 van Luijk WHJ, 507  
 van Meurs JB, 1913  
 van Riel PLCM, 339, 1762  
 van Roon JAG, 1229  
 van Rossum MAJ, 507  
 van Schaardenburg, 2415  
 van Soesbergen RM, 269, 507  
 Van Staa TP, 3224  
 van Suijlekom-Smit LWA, 507  
 van Venrooij WJ, 857, 2489, 2741  
 van Vollenhoven RF, 1500  
 van Vuuren AJ, 1229  
 Vanwanseele B, 3377  
 Varga J, 1767, 1964  
 Vargas E, 1158  
 Vasconcelos C, 1466  
 Vassallo A, 1109  
 Vaudo G, 2700  
 Vaughan TJ, 3253  
 Vauthier D, 3207  
 Veale DJ, 271, 1162, 3085  
 Veenstra RP, 1164  
 Verbeek S, 255  
 Verbeet NL, 2132  
 Verbruggen G, 1281  
 Verbruggen N, 1102  
 Verdrengh M, 1693  
 Vergin H, 1438  
 Vermes C, 1708  
 Vernon-Wilson E, 2472  
 Verstappen SMM, 1797  
 Verthelyi D, 1701  
 Verweij CL, 2132  
 Veys EM, 1015, 1281  
 Via CS, 1071  
 Vianen ME, 396  
 Vidal S, 824  
 Viemann D, 2622  
 Vignon E, 378  
 Vignon M, 378  
 Vilardell-Tarrés M, 1169  
 Vilim V, 675  
 Viljanen T, 3077  
 Villa AR, 471  
 Villa G, 1170  
 Villiger PM, 863  
 Vinje O, 2214  
 Viola S, 3509  
 Vis M, 2996  
 Vischer TL, 1420  
 Visco DM, 3452  
 Visconti KC, 2375  
 Visser H, 856  
 Visvanathan S, 737  
 Vitters EL, 3442  
 Vivarelli M, 1398  
 Vlachoyiannopoulos PG, 732  
 Vliet Vlieland TPM, 2415  
 Vogl T, 1676, 2622  
 Volanakis JE, 1602  
 Voll RE, 6  
 Volpe B, 2710  
 von der Mark K, 430  
 von der Recke P, 2434  
 von Landenberg P, 1939

Vos K, 1841  
 Vossenaar ER, 2489

## W

Wadell G, 2741  
 Wadsworth M, 1030, 3359  
 Wagenaar-Hilbers JPA, 2059  
 Wager RE, 3253  
 Wagner AD, 1468  
 Wagner EF, 3308  
 Wahren-Herlenius M, 2697, 3187  
 Wakefield RJ, 64, 285, 3039  
 Wakitani S, 268  
 Waksman BH, 1788  
 Walco GA, 2923  
 Waldman BA, 2509  
 Wallace CA, 218  
 Wallace DJ, 277, 719  
 Wallace GR, 807  
 Walsh DA, 2173  
 Walsh K, 3096  
 Walsh MB, 575  
 Walton R, 807  
 Wang AS, 689  
 Wang J, 1281  
 Wang N, 2585, 3295  
 Wang PS, 2207  
 Wang X, 495  
 Wanke L, 3046  
 Ward MM, 2519  
 Ward R, 370, 906, 3300  
 Warke VG, 1948  
 Warner E, 1770  
 Warner RE, 757  
 Warsi A, 2207  
 Watanabe M, 231  
 Watanabe N, 486  
 Waterman SA, 1167, 3597  
 Watrin A, 1594  
 Watts RA, 814  
 Wauben MHM, 2059  
 Wax S, 541  
 Weatherhead E, 2285  
 Weaver CT, 1602  
 Webb A, 1067  
 Weber M, 325  
 Weber RM, 418  
 Weber S, 3503  
 Webster ADB, 2146  
 Wechsler B, 3207  
 Wegener's Granulomatosis Etanercept Trial Research Group, 2299  
 Wei N, 1161  
 Weidekamm C, 325  
 Weill B, 3497  
 Weinberger A, 846  
 Weinblatt ME, 35, 576, 855, 944, 1493, 3013  
 Weisman MH, 35, 855  
 Weisman S, 1484  
 Welgus H, 1742  
 Welsh KI, 807  
 Wener MH, 906  
 Wernhoff P, 2332, 3584  
 Wesley R, 2285

Westendorp RGJ, 1841  
 White B, 2262  
 Whiteford ML, 2632, 2995  
 Whiteman M, 3140  
 Wick G, 2605  
 Wicks IP, 72, 81, 1177, 2700  
 Wien TN, 3266  
 Wigley FM, 2262  
 Wijngaarden S, 1229  
 Wilder RL, 906  
 Wiles NJ, 46  
 Williams CJ, 2627  
 Williams DA, 2916  
 Williams E, 3253, 3611  
 Williams GW, 3102  
 Williams K, 1833  
 Williams RO, 839  
 Wilson A, 81  
 Wilson D, 2173  
 Wilson JN, 90  
 Winter A, 418  
 Wise R, 2262  
 Wisemandle W, 2763, 3328  
 Witte T, 3542  
 Witteveen HJ, 1452  
 Wluka AE, 682  
 Wolbink GJ, 2996  
 Wolf RE, 3557  
 Wolfe F, 625, 1530, 2694, 2750  
 Wolfe R, 682  
 Wolvetang E, 1881  
 Wong B, 935  
 Wong M, 81  
 Wong PKK, 1177  
 Woo P, 2632, 2995, 3202  
 Woodburn J, 585  
 Woodham SE, 3518  
 Woods JM, 3568  
 Worda M, 2605  
 Wordsworth BP, 90, 2234, 2898  
 Worthington J, 3615  
 Worthington S, 2632, 2995  
 Wright EA, 560  
 Wright MO, 146  
 Wright TM, 193, 1363, 1956  
 Wu A, 2888  
 Wu D, 2509  
 Wu J, 3242  
 Wu Y, 3475  
 Wulffraat NM, 507, 2622

## X

Xiao HQ, 2262  
 Xiao X, 906  
 Xie C, 1080, 2343  
 Xiong M, 2585  
 Xu D, 982, 3475  
 Xu L, 1034, 2509  
 Xue JR, 1881

## Y

Yachie A, 2483  
 Yagüe J, 2632, 2995  
 Yamada A, 1445  
 Yamada S, 971  
 Yamakuchi M, 971

Yamamoto A, 2682  
Yamamoto K, 1117  
Yamamoto N, 3151  
Yamane I, 1732  
Yamane K, 1652  
Yamasaki D, 1732  
Yamashita S, 2442  
Yamazaki K, 3151  
Yan W, 1622  
Yang CD, 1622  
Yang G, 119  
Yang H, 2052  
Yang JM, 210  
Yao JQ, 2865  
Yao L, 585  
Yasuda M, 1239  
Yasuda T, 1271, 1762

Yasui N, 3603  
Yazici H, 2389  
Yazici Y, 2769, 3611  
Yelin E, 3046  
Yeoman S, 1814  
Yli-Kerttula T, 3077  
Yocum DE, 3328  
Yone K, 971  
Yonemura A, 3350  
Yoo DH, 1930  
Yoshida K, 3151  
Yoshie O, 2555  
Yoshikawa H, 2670  
Yoshizaki K, 1521  
Young F, 455  
Young V, 854  
Yu W, 1034

Yuan GH, 602  
Yung R, 746, 757

## Z

Zacks N, 1149  
Zahalka MA, 846  
Zanelli E, 1452  
Zanierato M, 2999  
Zapata-Zuñiga M, 471  
Zeidler HK, 270, 1468, 2224  
Zemmyo M, 2873  
Zerbini L, 1249  
Zeuner RA, 1701  
Zevin S, 571  
Zhang Y, 1034, 2898, 2903

Zhang Z, 746  
Zhou XD, 2652  
Zhou XJ, 1080, 2585  
Zhu J, 2275  
Zhu T, 2992  
Zien A, 3395  
Zimmer R, 860  
Zink A, 2224  
Zou J, 780  
Zühlsdorf S, 3338  
Zuniga A, 3296  
Zuniga R, 460  
Zuscik MJ, 1779  
Zusi FC, 2652  
Zwerina J, 2042  
Zwiderman AH, 507, 2415

## SUBJECT INDEX

*Arthritis & Rheumatism*. Volume 48, Numbers 1-12, 2003

### A

- AA amyloidosis, anti-TNF therapy in, 2019
- Abetimus sodium, LJP394 for prevention of renal flare in SLE, 442
- Acetaminophen, gastrointestinal toxicity and, 2074, 2075
- Activated protein C, anticardiolipin antibody reactivity with, 1622
- Activation-induced T cell-derived and chemokine-related cytokine/lymphotactin, expression in RA, 1838
- Activator protein 4 (AP-4), mediation of IL-1-stimulated TGF $\beta$ 1 expression in bovine articular chondrocyte cultures, 1569
- Activin A, in RA synovitis, 2442
- Adalimumab, RA, MTX treatment concomitant with, 35, 855
- ADAM-TS4, IL-1 induction of through activation of constitutively produced protein, 119
- Adenosine deaminase 1, in RA synovial fibroblasts, 668
- Adenosine receptors, MTX for inflammation inhibition and, 240
- Adherent synovial fluid cells, in RA, 1873
- Adhesion, integrin-mediated human chondrocyte adhesion to cartilage, 110
- Adhesion molecules, RA,  $\beta$ 1 integrin induces ICAM-1 and Fas on RA synoviocytes, 1239
- Adhesive capsulitis, intraarticular corticosteroids, supervised physiotherapy, or combined therapy for, 829
- Adipose tissue-derived stromal cells (ATSC), chondrogenic differentiation of in OA, 418
- Adjuvant-induced arthritis
- chemokine receptor expression and in vivo signaling pathways in rat joints, 3568
  - energy cost of in rats, 2979
  - immune regulation in, 1788
  - joint targeting of glucocorticoids with long-circulating liposomes, rat study, 2059
  - placental immunomodulator ferritin suppression of, 846
- Adolescents
- osteopenia in adolescents with early-onset JIA, 2214
  - Raynaud's phenomenon in children ages 12-15 years, 3518
- Adrenal gland, influence on anti-TNF treatment of RA patients, 1504
- African American population, OA, ethnic and sex differences in serum levels of cartilage oligomeric matrix protein, 675
- Age, OA, hip joint space and, 1041
- Aggrecan
- G1 domain cointernalizes with hyaluronan in bovine articular chondrocytes, 3431
  - immunogenicity/arthritisogenicity of G3 domain of, mouse study, 2959
  - inflammatory arthritis, type II collagen and aggrecan turnover at onset of, 3085
  - SpA, immunity to and, mouse study, 2903
- Aggrecanase 1 (ADAM-TS4), IL-1 induction of through activation of constitutively produced protein, 119
- Aging. *See also* Older adults
- chondrocyte survival reduced by oxidative stress, 3419
  - indentation testing of human cartilage, 3382
  - OA, development of in  $\alpha$ 1 integrin-deficient mice, 2873
  - RA, premature aging in, 2713
- Alendronate
- effect of on BMD in steroid-treated patients, 1102
  - multicentric reticulohistiocytosis treatment with, 3538
  - resistance to in Paget's disease, 2321
- Allergies, environmental factors in primary systemic vasculitis, 814
- Allodynia, FM, central sensitization in, 1420
- Altered peptide ligands, reduced production of IFN $\gamma$  and IL-10 by, 2375
- Alternative medicine. *See* Complementary and alternative medicine
- Alveolitis, leukotrienes in SSc-associated, 1478
- Amegakaryocytic thrombocytopenia, SSc, anti-thrombopoietin receptor autoantibody-induced and, 1647
- American College of Rheumatology
- 2002 Slide Competition winners, 2737
  - policy on disclosure of interest for journals, 873
  - presidential address, 869
- Amyloid-enhancing factor, mediates amyloid formation on fibroblasts, 1430
- Amyloidosis
- anti-TNF therapy in AA amyloidosis, 2019
  - in familial Mediterranean fever, MEFV and SAA1 genotypes and, 1149
  - infliximab for renal amyloidosis, 3298, 3299
  - TNF $\alpha$ , soluble receptor I, and -308 gene promoter polymorphism in, 3068
- Anakinra
- monitoring protocol for adverse effects, 2769
  - RA, large placebo-controlled safety study of, 927
  - RA, radiographic data from trials, 21, 2997
- Angiogenesis
- OA, inflammation and angiogenesis in, 2173
  - RA, Tie2 receptor tyrosine kinase regulates arthritis angiogenesis, 2461
- Angiography, coronary artery in SLE, 3168
- Animal models. *See names of specific animals*
- ANKH gene
- AS, genetic markers associated with, 791
  - CPPD crystal deposition disease, mutations in amino terminus, 2627
- Ankylosing spondylitis (AS)
- ANKH genetic markers associated with, 791
  - ANKH role in, mouse study, 2898
  - birth order and, 283, 284
  - etanercept treatment for, 1667, 3230
  - first American description of, 612
  - HLA haplotypes, B27 alleles, and, in Sardinia, 1385
  - IL1RN gene, single-nucleotide polymorphism in 3' region of, 2011
  - infliximab treatment, down-regulation of T cell cytokine response in, 780
  - infliximab treatment, long-term efficacy and safety of, 2224
  - loci controlling clinical manifestations of, 2234
  - MRI scoring system for spinal inflammation, 1126
  - pamidronate treatment, dose-response comparison, 583, 584
- Ansamycins, effects of geldanamycin on inflammatory cytokine production, 541
- Anti-B cell therapy, rituximab therapy and autoimmune disorders, 1484
- Anticardiolipin antibody
- activated protein C-reactive anticardiolipin antibodies, 1622
  - APS, diagnostic peptide for disease-associated anticardiolipin antibodies, 737
- Anti-CD40 ligand antibody, for lupus nephritis, 719
- Anti-CD154
- early vs. late treatment with in murine lupus nephritis, 2541
  - for murine SLE, 495
- Anticentromere antibodies, in SSc with limited cutaneous involvement, 203
- Anti-DNA topoisomerase I antibody, SSc, antibody levels correlate with disease severity and activity, 1363
- Anti-double-stranded DNA (anti-dsDNA) antibodies
- role of SmD1<sup>83-119</sup>-reactive T cells in generation of, 475
  - SLE and, 300

- Anti-endothelial cell antibody (AECA)  
 Behçet's disease,  $\alpha$ -enolase as target antigen of AECA in, 2025  
 SSc, apoptosis-inducing effect in, 2605
- Antifibrillar autoantibodies, antibodies to U3 small nucleolar RNP complex in SSc sclera, 210
- Antigen-induced arthritis, p53 regulation by macrophage migration inhibitory factor, 1881
- Antigens, cellular localization of in or on apoptotic blebs, 2080
- Anti-glucose-6-phosphate isomerase antibodies, RA, low prevalence of, 944
- Antidiabetic antibodies, autoantibodies inhibiting cholinergic neurotransmission neutralized by, 3597
- Antiinflammatory drugs, and arthritic cartilage, rat study, 1594
- Anti-interleukin-6 receptor, IL-6 receptor antagonist therapy for RA, 1471, 1521
- Antimalarial retinopathy  
 hydroxychloroquine dosage based on ideal body weight, 763  
 new American Academy of Ophthalmology recommendations on screening, 1764
- Antinuclear antibodies (ANAs)  
 in RA and SpA patients following infliximab treatment, 1015  
 SLE, polyreactive ANAs in lupus kidneys, mouse study, 2343  
 SSc, twin studies, 1956
- Antiphospholipid antibody  
 atherosclerosis reduction in mice by, 2974  
 binding to  $\beta_2$ GPI, 2111  
 fluvastatin effect on antiphospholipid antibody-mediated activity, mouse study, 3272  
 low molecular weight heparin plus aspirin vs. intravenous immunoglobulin for recurrent fetal loss, 728  
 parvovirus B19 infection and, in rheumatic disease, 1939
- Antiphospholipid syndrome (APS)  
 avascular necrosis in, 732  
 binding of antiphospholipid antibodies to  $\beta_2$ GPI, 2111  
 catastrophic, 3320  
 cytomegalovirus infection and, 3296  
 diagnostic peptide for disease-associated anticardiolipin antibodies, 737  
 Fc $\gamma$  receptor IIA polymorphism and, 1930  
 prevention of thrombosis in, 3004  
 valine/valine genotype at position 247 of  $\beta_2$ GPI gene in, 471
- Antiprotease antibodies, specificities, properties, and clinical significance of, 886
- Anti-SSA/Ro antibodies, disappearance of electrocardiographic abnormalities in first year in infants without congenital heart block, 266
- Anti-Th/To antibodies, in SSc with limited cutaneous involvement, 203
- Anti-tumor necrosis factor  $\alpha$  (anti-TNF $\alpha$ )  
 AA amyloidosis secondary to inflammatory arthritides, 2019  
 AS, long-term efficacy and safety of infliximab, 2224  
 infections and therapy with, 319, 1764, 3013  
*Listeria* infection as complication of therapy, 319, 1764  
 for multicentric reticulohistiocytosis, 864  
 RA, adalimumab and concomitant MTX treatment, 35, 855  
 RA, early TNF $\alpha$  blockade and synovial cell infiltrate, 2155  
 RA, eligibility of patients for major clinical trials of, 313, 3611  
 RA, hidden costs of, 868  
 RA, paraplegia in, 269  
 RA, *Salmonella* septicemia with anti-TNF antibody treatment, 1853  
 RA, sensitizes pituitary gland and favors adrenal androgen secretion, 1504  
 RA, susceptibility and HLA-DRB1-TNF haplotypes, 90  
 RA, tuberculosis risk and, 2122  
 in sarcoidosis, 3542
- Aortic aneurysm  
 in GCA, incidence and predictors of, 3522  
 in GCA, mortality of, 3532
- Aortic dissection  
 in GCA, incidence and predictors of, 3522  
 in GCA, mortality of, 3532
- Aortitis, unresolved issues in, 2406
- Apoptosis  
 cellular localization of antigens in or on apoptotic blebs, 2080  
 chondrocyte apoptosis induced by TNF $\alpha$  in mice, 2845  
 citrullinated peptide autoantibody production requires defects in regulation of B cell apoptosis, mouse study, 2353  
 heat shock protein 70 prevents nitric oxide-induced apoptosis in articular chondrocytes, 1562  
 OA, chondrocyte apoptosis in, 1166  
 RA,  $\beta_1$  integrin induces ICAM-1 and Fas on RA synoviocytes, 1239  
 RA, bone morphogenetic proteins modulated by, 2807  
 RA, osteoclastogenesis suppression by induction of, 3350  
 serum amyloid P (SAP) and, 248  
 SLE, apoptotic neutrophils in, 2888  
 SSc, apoptosis-inducing effect of AECAs, 2605
- APRIL, local production of in inflammatory arthritis, 982
- Aquaporins, in SS, 1167
- Arterial elasticity, RA, reduced in, 81
- Arterial thickening, RA and, 3061
- Arthritis & Rheumatism*, new policy on disclosure of interest for ACR journals, 873
- Arthropathy  
 in juvenile hemochromatosis, 227  
 in SLE, Jaccoud's arthropathy, 147
- Artificial neural network, to predict cancer in patients with inflammatory myopathy, 1168
- Aspergillus fumigatus*, anti-TNF $\alpha$  therapy and infection with, 3013
- Aspirin  
 COX-2 inhibitors and cardiovascular disease and, 12  
 low molecular weight heparin plus aspirin for recurrent antiphospholipid antibody-associated fetal loss, 728
- Assessment, of disease activity with power Doppler sonography, 285
- Astrocytic damage, in neuropsychiatric lupus, 2881
- Atherosclerosis  
 antiphospholipid antibody and prevention of in mice, 2974  
 association with inflammation markers, 1833  
 RA, inflammation and bone resorption as independent factors, 3061  
 RA, premature aging in, 2713  
 RA, reduced arterial elasticity in, 81  
 RA, screening for in patients, 72
- Atlantoaxial subluxations, cervical spine disorders in RA, 1808
- Autoantibodies. *See names of specific autoantibodies*
- Autoimmune diseases  
 ecotropic murine leukemia viruses and exogenous mouse mammary tumor viruses and pristane-induced lupus, 2900  
 high-dose cyclophosphamide therapy without stem cell rescue, 1463  
 HLA-DQA1 not correlated with microchimerism, 2567  
 hydroxychloroquine safety in pregnant patients with connective tissue diseases, 3207  
 low prevalence of antibodies to glucose-6-phosphate isomerase in, 944  
 rituximab therapy and, 1484  
 ultraviolet radiation and expression of autoimmune muscle disease, 2285
- Autoimmune exocrinopathy, resembling SS in mice with autoreactive CD4+ T cells, 3603
- Autoimmune thrombocytopenia, rituximab therapy for, 1484
- Autoimmunity  
 C-reactive protein as regulator of, 1475  
 disposal of dying cells and, 6
- Autologous chondrocyte implantation (ACI), integrin-mediated human chondrocyte adhesion to cartilage, 110
- Avascular necrosis, in APS, 732

## B

- B cell lymphoma, rituximab for, 1484
- B cells
  - citruinated peptide autoantibody production requires defects in regulation of B cell apoptosis, mouse study, 2353
  - SLE, anti-CD154 treatment, effect on murine B cells, 495
  - SLE, B cell depletion by rituximab, 455
- B lymphocyte stimulator
  - expression in SLE, 3475
  - inflammation and, 882
  - local production of in inflammatory arthritis, 982
  - LymphoStat-B human monoclonal antibody against, 3253
- B lymphocytes, RA, depletion in, 2146
- Bacteria. *See also names of specific bacteria*
  - RA, bacterial peptidoglycan activation of synovial fibroblasts via Toll-like receptor signals, 642
- Behçet's disease
  - AECA against  $\alpha$ -enolase in, 2025
  - thrombotic thrombocytopenic purpura in, 1468
  - TNF polymorphisms in, 807
- Benzodiazepine, treatment of mouse SLE with, 757
- Benzoquinone ansamycins, effects of geldanamycin on inflammatory cytokine production, 541
- $\beta$ 1 integrin, induces ICAM-1 and Fas on RA synoviocytes, 1239
- $\beta$ <sub>2</sub>-Glycoprotein I ( $\beta$ <sub>2</sub>GPI), binding of antiphospholipid antibodies to, 2111
- $\beta$ <sub>2</sub>-Glycoprotein I gene, APS, valine/valine genotype at position 247 of, 471
- BG9588, anti-CD40 ligand antibody for lupus nephritis, 719
- Bicipital tendon sheath, Doppler sonography of in RA and degenerative shoulder disorders, 1828
- BIOBADASER database, tuberculosis risk with anti-TNF therapy for RA, 2122
- Biomarkers
  - AS, *ANKH* genetic markers, 791
  - atherosclerosis association with inflammation markers, 1833
  - pulmonary artery hypertension in patients with SSc, N-terminal pro-brain natriuretic peptide and effects of calcium-channel blockers, 3503
  - RA, galectin 3 and its binding protein in, 2788
  - relapsing polychondritis, urinary type II collagen neopeptide as outcome measure for, 2942
  - SLE, blood lipids as marker of disease activity in, 2533
- Bioreactor-derived hyaline cartilage, MRI analysis of, 1047
- Birth order
  - AS, effect on, 283, 284
  - JIA, lack of association, 2989
- Bisphosphonates
  - minodrinic acid treatment and BMD in rats with collagen-induced arthritis, 1732
  - multicentric reticulohistiocytosis treatment with alendronate, 3538
  - resistance to in Paget's disease, 2097, 2321
- Blood dendritic cell antigen (BDCA), expression of in SLE, 2524
- Blood lipids, as marker of disease activity in SLE, 2533
- B-mode ultrasonography
  - RA, with Doppler sonography for hand and finger joint imaging, 325
  - SpA, peripheral enthesitis by B-mode ultrasonography combined with power Doppler, 523
- BMS-345541, I $\kappa$ B kinase inhibitor blocks inflammation and destruction in collagen-induced arthritis in mice, 2652
- Body mass index (BMI), association with knee OA, 1024
  - Body weight
  - hand OA, weight from birth to middle age and, 1030
  - knee OA, BMI associated with, 1024
- Bone
  - JIA, osteopenia in adolescents with early onset, 2214
  - oncostatin M-induced growth plate damage, mouse study, 1750

## Bone (cont'd)

- osteoblast MMP-13 production regulated by T cells, 993
- osteoprotegerin and TNF-mediated generalized bone loss, mouse study, 2042
- Paget's disease, resistance to bisphosphonates in, 2097, 2321
- Paget's disease, serum osteoprotegerin and RANKL in, 824
- RA, atherosclerosis and bone resorption, 3061
- RA, infliximab treatment and early changes in bone metabolism, 2996
- RA, premature aging in, 2713
- Bone damage
  - APS, avascular necrosis in, 732
  - hepatitis C-associated osteosclerosis, 268
  - oncostatin M-induced growth plate damage, mouse study, 1750
  - RA, laser microdissection analysis of gene expression in synovium, 97
  - RA, MCP joint anatomic factors in early RA synovitis and bone erosion, 1214
  - RA, MRI for evaluation of, 585
  - RA, synovitis and, MRI study, 64
- Bone loss
  - alendronate effects on BMD in steroid-treated patients, 1102
  - osteoblast MMP-13 production regulated by T cells, 993
  - RA, atherosclerosis and bone resorption, 3061
- Bone marrow-derived mesenchymal stem cells (BMSC), chondrogenic differentiation of in OA, 418
- Bone mineral density (BMD)
  - alendronate effects on in steroid-treated patients, 1102
  - in juvenile DM, 2294
  - osteoprotegerin and TNF-mediated generalized bone loss, mouse study, 2042
  - as predictor of vertebral fractures following glucocorticoid therapy, 3224
- Bone morphogenetic proteins
  - experimental OA, reduction of osteophyte formation and synovial thickening by overexpression of TGF $\beta$ /bone morphogenetic protein inhibitors, 3442
  - OA articular chondrocytes, bone morphogenetic protein 6 in, 2501
  - in synovium in chronic arthritis, 2807
- Bone turnover, IL-6 and, 1177
- Bovine studies
  - aggrecan G1 domain coinertializes with hyaluronan in articular chondrocytes, 3431
  - mechanical stress-induced depolymerization of hyaluronan, reactive oxygen species and, 3151
- Brachial artery flow-mediated dilatation (FMD), in RA, 72

## C

- C48, placental immunomodulator ferritin suppression of experimental arthritis, 846
- Caffeine
  - RA, coffee consumption and RA risk, 3055
  - RA, decaffeinated coffee and, 862
  - RA, MTX treatment efficacy and, 571
- Calcinosis, tumoral calcinosis associated with sarcoidosis, 1770
- Calcium-channel blockers, pulmonary artery hypertension, diagnostic marker for in patients with SSc, 3503
- Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease
  - ANKH* mutations in two US families with, 2627
  - neuropathic joint image, 1170
- Cancer
  - anti-TNF therapy, lymphoma after, 2389
  - body pain and risk of cancer and reduced cancer survival, 1686
  - inflammatory myopathy, artificial neural network to predict cancer in patients with, 1168
  - pseudoscleroderma associated with TGF $\beta$ 1-producing advanced gastric carcinoma, 1766

## Cancer (cont'd)

- RA, lymphoma subtypes and, 1543
- RA, malignant lymphoma risk in patients and first-degree relatives, 963
- RA, rate of death due to leukemia/lymphoma, 2694
- rituximab for B cell lymphoma, 1484
- SS, extrasalivary lymphoma development, 3181
- Capillaroscopy, Raynaud's phenomenon and, 3023
- Caprine study, stem cell therapy in OA model, 3464
- Cardiovascular disease
  - antiphospholipid antibody and atherosclerosis reduction in mice, 2974
  - atherosclerosis, association with inflammation markers, 1833
  - COX-2 inhibitors and aspirin and, 12
  - infants, disappearance of electrocardiographic abnormalities in first year of life in infants without congenital heart block at birth, 266
  - RA, atherosclerosis screening in, 72
  - RA, inflammation and bone resorption as independent factors of atherosclerosis, 3061
  - RA, premature aging and atherosclerosis, 2713
  - RA, reduced arterial elasticity in, 81
  - SLE, hospitalization for coronary artery disease in, 2519
  - SLE, risk factors in women, 3159
  - SSc, common glutathione S-transferase gene variations and, 854

## Cartilage

- aggrecanase 1 (ADAM-TS4), IL-1 induction and, 119
- antiinflammatory drugs and arthritic cartilage, rat study, 1594
- blood-induced joint damage, dog study, 396
- CD44 in MMP induction by fibronectin fragment, 1271, 1763
- control of normal cartilage homeostasis by IL-1RII, 1281
- extracellular nucleotide metabolism and signaling in joint disease, 2722
- hydrostatic pressure in matrix turnover in, 2865
- immunogenicity/arthritisogenicity of G3 domain of cartilage aggrecan, mouse study, 2959
- indentation testing of, 3382
- inflammatory arthritis, type II collagen and aggrecan turnover at onset of, 3085
- insulin-like growth factor binding protein 3 (IGFBP-3) synthesis in human articular cartilage cultures, 410
- integrin-mediated human chondrocyte adhesion, 110
- leptin and systemic and local regulation of articular cartilage metabolism, 3009
- molecular phenotyping of human chondrocyte cell lines T/C-28a2, T/C-28a4, and C-28/12, 3395
- OA, bone morphogenetic protein 6 in articular chondrocytes, 2501
- OA, cartilage repair by cell-mediated gene therapy, rat study, 430
- OA, development of in  $\alpha 1$  integrin-deficient mice, 2873
- OA, focal lesion development and molecular matrix changes, 1261
- OA, hyaluronic acid plus phospholipid in experimental OA, rabbit study, 1923
- OA, immunologic intervention in pathogenesis, 602
- OA, key role of leptin in, 3118
- OA-like changes in articular cartilage in knee and temporomandibular joint of mice with *cho* gene, 2509
- OA, mitochondrial respiratory activity in human chondrocytes, 700
- OA, MMP-1 gene expression, regulation by SAF-1, 134
- OA, MRI-based T and Z scoring of cartilage loss, 2829
- OA, RANTES production by articular chondrocytes, 278
- OA, tachykinin expression in, 146
- OA, tissue engineering and gene therapy approach, 709
- proteoglycan degradation after injurious compression of, 1292
- RA, p16 induction at sites of cartilage invasion in SCID mouse coimplantation model of, 2069
- RA, synovial fluid exoglycosidases and cartilage glycosaminoglycan depletion in, 2163

## Cartilage (cont'd)

- relapsing polychondritis, urinary type II collagen neoepitope as outcome measure for, 2942
- spinal cord injuries, cartilage atrophy in knees of patients with, 3377
- Cartilage degradation
  - furin-like enzymes and, 1057
  - immune complex-mediated arthritis, Fc $\gamma$  receptors and, 255
  - OA, endothelin 1 and, 2855
  - OA, hyaluronic acid plus phospholipid in experimental OA, rabbit study, 1923
  - TNF $\alpha$  combined with oncostatin induces, 3404
- Cartilage intermediate-layer protein, as insulin-like growth factor 1 antagonist, 1302
- Cartilage oligomeric matrix protein, OA, ethnic and sex differences in serum levels of, 675
- Cartilage repair, by cell-mediated gene therapy, rat study, 430
- Catastrophic antiphospholipid syndrome (CAPS), 3320
- Caucasian population
  - OA, ethnic and sex differences in serum levels of cartilage oligomeric matrix protein, 675
  - prevalence of hand OA in China vs. US, 1034
- CCR2, T cell-mediated response during SLE flare and, 3487
- CCR5, inflammatory arthritis, genetic variation in CCR5 and clinical outcome, 3615
- CD4+ T cells
  - role of stromal cell-derived factor 1 in CD4+ T cell migration, 2472
  - SS, autoreactive CD4+ T cells and autoimmune exocrinopathy, 3603
- CD8+ T cells
  - role of stromal cell-derived factor 1 in CD8+ T cell migration, 2472
  - in SSc lung disease, 2262
- CD22, ligand expression in murine SLE, 1612
- CD25, collagen-induced arthritis, CD25+ cell depletion and disease severity in, mouse study, 1452
- CD27<sup>high</sup> plasma cells, SLE disease activity and, 1332
- CD34, CD34-selected vs. unmanipulated grafts for severe RA, 1463
- CD44
  - aggrecan G1 domain cointernalizes with hyaluronan in bovine articular chondrocytes mediated by, 3431
  - in MMP induction by fibronectin fragment, 1271, 1763
- CD64-ricin A, RA, elimination of macrophages by Fc $\gamma$  receptor-directed immunotoxin, 1229
- Celecoxib, comparison of efficacy with rofecoxib for OA, 3102
- Cell clearance, apoptotic, in SLE, 2888
- Central sensitization, in FM, 1420
- Cervical spine disease, in RA, 1775, 1808
- Chemokine receptors
  - adjuvant-induced arthritis, expression in, 3568
  - SLE, CCR2 and CXCR3 in T cell-mediated response during disease flare, 3487
- Children. *See also* Juvenile
  - body pain in, predicting, 2615
  - congenital heart block, prevention of recurrence with intravenous immunoglobulin and corticosteroid therapy, 280, 281
  - electrocardiographic abnormalities, disappearance in first year in infants without congenital heart block, 266
  - FM, temperament and stress response in children with juvenile primary FM syndrome, 2923
  - osteopenia in adolescents with early-onset JIA, 2214
  - pain in, pathologic, 2402
  - polyarticular arthritis, pain in children, 1390
  - predicting widespread body pain among children, 2615
  - Raynaud's phenomenon in children ages 12-15 years, 3518
  - uveitis, long-term outcome of etanercept therapy, 2079
- Chinese population, prevalence of hand OA in China vs. US, 1034
- cho* gene, OA-like changes in articular cartilage in knee and temporomandibular joint of mice, 2509

- Cholinergic neurotransmission, antiidiotypic antibodies neutralize autoantibodies that inhibit, 3597
- Chondrocytes
- aggrecan G1 domain cointernalizes with hyaluronan in bovine chondrocytes, 3431
  - aggrecanase 1 (ADAM-TS4), IL-1 induction and, 119
  - AP-4 mediation of IL-1-stimulated TGF $\beta$ 1 expression in bovine chondrocyte cultures, 1569
  - apoptosis induced by TNF $\alpha$  in mice, 2845
  - extracellular nucleotide metabolism and signaling in joint disease, 2722
  - heat shock protein 70 prevents nitric oxide-induced apoptosis in, 1562
  - high binding capacity of cyclophilin B to heparan sulfate proteoglycans and release from cell surface by MMP, 2197
  - inhibition of hypochlorous acid-induced toxicity, 3140
  - molecular phenotyping of human chondrocyte cell lines T/C-28a2, T/C-28a4, and C-28/I2, 3395
  - multilineage differentiation of, 1315
  - OA, bone morphogenetic protein 6 in chondrocytes, 2501
  - OA, cartilage intermediate-layer protein as insulin-like growth factor 1 antagonist, 1302
  - OA, chondrocyte apoptosis in, 1166
  - OA, chondrogenic differentiation of mesenchymal stem cells, 418
  - OA, immunologic intervention in pathogenesis, 602
  - OA, integrin-mediated human chondrocyte adhesion to cartilage, 110
  - OA, key role of leptin in, 3118
  - OA, mitochondrial respiratory activity in, 700
  - OA, RANTES production by articular chondrocytes, 278
  - OA, substance P and neurokinin 1 (NK1) in mechanotransduction, 146
  - oxidative stress in aging reduces survival of, 3419
  - regulation of extracellular signal-regulated kinase activity in, 689
  - signaling of NO induction by leptin and IFN $\gamma$ , in vitro study, 404
  - stimulation by combination of insulin-like growth factor 1 and osteogenic protein 1, 2188
- Chondrodysplasia gene, OA-like changes in articular cartilage in knee and temporomandibular joint of mice and, 2509
- Chronic fatigue syndrome, in macrophagic myofasciitis (MMF), 569
- Churg-Strauss syndrome, artificial neural network to predict cancer in patients with inflammatory myopathy, 1168
- Citrullinated peptides
- citrullinated peptide autoantibody production requires defects in regulation of B cell apoptosis, mouse study, 2353
  - RA, antibodies against cyclic citrullinated peptide predict development, 2741
  - RA, anti-cyclic citrullinated peptide antibody in early RA, 857
  - RA, citrullination of synovial proteins in murine RA models, 2489
- CL154C, APS, diagnostic peptide for disease-associated anticardiolipin antibodies, 737
- Clinical trials
- interpretation of methodology, 2693
  - OA, evaluation of clinical trials in, 3001
  - RA, comparison of outcome measures, 3031
  - RA, inclusion criteria for, 313, 3611
  - RA, MTX dosage and mode of administration in, 863
  - TNF $\alpha$  antagonists, distributions of clinical responses to, 1500
- Coffee, RA risk and consumption of, 3055
- Cold agglutinin disease, 2738
- Collagen
- furin-like enzymes and cartilage degradation, 1057
  - inflammatory arthritis, type II collagen and aggrecan turnover at onset of, 3085
  - OA, type II collagen fragments in synovial fluid, 3130
  - SSc, connective tissue growth factor/insulin stimulation of collagen synthesis in, 798
- Collagen (*cont'd*)
- SSc, Th2 cells inhibit collagen synthesis by dermal fibroblasts, 2593
  - SSc, TNF receptor p55-mediated signaling in pathogenesis, 1117
  - type I collagen gene expression in murine fibroblasts, 2275
- Collagen-induced arthritis
- BMS-345541 I $\kappa$ B kinase inhibitor blocks inflammation and destruction in, 2652
  - CD25+ cell depletion and disease severity in, mouse study, 1452
  - comparative genetic analysis between collagen-induced arthritis and pristane-induced arthritis, rat study, 2332
  - counteracting high mobility group box chromosomal protein 1 in mice and rats, 2052
  - FR167653 inhibition of p38 MAPK in rats, 2670
  - minodrinic acid treatment and BMD, rat study, 1732
  - platelet endothelial cell adhesion molecule 1 and accelerated onset of in mice, 3280
  - rosiglitazone treatment of, 3544
  - soluble IL-1 receptor accessory protein gene transfer for amelioration of, 2949
  - VEGF-B role in, 2660
- Combination therapy
- GCA, MTX with corticosteroids, 1158, 1159
  - RA, MTX with adalimumab, 35, 855
  - RA, MTX with tacrolimus, 2763
  - SSc, oral cyclophosphamide and prednisolone in early diffuse, 2256
- Comorbidity, RA, mortality and disease severity in, independent of comorbidity, 2425
- Complementary and alternative medicine, OA, willow bark extract as, 278, 280
- Complementary DNA, DNA microarray analysis, 860, 861
- Compression fractures, osteoporotic vertebral, intravertebral clefts in, 1414
- Computed tomography (CT)
- juxtaarticular osteoid osteoma misdiagnosis, 776
  - pulmonary rheumatoid nodules in etanercept-treated patient, 2077
- Congenital heart block
- prevention of recurrence with intravenous immunoglobulin and corticosteroid therapy, 280, 281
  - SLE development with, 2697
- Connective tissue diseases, hydroxychloroquine safety in pregnant patients with, 3207
- Connective tissue growth factor, SS, connective tissue growth factor/insulin stimulation of collagen synthesis in, 798
- Coronary artery angiography, in SLE, 3168
- Coronary heart disease. *See* Cardiovascular disease
- Corticosteroids
- adhesive capsulitis of the shoulder, intraarticular corticosteroids for, 829
  - GCA, MTX with, 1158, 1159
  - GCA, vision loss in patients treated with alternate-day corticosteroids, 1159
  - predictors of vertebral fractures after therapy with, 3224
  - prevention of congenital heart block with intravenous immunoglobulin and corticosteroid therapy, 280, 281
- Cost. *See* Energy cost; Medical costs
- C-reactive protein
- in glomerular immune deposits, 460
  - as regulator of autoimmunity and inflammation, 1475
  - SLE, delayed onset in mice expressing human C-reactive protein transgene, 1602
- Criteria
- FM, ACR classification criteria, 276, 277
  - RA, inclusion criteria for major clinical trials, 313
  - SLE, ACR revised classification criteria, 2067
- Crk-associated substrate lymphocyte type, RA in mice and humans, 1890

Cryoglobulinemia  
 hepatitis C-associated, IFN $\alpha$  and ribavirin treatment and, 580  
 pseudoleukocytosis in, 3000  
*Cryptococcus neoformans*, anti-TNF $\alpha$  therapy and infection with, 3013  
*CTLA4* gene, SS, gene expression in salivary gland in, 174  
 CXC receptor 3  
   lupus flare, T cell-mediated response during, 3487  
   SS, expression of in salivary gland lesions, 2390  
 Cyclooxygenase 2 (COX-2), selective inhibition of COX-2-generated  
 prostaglandin E<sub>2</sub> synthesis in RA synoviocytes by taurine chlora-  
 mine, 1551  
 Cyclooxygenase 2 (COX-2) inhibitors  
   aspirin and cardiovascular disease and, 12  
   comparing efficacy of for OA, 3102  
   uncoupling of mitochondria in intact cells, 1438  
 Cyclophilin B, in chondrocyte and cartilage pathobiology, 2197  
 Cyclophosphamide  
   high-dose cyclophosphamide therapy without stem cell rescue for  
   severe refractory autoimmune illnesses, 1463  
   lupus nephritis, low-dose vs. high-dose, 1466  
   SLE, high-dose treatment without stem cell transplantation in, 166  
   SLE-associated type B insulin resistance syndrome, 1067  
   SSc, combination oral cyclophosphamide and prednisolone in early  
   diffuse SSc, 2256  
 Cytokines  
   AS, down-regulation of T cell cytokine response in infliximab-  
   treated, 780  
   elicited by T cell epitopes from synovial autoantigen, 2375  
   FCP: bioinformatic tool assisting in PubMed searches, 2083  
   geldanamycin, effects on production of, 541  
   high mobility group box chromosomal protein 1 as, 876, 971  
   I $\kappa$ B kinase 2 and cytokine production in RA, 1901  
   IL-6 and inflammatory arthritis and bone turnover, 1177  
   infections and anti-TNF $\alpha$  therapy, 3013  
   lupus nephritis, expression of urinary cytokine genes in, 1326  
   OA, immunologic intervention in pathogenesis, 602  
   oncostatin M combined with TNF $\alpha$  induces cartilage damage and  
   MMP expression, 3404  
   PsA, cytokine gene polymorphisms and susceptibility and severity,  
   1408  
   RA, bone morphogenetic proteins regulated by proinflammatory  
   cytokines, 2807  
   RA, IL-17 in, 594  
   in rheumatoid nodules, 334  
 Cytomegalovirus infection, APS and, 3296

## D

Degenerative shoulder disorders, Doppler sonography of bicipital  
 tendon sheath in RA and, 1828  
 Dehydroepiandrosterone (DHEA), SLE, sex hormones and, 2100  
 Demyelination, RA, anti-TNF $\alpha$  therapy, paraplegia and, 269  
 Dendritic cells  
   dendritic cell-associated C-type lectin DC-SIGN expression in RA  
   synovium, 360  
   human apoptotic and necrotic neutrophils, effect of on, 2362  
   SLE, IFN $\alpha$  production by plasmacytoid dendritic cells in, 2524  
   SLE, IFN $\alpha$ -induced dendritic cell differentiation abrogated by in-  
   travenous immunoglobulin, 3497  
 Depression, temperament and stress response in juvenile primary FM  
 syndrome, 2923  
 Dermatomyositis (DM), global surface ultraviolet radiation intensity  
 and, 2285  
 Dexamethasone, effect on arthritic cartilage, rat study, 1594  
 Diagnosis, of early arthritis, 856, 857  
 Differentiation plasticity, of clonal populations of adult human artic-  
 ular chondrocytes, 1315  
 Dimethylarginine, in secondary Raynaud's phenomenon, 1902

Disability  
   JIA, predictors for in, 3509  
   RA, anti-TNF therapy and paraplegia, 269  
   RA, etanercept use and employment outcomes, 3046  
   RA, measuring parenting disability in women with, 935  
   vocational rehabilitation and reduction of job loss, 3212  
 Disc degeneration, risk factors for progression of lumbar, 3112  
 Disease activity  
   RA, HLA class II genes and, 2779  
   SLE, blood lipids and TNF $\alpha$  activity in, 2533  
   SLE, CD27<sup>high</sup> plasma cells and, 1332  
   SSc, topoisomerase I antibody levels and, 1363  
 Disease flare  
   SLE, 581, 582  
   SLE, CCR2 and CXCR3 in T cell-mediated response during, 3487  
   SLE, LJP394 for prevention of renal flare, 442  
 Disease-modifying antirheumatic drugs (DMARDs). *See also names of  
 individual drugs*  
   inflammatory polyarthritis, radiographic outcome and, 46  
   monitoring protocol for adverse effects, 2769  
   RA, early treatment with, 1  
   RA, five-year followup of early DMARD vs. pyramid approach,  
   1797  
 Disease severity  
   collagen-induced arthritis, CD25<sup>+</sup> cell depletion and disease sever-  
   ity in, mouse study, 1452  
   JIA, predictors for radiographic progression, radiographic damage,  
   and disability in, 3509  
   PsA, cytokine gene polymorphisms and, 1408  
   RA, mortality associated with, independent of comorbidity, 2425  
   RA, polymorphism in stromelysin 1 (MMP-3) promoter gene, 2695  
   relapsing polychondritis, urinary type II collagen neoepitope as  
   outcome measure for, 2942  
   SSc, *IL1A* polymorphisms in Japanese patients, 186  
   SSc, topoisomerase I antibody levels and, 1363  
 Disease status  
   JIA, radiologic features in, 507  
   Modified Disease Activity Score vs. radiologic progression as indi-  
   cator, 272  
   power Doppler sonography for disease activity assessment, 285  
 DNA  
   in epidermal basement membrane in lupus nephritis, 1355  
   inflammatory arthritis, influence of DNA motifs on, mouse study,  
   1701  
   microarray analysis, 860, 861  
   Dog studies, blood-induced joint damage, 396  
 Doppler sonography  
   of bicipital tendon sheath in RA and degenerative shoulder disor-  
   ders, 1828  
   for disease activity assessment, 285  
   RA, hand and finger joint imaging with, 325  
   RA, vs. MRI for synovial inflammation, 2434  
   SpA, peripheral enthesitis by B-mode ultrasonography combined  
   with power Doppler, 523  
 Dosage  
   of cyclophosphamide in lupus nephritis, efficacy and, 1466  
   of hydroxychloroquine based on ideal body weight, 763  
   of MTX in clinical trials, 863  
 Drugs. *See also names of individual drugs*  
   add-on or step-up trials for new drug development, 1481  
   availability of drugs disclosed by manufacturers, 2389  
 Dyslipoproteinemia, disease activity in SLE and, 2533

## E

Early growth response 1, RA, expression of TIMP-1 in synovial  
 fibroblasts and, 348  
 Education, arthritis self-management education programs, 2207

- Efficacy**  
 assessing efficacy and safety of treatments, 1781  
 questionnaire measures index to distinguish, 625
- Elderly. See Older adults**
- Electrocardiogram**, disappearance of electrocardiographic abnormalities in first year of life in infants without congenital heart block at birth, 266
- Elution**, polyreactive ANAs in lupus kidneys by urea-based elution, mouse study, 2343
- Employment**  
 RA, employment outcomes and etanercept use, 3046  
 vocational rehabilitation and reduction of job loss, 3212
- Endogenous retroviruses**, ecotropic murine leukemia viruses and exogenous mouse mammary tumor viruses and pristane-induced lupus, 2900
- Endothelial function**, combination oral cyclophosphamide and prednisolone in early diffuse SSc, 2256
- Endothelin**  
 OA, endothelin 1 and cartilage degradation, 2855  
 in secondary Raynaud's phenomenon, 1902  
 in systemic rheumatic disease, 1190
- Endothelin receptor antagonists**, in systemic rheumatic disease, 1190
- Energy cost**, of adjuvant-induced arthritis in rats, 2979
- Engineered neocartilage**, MRI analysis of, 1047
- $\alpha$ -Enolase protein**, as target antigen of AECA in Behçet's disease, 2025
- Enthesitis**  
 Second International Enthesitis Workshop report, 896  
 SpA, by B-mode ultrasonography combined with power Doppler, 523
- Environmental factors**  
 global surface ultraviolet radiation intensity and autoimmune muscle disease, 2285  
 in primary systemic vasculitis, 814
- Epidermal basement membrane**, lupus nephritis, deposition of nucleosomal antigens in, 1355
- Epidermal growth factor**, SSc, resistance to stimulation by, 1652
- Epitope spreading**, in SLE, 582
- Epitopes**  
 cytokines elicited by T cell epitopes from synovial autoantigen, 2375  
 immunogenicity/arthritisogenicity of G3 domain of cartilage aggrecan, mouse study, 2959
- Epstein-Barr virus**, RA, quantitative assay using real-time PCR, 1223
- Erosion**, RA, radiographic data from trials, 21, 2997
- Erosion volumes**, RA, computerized MRI erosion volumes in, 614
- Errata**, 284, 855, 1763, 2995
- Erysipelothrix rhusiopathiae*** septic arthritis, 1156
- ESE-1**, in RA, 1249
- Estradiol**, SLE, sex hormones and, 2100
- Estrogen receptor  $\alpha$  gene**, radiographic knee OA and, 1913
- Etanercept**  
 acute injection site reaction, 2078  
 AS, trials of, 1667, 3230  
 in hyperimmunoglobulinemia D, 2645  
 JIA, efficacy according to onset type, 1093  
 JRA, long-term efficacy and safety of, 218  
*Listeria* infection as complication of therapy, 319, 1764  
 monitoring protocol for adverse effects, 2769  
 pulmonary rheumatoid nodules and, 2077  
 RA, employment outcomes and use of, 3046  
 RA, etanercept-induced lupus-like syndrome in, 1165  
 RA, MTX plus, 1493  
 RA, radiographic data from trials, 21, 2997  
 RA, tuberculosis risk and, 2122  
 uveitis in children, long-term outcome, 2079  
 WG, baseline data on WG Etanercept Trial patients, 2299
- Ethnic differences**, OA, serum levels of cartilage oligomeric matrix protein and, 675
- Evidence-based medicine**, MTX monitoring guidelines, 2706
- Exercise**  
 adhesive capsulitis of the shoulder, supervised physiotherapy and, 829  
 in RA, 2393, 2415
- Exoglycosidases**, synovial fluid, and cartilage glycosaminoglycan depletion in RA, 2163
- Extracellular matrix**  
 CD44 in MMP induction by fibronectin fragment, 1271, 1763  
 control of normal cartilage homeostasis by IL-1RII, 1281  
 marimastat-induced musculoskeletal side effects in rats, 1742
- Extracellular signal-regulated kinase**  
 in chondrocytes, 689  
 hydralazine inhibits extracellular signal-regulated kinase pathway signaling, 746

## F

- Familial Mediterranean fever**  
 MEFV and SAA1 genotypes in, 1149  
 in patients of Karabakh and MEFV gene analysis, 2324
- Familiality**  
 JIA, -174G allele of the IL-6 gene and susceptibility to, 3202  
 RA, risk of malignant lymphoma, 963  
 RA, susceptibility genes in multicase families, 906
- Families**, RA, measuring parenting disability in women with RA, 935
- Fas gene**  
 RA,  $\beta$ 1 integrin induces ICAM-1 and Fas on RA synoviocytes, 1239  
 SS, gene expression in salivary gland in, 174
- Fas monoclonal antibody**, osteoclastogenesis suppression in RA, 3350
- FasL gene**, SS, gene expression in salivary gland in, 174
- Fatigue**, macrophagic myofasciitis (MMF), chronic fatigue syndrome in, 569
- Fc $\gamma$  receptors**  
 Fc $\gamma$  receptor IIA polymorphism in APS, 1930  
 Fc $\gamma$  receptor IIB, (CD32HB) polymorphism and receptor signaling, 3242  
 immune complex-mediated arthritis and, 255  
 lupus nephritis, composition of glomerular immune deposits related to Fc $\gamma$  receptor type IIA alleles, 460  
 RA, elimination of macrophages by Fc $\gamma$  receptor-directed immunotoxin, 1229  
 RA, expression of Fc $\gamma$  receptors and production of TNF $\alpha$  and MMP, 1002
- FCP bioinformatic tool** for PubMed searches, 2083
- Feet**, RA, early use of MRI predicts future radiographic damage, 1814
- Fetal cell microchimerism**  
 fetal loss and, 3237  
 in SSc, 1109
- Fetal loss**  
 fetal cell microchimerism and, 3237  
 low molecular weight heparin plus aspirin vs. intravenous immunoglobulin for recurrent antiphospholipid antibody-associated, 728
- Fibrillin 1**, as autoantigen in SpA, 3610
- Fibroblast-like synoviocytes**  
 RA, activin A induces cell proliferation of, 2442  
 RA, apoptosis modulated by bone morphogenetic proteins, 2807  
 RA, control of proliferation by macrophage migration inhibitory factor, 103  
 RA, role of stromal cell-derived factor 1 in CD4+ and CD8+ T cell migration, 2472
- Fibroblasts**  
 amyloid-enhancing factor mediates amyloid formation on, 1430  
 OA, aggrecanase 1 (ADAM-TS4), IL-1 induction and, 119  
 peptidoglycan activation of via Toll-like receptor signals, 642  
 RA, adenosine deaminase 1 in, 668

# Fibroblasts (cont'd)

- RA, early growth response 1 activity and TIMP-1 in synovial fibroblasts, 348
- RA, galectin 3 and its binding protein in, 2788
- RA, prostaglandin E<sub>2</sub> as enhancer of membrane-associated prostaglandin E synthase expression in, 2819
- SSc, aberrant constitutive *IL1A* gene expression in, 193
- SSc, connective tissue growth factor/insulin stimulation of collagen synthesis in, 798
- SSc, epidermal growth factor up-regulates expression of TGF $\beta$  receptor in, 1652
- SSc, *IL1A* polymorphisms in Japanese patients, 186
- SSc, Th2 cells inhibit collagen synthesis by dermal fibroblasts, 2593
- type I collagen gene expression in murine fibroblasts, 2275
- Fibromyalgia (FM)
  - ACR classification criteria, 276, 277
  - body pain and risk of cancer and reduced cancer survival, 1686
  - central sensitization in, 1420
  - expression and localization of opioid receptors in muscle satellite cells in, 3291
  - pyridostigmine for, 277
  - subgrouping patients by neurobiologic and psychosocial factors, 2916
  - temperament and stress response in children with juvenile primary FM syndrome, 2923
- Fibronectin, CD44 in MMP induction by fibronectin fragment, 1271, 1763
- Fibrosis
  - FCP: bioinformatic tool assisting in PubMed searches, 2083
  - monocyte chemoattractant protein 3 as mediator in SSc and type I tight-skin mouse, 1979
  - SSc, CD8+ T cells in SSc lung disease, 2262
  - type I collagen gene expression in murine fibroblasts, 2275
- Fingers
  - B-mode and Doppler sonography for joint imaging, 325
  - RA, ultrasonography and interobserver agreement in assessing, 955
  - SLE, Jaccoud's arthropathy in, 147
- Flare. *See* Disease flare
- FLICE-inhibitory protein, RA, fibroblast-like synoviocytes and, 858
- Flow-mediated vasodilatation
  - assessment of brachial artery, 2700
  - in RA, 72, 2700
- Fluvastatin, effects on antiphospholipid antibody-mediated activity, mouse study, 3272
- Focal lesions, in OA, 1261
- FR167653, inhibition of p38 MAPK in rat collagen-induced arthritis by, 2670
- Fractures
  - osteoporotic vertebral compression, intravertebral clefts in, 1414
  - predictors of vertebral fractures after glucocorticoid therapy, 3224
- Functional status
  - knee OA, physical functioning over 3 years, 3359
  - total hip replacement, caseload and patient-reported results of, 560
- Furin-like enzymes, cartilage degradation and, 1057

# G

- Galectin 3, binding protein in RA, 2788
- Gastrointestinal toxicity, of acetaminophen, 2074, 2075
- Geldanamycin, effects on inflammatory cytokine production, 541
- Gender
  - OA, hip joint space and, 1041
  - OA, interphalangeal hand joint involvement in, 3371
  - OA, serum levels of cartilage oligomeric matrix protein and, 675
  - RA, IFN $\gamma$ /IL-26 polymorphisms and sex bias in susceptibility to, 2773
  - RA, sex-controlled clinical traits in, mouse study, 1708
  - SLE, sex hormones and, 2100

# Gene therapy

- cartilage repair by cell-mediated gene therapy, rat study, 430
- gouty arthritis, prostaglandin D synthase in treatment of in mice, 2931
- OA, cartilage tissue engineering and gene therapy approach, 709
- Genetics. *See also* Gene therapy; Heredity; Mutations; Polymorphism
  - ANKH* gene, mutations in amino terminus in two families with CPPD crystal deposition disease, 2627
  - APS, Fc $\gamma$  receptor IIA polymorphism and, 1930
  - APS, valine/valine genotype at position 247 of  $\beta_2$ -GPI gene in, 471
  - AS, *ANKH* genetic markers associated with, 791
  - AS, *ANKH* in, role, mouse study, 2898
  - AS, HLA haplotypes, B27 alleles, and, in Sardinia, 1385
  - AS, major loci controlling clinical manifestations of, 2234
  - AS, single-nucleotide polymorphism in 3' region of *IL1RN* gene, 2011
  - Behçet's disease, TNF polymorphisms in, 807
  - collagen-induced arthritis and pristane-induced arthritis, comparative genetic analysis, rat study, 2332
  - collagen-induced arthritis, soluble IL-1 receptor accessory protein gene transfer for amelioration of, 2949
  - CPPD crystal deposition disease, *ANKH* mutations in, 2627
  - familial Mediterranean fever, MEFV and SAA1 genotypes and, 1149
  - familial Mediterranean fever, *MEFV* gene analysis, 2324
  - Fc $\gamma$  receptor IIB (CD32HB) polymorphism and receptor signaling, 3242
  - GCA, endothelial NOS gene polymorphisms in, 3219
  - H-2 haplotype in Fas-intact lupus-prone mice, 2992
  - heavy-chain deposition disease, genetic structure and protein products underlying, 3266
  - inflammatory arthritis, genetic variation in CCR5 and clinical outcome, 3615
  - inflammatory arthritis, p53 regulation by macrophage migration inhibitory factor in, 1881
  - JIA, -174G allele of the IL-6 gene and susceptibility to, 3202
  - JIA, macrophage migration inhibitory factor promoter polymorphism in systemic-onset JIA, 1398
  - lupus nephritis, composition of glomerular immune deposits related to Fc $\gamma$  receptor type IIA alleles, 460
  - lupus nephritis, expression of urinary cytokine genes in, 1326
  - molecular phenotyping of human chondrocyte cell lines T/C-28a2, T/C-28a4, and C-28/I2, 3395
  - OA, cartilage-like gene expression in differentiated human stem cell spheroids, 418
  - OA, deletion of IL-1 $\beta$ , IL-1 $\beta$ -converting enzyme, iNOS, or stromelysin 1 genes and development of in mice, 3452
  - OA, estrogen receptor  $\alpha$  gene and radiographic knee OA, 1913
  - OA, inheritance of hand OA in Iceland, 391
  - OA, MMP-1 gene expression, regulation by SAF-1, 134
  - OA, primary hip and restricted areas on chromosome 11q, 1461
  - OA-like changes in articular cartilage in knee and temporomandibular joint of mice with *cho* gene, 2509
  - PsA, cytokine gene polymorphisms and susceptibility and severity, 1408
  - quantitative trait loci (QTLs) and arthritis development in rats, 551
  - RA, gender differences in individuals encoding low-risk HLA-DRB1 alleles, 1762
  - RA, gene expression profiles and RA heterogeneity, 2132
  - RA, genetic control of RF production in RA rat model, 3584
  - RA, genome-wide linkage studies, 1200
  - RA, HLA class II genes and disease susceptibility and progression, 2779
  - RA, HLA-DRB1 genes and progression of joint damage, early treatment and, 579
  - RA, IFN $\gamma$ /IL-26 polymorphisms and sex bias in susceptibility to, 2773

# Genetics (cont'd)

- RA, IL promoter polymorphisms with autoantibody production and joint destruction, 1841
- RA, laser microdissection analysis of gene expression in synovium, 97
- RA, MMP-3 genotype and radiographic progression, 1162
- RA, polymorphism in stromelysin 1 (MMP-3) promoter gene and disease severity, 2695
- RA, Ras-mediated signaling pathways in synovial fibroblast-like cells and joint destruction, 2682
- RA, screening for susceptibility genes, 906
- RA, sex-controlled clinical traits in, mouse study, 1708
- RA, susceptibility and HLA-DRB1-TNF haplotypes, 90
- RA, susceptibility and poly(ADP-ribose) polymerase gene promoter, 638
- RA, susceptibility genes in multicase families, 906
- RA, TNF gene polymorphism and infliximab therapy outcome, 1849
- RA, TNF $\alpha$  -308 gene promoter polymorphism in, 3068
- RA, *TNFR2* polymorphism in Japanese patients, 273
- SLE, delayed onset in mice expressing human C-reactive protein transgene, 1602
- SLE, *DNASE1* gene A/T mutation in, 3297
- SLE, epitope spreading in, 582
- SLE, Fc $\gamma$ RIIIa genotype and degree of B cell depletion by rituximab, 455
- SLE, intrinsic susceptibility to renal disease in NZW mice, 1080
- SLE, triplets with, 3176
- SpA, HLA-B\*2709 and, 866
- SpA, immunity to versican and aggrecan in mice, 2903
- SS, gene expression in salivary gland in, 174
- SS, humoral immunity to Ro52 not associated with Ro52 9571 C/T polymorphism, 3293
- SSc, aberrant constitutive *IL1A* gene expression in, 193
- SSc, amplification of SRY-positive cells in, 1109
- SSc, CD8+ T cells in SSc lung disease, 2262
- SSc, glutathione S-transferase gene variations and cardiovascular disease in, 854
- SSc, *IL1A* polymorphisms in Japanese patients, 186
- SSc, susceptibility genes in Choctaw Indians with, 2585, 3295
- TRAPS, 1768
- TRAPS, characterized by mutation affecting cleavage site of the receptor, 2386
- TRAPS, genetic background in patients with, 2632, 2995
- type I collagen gene expression in murine fibroblasts, 2275
- vasculitis, tissue specificity of, mouse studies, 1445
- Germinal center, SS, ectopic germinal center formation in, 3187
- Giant cell arteritis (GCA)
  - endothelial NOS gene polymorphisms in, 3219
  - large-artery complications in, incidence and predictors of, 3522
  - large-artery complications in, mortality of, 3532
  - MTX with corticosteroids, 1158, 1159
  - unresolved issues in, 2406
  - vision loss in patients treated with alternate-day corticosteroids, 1159
- Glomerulonephritis, SLE, Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice, 486
- Glucocorticoids
  - alendronate effects on BMD in steroid-treated patients, 1102
  - joint targeting of glucocorticoids with long-circulating liposomes, rat study, 2059
  - predictors of vertebral fractures after therapy with, 3224
- Glucose-6-phosphate isomerase antibodies, RA, low prevalence of, 944
- Glutathione, oxidative stress of aging reduces chondrocyte survival, 3419

- Glutathione S-transferase gene, SSc, common genetic variations and cardiovascular disease in, 854
- Glycosaminoglycan, synovial fluid exoglycosidases and cartilage glycosaminoglycan depletion in RA, 2163
- Gout
  - peroxisome proliferator-activated receptor  $\gamma$  expression in acute gout, 231
  - tophaceous gout of the hand, image, 2738
- Gouty arthritis
  - prostaglandin D synthase in treatment of, mouse study, 2931
  - S100 proteins in neutrophil recruitment in, 2310
- Granuloma
  - cytokine profile of rheumatoid nodule, 334
  - parathyroid hormone-related protein in streptococcal cell wall-induced arthritis, 1721
- Growth plate, oncostatin M-induced damage, mouse study, 1750

## H

- H-2 haplotype, in *Fas*-intact lupus-prone mice, 2992
- Hand
  - B-mode and Doppler sonography for joint imaging, 325
  - OA, gender and interphalangeal joint involvement in, 3371
  - OA, inheritance of in Iceland, 391
  - OA, prevalence of in China vs. US, 1034
  - OA, weight from birth to middle age and, 1030
  - RA, Doppler ultrasound vs. MRI for synovial inflammation, 2434
  - RA, early use of MRI predicts future radiographic damage, 1814
  - RA, synovitis and bone damage, MRI study, 64
  - SLE, Jaccoud's arthropathy in, 147
  - undifferentiated arthritis, clinical outcome of patients, 3039
- Heat shock protein
  - geldanamycin, effects on inflammatory cytokine production, 541
  - heat shock protein 70 prevents nitric oxide-induced apoptosis in articular chondrocytes, 1562
- JIA, T cell reactivity to heat shock protein 60 in, 2001
- Heavy-chain deposition disease, genetic structure and protein products underlying, 3266
- Hematopoietic stem cell transplantation, for SLE, 2696
- Hemochromatosis, arthropathy in juvenile hemochromatosis, 227
- Heparin, low molecular weight heparin plus aspirin for recurrent antiphospholipid antibody-associated fetal loss, 728
- Hepatitis C
  - cryoglobulinemia associated with, IFN $\alpha$  and ribavirin treatment, 580
  - osteosclerosis associated with, 268
- Herbals. *See* Complementary and alternative medicine
- Heredity. *See also* Genetics
  - OA, inheritance of hand OA in Iceland, 391
- Hierarchical clustering
  - RA, gene expression profiles and RA heterogeneity, 2132
  - SSc, CD8+ T cells in SSc lung disease, 2262
- High-density lipoprotein, as marker of disease activity in SLE, 2533
- High mobility group box chromosomal protein 1
  - arthritis induced by, mouse study, 1693
  - counteracting high mobility group box chromosomal protein 1 as arthritis therapy in mice and rats, 2052
  - as nuclear protein, cytokine, and potential therapeutic target, 876, 971
- Hip
  - OA, age and sex differences in joint space, 1041
  - OA, asymmetric knee loading in advanced unilateral hip OA, 1556
  - OA, genetic linkage of primary hip OA with restricted areas on chromosome 11q, 1461
- Hip replacement, caseload and patient-reported results of total hip replacement, 560
- Histones, in epidermal basement membrane in lupus nephritis, 1355
- Histoplasma capsulatum*, anti-TNF $\alpha$  therapy and infection with, 3013

## HLA

- Behçet's disease, mapping HLA association in, 807
- in primary SS, 2240
- HLA-B\*2709, SpA and, 866
- HLA-B27 alleles, and AS in Sardinia, 1385
- HLA class II genes, RA, susceptibility and progression, 2779
- HLA-DQA1, not correlated with microchimerism, 2567
- HLA-DRB1 genes
  - RA, gender differences in individuals encoding low-risk HLA-DRB1 alleles, 1762
  - RA, progression of joint damage and early treatment, 579
  - RA, susceptibility and HLA-DRB1-TNF haplotypes, 90
- Hollow-fiber bioreactor-derived hyaline cartilage, MRI analysis of, 1047
- Homeostasis, control of normal cartilage homeostasis by IL1RII, 1281
- Hormones, RA, premature aging in, 2713
- Hyaluronan
  - acute adverse reaction to, 866
  - aggrecan G1 domain cointernalizes with hyaluronan in bovine articular chondrocytes, 3431
  - mechanical stress-induced depolymerization of, role of reactive oxygen species in, bovine study, 3151
- Hyaluronic acid, plus intraarticular phospholipid in experimental OA, rabbit study, 1923
- Hydralazine, extracellular signal-regulated kinase pathway signaling inhibited by, 746
- Hydrostatic pressure, effect of on proteoglycan metabolism in chondrocytes, 2865
- Hydroxychloroquine
  - dosage based on ideal body weight, 763
  - new American Academy of Ophthalmology recommendations on screening, 1764
  - safety in pregnant patients with connective tissue diseases, 3207
- Hyperimmunoglobulinemia D, etanercept in, 2645
- Hyperparathyroidism, CPPD deposition disease, 1170
- Hypochlorous acid, inhibition of hypochlorous acid-induced chondrocyte toxicity, 3140

## I

- Iceland, hand OA, inheritance of, 391
- Idiopathic inflammatory myopathies, HLA-DQA1 not correlated with microchimerism, 2567
- IgG, in glomerular immune deposits in lupus nephritis, 460
- I $\kappa$ B kinase
  - BMS-345541 I $\kappa$ B kinase inhibitor blocks inflammation and destruction in collagen-induced arthritis in mice, 2652
  - role in cytokine and MMP production in RA, 1901
- IL-18, synovial expression of in relation to proinflammatory responses, 339
- IL1A gene
  - SSc, aberrant constitutive IL1A gene expression in, 193
- SSc, polymorphisms in Japanese patients, 186
- IL1RN gene, AS, single-nucleotide polymorphism in 3' region of, 2011
- Imaging
  - activated protein C-reactive anticardiolipin antibodies, 1622
  - aggrecanase 1 (ADAM-TS4), IL-1 induction and, 119
  - amyloid-enhancing factor mediates amyloid formation on fibroblasts, 1430
  - anti-CD154 treatment in murine lupus nephritis, 2541
  - antigen-induced arthritis, p53 regulation by macrophage migration inhibitory factor, 1881
  - antiinflammatory drugs and arthritis cartilage, rat study, 1594
  - APS, avascular necrosis in, 732
  - AS, MRI scoring system for spinal inflammation, 1126
  - atherosclerosis reduction in mice by antiphospholipid antibody, 2974
  - bone morphogenetic proteins in chronic arthritis, 2807
  - cellular localization of antigens in or on apoptotic blebs, 2080
  - Imaging (*cont'd*)
    - chondrocyte apoptosis induced by TNF $\alpha$  in mice, 2845
    - cold agglutinin disease, 2738
    - collagen-induced arthritis
      - BMS-345541 I $\kappa$ B kinase inhibitor blocks inflammation and destruction in, 2652
      - CD25+ cell depletion and disease severity in, 1452
      - FR167653 inhibition of p38 MAPK in rats by, 2670
      - soluble IL-1 receptor accessory protein gene transfer for amelioration of, 2949
      - VEGF-B role in, 2660
    - counteracting high mobility group box chromosomal protein 1 as arthritis therapy in mice and rats, 2052
    - CPPD deposition disease, neuropathic joint image, 1170
    - cryoglobulinemia, pseudoleukocytosis in, 3000
    - cyclophilin B, high binding capacity of to chondrocyte heparan sulfate proteoglycans and release from cell surface by MMP, 2197
    - disease activity assessment with power Doppler sonography, 285
    - FM, opioid receptors in muscle satellite cells, 3291
    - gout, tophaceous hand, 2738
    - heat shock protein 70 prevents nitric oxide-induced apoptosis in articular chondrocytes, 1562
    - hepatitis C-associated osteosclerosis, 268
    - high mobility group box chromosomal protein 1, arthritis induced by, mouse study, 1693
    - human apoptotic and necrotic neutrophils, effect of on dendritic cells, 2362
    - hyperimmunoglobulinemia D with periodic fever syndrome, 2645
    - immune complex-mediated arthritis, Fc $\gamma$  receptors and cartilage destruction, 255
    - immunogenicity/arthritis of G3 domain of aggrecan, mouse study, 2959
    - inflammatory polyarthritis, DMARDs and radiographic outcome, 46
    - JIA, predictors for radiographic progression, radiographic damage, and disability in, 3509
    - JIA, radiologic features in, 507
    - JRA, myeloid-related protein expression in, 2622
    - juvenile hemochromatosis, arthropathy in, 227
    - juxtaarticular osteoid osteoma misdiagnosis, 776
    - large-vessel vasculitis, 2406
    - lumbar spine disc degeneration, 3112
    - lupus nephritis, ameliorated by monocyte chemoattractant protein 1 antagonist, mouse study, 2555
    - lupus nephritis, IgG subclasses and C-reactive protein in glomerular immune deposits, 460
    - lupus nephritis, nucleosomal antigens in epidermal basement membrane in, 1355
    - macrophagic myofasciitis (MMF), chronic fatigue syndrome in, 569
    - marimastat-induced musculoskeletal side effects in rats, 1742
    - mechanical stress-induced depolymerization of hyaluronan, reactive oxygen species and, 3151
    - minodrinic acid treatment and BMD in rats with collagen-induced arthritis, 1732
    - multicentric reticulohistiocytosis, anti-TNF for, 864
    - neocartilage analysis by MRI, 1047
    - OA, cartilage repair by cell-mediated gene therapy, rat study, 430
    - OA, chondrocyte stimulation by combination of insulin-like growth factor 1 and osteogenic protein 1, 2188
    - OA, comparison of AP and Lyon schuss views to measure joint space width in knee, 378
    - OA, development of in  $\alpha$ 1 integrin-deficient mice, 2873
    - OA, endothelin 1 and cartilage degradation, 2855
    - OA, estrogen receptor  $\alpha$  gene and radiographic knee OA, 1913
    - OA, focal lesion development in cartilage and molecular matrix changes, 1261
    - OA, hyaluronic acid plus phospholipid in experimental OA, rabbit study, 1923

## Imaging (cont'd)

- OA, immunologic intervention in pathogenesis, 602
- OA, inflammation and angiogenesis in, 2173
- OA, joint space narrowing by standardized knee radiography, 385
- OA, key role of leptin in, 3118
- OA, mitochondrial respiratory activity in human chondrocytes, 700
- OA, MRI-based T and Z scoring of cartilage loss, 2829
- OA, MRI detection of periarticular lesions in knee OA, 2836
- OA, radiography and MRI in defining knee OA, 682
- OA, selective inhibition of MAPK kinase 1/2 in rabbit experimental OA, 1582
- OA, tachykinin expression in, 146
- OA-like changes in articular cartilage in knee and temporomandibular joint of mice with *cho* gene, 2509
- oncostatin M-induced growth plate damage, mouse study, 1750
- osteoporotic vertebral compression fractures, intravertebral clefts in, 1414
- osteoprotegerin and TNF-mediated generalized bone loss, mouse study, 2042
- osteosclerosis, hepatitis C-associated, 268
- parathyroid hormone-related protein in streptococcal cell wall-induced arthritis, 1721
- placental immunomodulator ferritin suppression of experimental arthritis, 846
- plasticity of clonal populations of dedifferentiated adult human articular chondrocytes, 1315
- positron emission tomography vs. MRI of proliferation of synovium, 3077
- PsA, myeloid-related proteins in, 1676
- pseudoscleroderma associated with TGF $\beta$ 1-producing advanced gastric carcinoma, 1766
- pulmonary rheumatoid nodules in etanercept-treated patient, 2077
- RA, activation-induced T cell-derived and chemokine-related cytokine/lymphotactin expression in, 1838
- RA, activin A induces cell proliferation of fibroblast-like synovocytes, 2442
- RA, adherent synovial fluid cells, 1873
- RA, anti-glomerular basement membrane antibody-associated renal failure in leflunomide-treated patient, 1164
- RA, bone damage evaluation by MRI, 585
- RA, citrullination of synovial proteins in murine RA models, 2489
- RA, computerized MRI erosion volumes in, 614
- RA, Crk-associated substrate lymphocyte type and, 1890
- RA, dendritic cell-associated C-type lectin DC-SIGN expression in synovium, 360
- RA, Doppler ultrasound vs. MRI for synovial inflammation, 2434
- RA, dynamic gadolinium-enhanced MRI discriminates active from inactive disease, 1207
- RA, early TNF $\alpha$  blockade and synovial cell infiltrate, 2155
- RA, early use of MRI predicts future radiographic damage, 1814
- RA, ESE-1 in, 1249
- RA, expression of Fc $\gamma$  receptors and production of TNF $\alpha$  and MMP, 1002
- RA, galectin 3 and its binding protein, 2788
- RA, hand and finger joint imaging with B-mode and Doppler sonography, 325
- RA, hidden costs of anti-TNF $\alpha$  therapy, 868
- RA, high mobility group box chromosomal protein 1 and, 971
- RA, laser microdissection analysis of gene expression in synovium, 97
- RA, leflunomide and MTX, MRI comparison, 270, 271
- RA, MAPK as regulators of JNK in RA, 2450
- RA, MCP joint anatomic factors in early RA synovitis and bone erosion, 1214
- RA, MMP-3 genotype and radiographic progression, 1162
- RA, Modified Disease Activity Score vs. radiologic progression as indicator of disease status, 272

## Imaging (cont'd)

- RA, p16 induction at sites of cartilage invasion in SCID mouse coimplantation model of, 2069
- RA, pleiotrophin in, 660
- RA, radiographic data from trials, 21, 2997
- RA, Ras-mediated signaling pathways in synovial fibroblast-like cells and joint destruction, 2682
- RA, shoulder joint, comparison of imaging techniques, 3338
- RA, synovial IL-18 expression in relation to proinflammatory responses in, 339
- RA, synovitis and bone damage, MRI study, 64
- RA, Tie2 receptor tyrosine kinase regulates arthritis angiogenesis, 2461
- RA, tissue factor pathway in synovial inflammation, 651
- RA, ultrasonography and interobserver agreement in assessing finger and toe joints, 955
- RA and degenerative shoulder disorders, Doppler sonography of bicipital tendon sheath in, 1828
- Raynaud's phenomenon and capillaroscopy, 3023
- sarcoidosis, tumoral calcinosis associated with, 1770
- SLE, apoptotic neutrophils in SLE, 2888
- SLE, benzodiazepine treatment of mouse lupus, 757
- SLE, coronary artery angiography in, 3168
- SLE, delayed onset in mice expressing human C-reactive protein transgene, 1602
- SLE, Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRS/*pr* mice, 486
- SLE, intrinsic susceptibility to renal disease in NZW mice, 1080
- SLE, Jaccoud's arthropathy in, MRI study, 147
- SLE, T cell receptor  $\zeta$  chain reconstitution restores T cell signaling and augments IL-2 production in, 1948
- SpA, immunity to versican and aggrecan in mice, 2903
- SpA, MRI localization of sacroiliitis in, 1374
- SpA, Second International Enthesitis Workshop, 896
- spontaneous arthritis in IFN $\gamma$  receptor-deficient mice, 2983
- SS, ectopic germinal center formation in, 3187
- SS, gene expression in salivary gland in, 174
- SS, protein degradation by MMPs from labial salivary glands, 2573
- SSc, AECAs and apoptosis in, 2605
- SSc, anti-thrombopoietin receptor autoantibody-induced megakaryocytic thrombocytopenia in, 1647
- SSc, monocyte chemoattractant protein 3 as mediator of fibrosis in, mouse study, 1979
- SSc, shrinking lung syndrome in, 2999
- SSc, SMAD signaling in fibroblasts, 1964
- SSc, TNF receptor p55-mediated signaling in pathogenesis, 1117
- SSc, watermelon stomach, 2738
- TRAPS, 1768
- TRAPS, characterized by mutation affecting cleavage site of the receptor, 2386
- vasculitis, genetics of tissue specificity of, mouse studies, 1445
- Immune complex-mediated arthritis, Fc $\gamma$  receptors in, 255
- Immune regulation, in adjuvant-induced arthritis, 1788
- Immune system
  - infections and anti-TNF $\alpha$  therapy, 3013
  - OA, immunologic intervention in pathogenesis, 602
  - RA, contribution of innate immune system to, 590
  - RA, premature aging in, 2713
  - SpA, immunity to versican and aggrecan and, mouse study, 2903
  - tuberculosis: what rheumatologists need to know, 2085
- Immunity, SS, humoral immunity to Ro52 not associated with Ro52 9571 C/T polymorphism, 3293
- Immunoglobulin
  - intravenous immunoglobulin for recurrent antiphospholipid antibody-associated fetal loss, 728
  - prevention of congenital heart block with intravenous immunoglobulin and corticosteroid therapy, 280, 281

### Immunoglobulin (*cont'd*)

SLE, IFN $\alpha$ -induced dendritic cell differentiation abrogated by intravenous immunoglobulin, 3497

Immunotoxin, RA, elimination of macrophages by Fc $\gamma$  receptor-directed immunotoxin, 1229

In memoriam, Currier McEwen, 2739

### In vitro studies

insulin-like growth factor binding protein 3 (IGFBP-3) synthesis in human articular cartilage cultures, 410

signaling of NO induction by leptin and IFN $\gamma$  in chondrocytes, 404

### Incidence

GCA, large-artery complications in, 3522

SSc, in large US population, 2246

Indentation testing, of human cartilage, 3382

Inducible nitric oxide synthase (iNOS), OA, deletion of IL-1 $\beta$ , IL-1 $\beta$ -converting enzyme, iNOS, or stromelysin 1 genes and development of in mice, 3452

Infants. *See* Children

### Infection

antiphospholipid antibodies associated with parvovirus B19 infection, 1939

anti-TNF $\alpha$  therapy and, 1764, 3013

APS, cytomegalovirus infection and, 3296

disposal of dying cells and, 6

*Listeria* infection as complication of anti-TNF $\alpha$  therapy, 319, 1764

RA, T cell expansion in tonsil and synovium in patient with RA and tonsillitis, 2483

tuberculosis: what rheumatologists need to know, 2085

### Inflammation

AS, MRI scoring system for spinal inflammation, 1126

atherosclerosis, association with inflammation markers, 1833

B lymphocyte stimulator protein and, 882

B lymphocyte stimulator protein and APRIL in, 982

BMS-345541 I $\kappa$ B kinase inhibitor blocks inflammation and destruction in collagen-induced arthritis in mice, 2652

C-reactive protein as regulator of, 1475

geldanamycin, effects on inflammatory cytokine production, 541

high mobility group box chromosomal protein 1, arthritis induced by, mouse study, 1693

high mobility group box chromosomal protein 1 and, 876, 971

immune complex-mediated arthritis, Fc $\gamma$  receptors and cartilage destruction, 255

inhibition of hypochlorous acid-induced chondrocyte toxicity, 3140

MTX inhibition of, adenosine receptors and, 240

OA, angiogenesis and inflammation in, 2173

OA, immunologic intervention in pathogenesis, 602

positron emission tomography vs. MRI of proliferation of synovium, 3077

proinflammatory, use of word, 1469

RA, atherosclerosis and, 3061

RA, atherosclerosis in RA patients, 72

RA, Doppler ultrasound vs. MRI for synovial inflammation, 2434

RA, galectin 3 and its binding protein in, 2788

RA, reduced arterial elasticity in, 81

RA, synovial IL-18 expression in relation to proinflammatory responses in, 339

RA, tissue factor pathway in synovial inflammation, 651

streptococcal cell wall-induced, parathyroid hormone-related protein and, 1721

type II collagen and aggrecan turnover at onset of inflammatory arthritis, 3085

### Inflammatory arthritis

anti-TNF therapy for secondary AA amyloidosis, 2019

genetic variation in CCR5 and clinical outcome, 3615

IL-6, 1177

local production of B lymphocyte stimulator protein and APRIL, 982

### Inflammatory arthritis (*cont'd*)

p53 regulation by macrophage migration inhibitory factor in, 1881

stimulatory and suppressive DNA motifs and, mouse study, 1701

type II collagen and aggrecan turnover at onset of, 3085

undifferentiated arthritis of the hands, clinical outcome of patients, 3039

Inflammatory myopathy, artificial neural network to predict cancer in patients, 1168

### Inflammatory polyarthritis

DMARDs and radiographic outcome, 46

mortality in, 1462

### Infliximab

AS, down-regulation of T cell cytokine response in infliximab-treated AS, 780

AS, long-term efficacy and safety of use, 2224

AS, MRI scoring system for spinal inflammation before and after treatment, 1126

*Listeria* infection as complication of therapy, 319, 1764

monitoring protocol for adverse effects, 2769

RA, ANAs in, 1015

RA, early changes in bone metabolism and, 2996

RA, early TNF $\alpha$  blockade and synovial cell infiltrate, 2155

RA, radiographic data from trials, 21, 2997

RA, TNF gene polymorphism and infliximab therapy outcome, 1849

RA, tuberculosis risk and, 2122

for renal amyloidosis, 3298, 3299

for sarcoidosis, 3542

SpA, ANAs in, 1015

Injection, knee OA, safety and efficacy of long-term intraarticular steroid injections, 370

Insulin, SS, connective tissue growth factor/insulin stimulation of collagen synthesis in, 798

### Insulin-like growth factor 1

chondrocyte stimulation by combination of insulin-like growth factor 1 and osteogenic protein 1, 2188

control of normal cartilage homeostasis by IL-1RII and, 1281

Insulin-like growth factor 1 antagonist, cartilage intermediate-layer protein as, 1302

Insulin-like growth factor binding protein 3 (IGFBP-3), synthesis in human articular cartilage cultures, 410

Insulin resistance, cyclophosphamide and mycophenolate mofetil for SLE-associated type B insulin resistance syndrome, 1067

### Integrins

human chondrocyte adhesion to cartilage mediated by, 110

OA, development of in  $\alpha$ 1 integrin-deficient mice, 2873

RA,  $\beta$ 1 integrin induces ICAM-1 and Fas on RA synoviocytes, 1239

### Interferon- $\alpha$ (IFN $\alpha$ )

new target for SLE therapy, 2396

and ribavirin treatment on hepatitis C-associated cryoglobulinemia and RF, 580

SLE, intravenous immunoglobulin abrogates dendritic cell differentiation induced by, 3497

SLE, production of by plasmacytoid dendritic cells in SLE, 2524

### Interferon- $\gamma$ (IFN $\gamma$ )

RA, polymorphisms in IFN $\gamma$ /IL-26 gene and sex bias in susceptibility, 2773

RA, *Salmonella* septicemia with anti-TNF antibody treatment, 1853

reduced production of by altered peptide ligands, 2375

signaling of NO induction by in chondrocytes, in vitro study, 404

spontaneous arthritis in IFN $\gamma$  receptor-deficient mice, 2983

SS, in salivary gland lesions, 2390

### Interleukin-1 (IL-1)

aggrecanase 1 (ADAM-TS4) production and, 119

AP-4 mediation of IL-1-stimulated TGF $\beta$ 1 expression in bovine articular chondrocyte cultures, 1569

OA, deletion of IL-1 $\beta$ , IL-1 $\beta$ -converting enzyme, iNOS, or stromelysin 1 genes and development of in mice, 3452

### Interleukin-1 (IL-1) (*cont'd*)

- RA, ESE-1 and, 1249
- RA, I $\kappa$ B kinase 2 and cytokine production in, 1901
- SSc, aberrant constitutive *IL1A* gene expression in, 193
- Interleukin-1 receptor II (IL-1RII), control of normal cartilage homeostasis by, 1281
- Interleukin-1 (IL-1) receptor accessory protein, as inhibitor of IL-1 in collagen-induced arthritis, 2949
- Interleukin-1 receptor antagonist (IL-1Ra)
  - RA, large placebo-controlled safety study of anakinra, 927
  - RA, radiographic data from trials, 21, 2997
- Interleukin-2 (IL-2), SLE, T cell receptor  $\zeta$  chain reconstitution augments IL-2 production in, 1948
- Interleukin-4 (IL-4), type 1 collagen gene expression in murine fibroblasts, 2275
- Interleukin-6 (IL-6)
  - I $\kappa$ B kinase 2 and cytokine production in RA, 1901
  - in inflammatory arthritis and bone turnover, 1177
  - JIA, -174G allele of the IL-6 gene and susceptibility to, 3202
- Interleukin-6 (IL-6) receptor, IL-6 receptor antagonist therapy for RA, 1471, 1521
- Interleukin-8 (IL-8), I $\kappa$ B kinase 2 and cytokine production in RA, 1901
- Interleukin-10 (IL-10)
  - JIA, T cell reactivity to heat shock protein 60 and IL-10 production, 2001
  - RA, IL-10 promoter polymorphism, autoantibody production and joint destruction, 1841
  - reduced production of by altered peptide ligands, 2375
- Interleukin-17 (IL-17), in RA, 594
- Interleukin-18 (IL-18)
  - RA, synovial IL-18 expression in relation to proinflammatory responses in, 339
  - RA, synovium cell responses, 631
- Internet searching, FCP: bioinformatic tool assisting in PubMed searches, 2083
- Intraarticular bleeding, blood-induced joint damage, dog study, 396
- Intraarticular injection, knee OA, safety and efficacy of long-term steroid injections, 370
- Intracellular adhesion molecule 1 (ICAM-1), RA,  $\beta$ 1 integrin induces ICAM-1 and Fas on RA synoviocytes, 1239
- Intracellular adhesion molecule 3 (ICAM-3), RA, dendritic cell-associated C-type lectin DC-SIGN expression by MMP macrophages in synovium, 360
- Intravenous immunoglobulin
  - congenital heart block, prevention of recurrence with intravenous immunoglobulin and corticosteroid therapy, 280, 281
  - for recurrent antiphospholipid antibody-associated fetal loss, 728
- Intravertebral clefts, in osteoporotic vertebral compression fractures, 1414

## J

- Jaccoud's arthropathy, in SLE, 147
- JAK/STAT pathway, in RA, 2092
- Japanese population
  - RA, *TNFR2* polymorphism in Japanese patients, 273
  - SSc, *IL1A* gene polymorphisms in SSc patients, 186
- JNK, MAPK as regulators of JNK in RA, 2450
- Job loss. *See* Employment
- Joint damage. *See also* Joints
  - blood-induced, dog study, 396
  - BMS-345541 I $\kappa$ B kinase inhibitor blocks inflammation and destruction in collagen-induced arthritis in mice, 2652
  - immune complex-mediated arthritis, Fc $\gamma$  receptors and cartilage destruction, 255
  - JIA, predictors for radiographic progression, radiographic damage, and disability in, 3509
  - juvenile hemochromatosis, arthropathy in, 227

### Joint damage (*cont'd*)

- OA, RANTES production by articular chondrocytes, 278
- parathyroid hormone-related protein in streptococcal cell wall-induced arthritis, 1721
- RA, early use of MRI predicts future radiographic damage, 1814
- RA, erosiveness in peripheral joints as predictor of cervical spine disorders in, 1808
- RA, hand and finger joint imaging with B-mode and Doppler sonography, 325
- RA, HLA-DRB1 genes and progression of, early treatment and, 579
- RA, IL-10 promoter polymorphisms with autoantibody production and joint destruction, 1841
- RA, laser microdissection analysis of gene expression in synovium, 97
- RA, MRI study of synovitis and bone damage, 64
- RA, Ras-mediated signaling pathways in synovial fibroblast-like cells and joint destruction, 2682
- SLE, Jaccoud's arthropathy in, 147
- Joint disease, extracellular nucleotide metabolism and signaling in, 2722
- Joint fluid. *See* Synovial fluid
- Joint hemorrhage, blood-induced joint damage, dog study, 396
- Joint injury, type II collagen fragments in synovial fluid, 3130
- Joint lubrication, OA, hyaluronic acid plus phospholipid in experimental OA, rabbit study, 1923
- Joint space narrowing
  - OA, radiography and MRI in defining knee OA, 682
  - OA, standardized knee radiography, 385
  - RA, radiographic data from trials, 21, 2997
- Joint space width
  - hip OA, age and sex differences in hip joint space, 1041
  - knee OA, comparison of AP and Lyon schuss views, 378
- Joints. *See also* Joint damage
  - adjuvant-induced arthritis, chemokine receptor expression and in vivo signaling pathways in rat joints, 3568
  - bone morphogenetic protein 6 in OA articular chondrocytes, 2501
  - inhibition of hypochlorous acid-induced chondrocyte toxicity, 3140
  - joint targeting of glucocorticoids with long-circulating liposomes, rat study, 2059
  - OA, hyaluronic acid plus phospholipid in experimental OA, rabbit study, 1923
  - OA and joint injury, type II collagen fragments in synovial fluid, 3130
  - proteoglycan degradation after injurious compression of cartilage, 1292
  - RA, MCP joint anatomic factors in early RA synovitis and bone erosion, 1214
  - Second International Enthesitis Workshop report, 896
- Juvenile chronic arthritis. *See also* Juvenile idiopathic arthritis
  - juxtaarticular osteoid osteoma misdiagnosed as, 776
  - parvovirus B19 in, 1631
- Juvenile dermatomyositis (DM), BMD in, 2294
- Juvenile hemochromatosis, arthropathy in, 227
- Juvenile idiopathic arthritis (JIA). *See also* Juvenile chronic arthritis
  - antiphospholipid antibodies associated with parvovirus B19 infection, 1939
  - birth order and, 1989
  - etanercept efficacy according to onset type, 1093
  - macrophage migration inhibitory factor promoter polymorphism in systemic-onset JIA, 1398
  - oncostatin M-induced growth plate damage, mouse study, 1750
  - osteopenia in adolescents with early-onset JIA, 2214
  - outcome in adults, 767
  - predictors for radiographic progression, radiographic damage, and disability in, 3509
  - radiologic features in, 507
  - susceptibility and -174G allele of the IL-6 gene, 3202

Juvenile idiopathic arthritis (JIA) (*cont'd*)  
 T cell reactivity to heat shock protein 60 in, 2001  
 Juvenile polyarticular arthritis, daily pain and symptoms in, 1390  
 Juvenile primary FM syndrome, temperament and stress response in children with, 2923  
 Juvenile rheumatoid arthritis (JRA). *See also* Juvenile chronic arthritis; Juvenile idiopathic arthritis  
 etanercept, long-term efficacy and safety of, 218  
 myeloid-related protein expression in, 2622  
 Juxtaarticular osteoid osteoma, misdiagnosis of, 776

## K

Kidneys  
 lupus kidneys in mice, polyreactive ANAs in, 2343  
 lupus nephritis, ameliorated by monocyte chemoattractant protein 1 antagonist, mouse study, 2555  
 lupus nephritis, anti-CD40 ligand antibody treatment of, 719  
 lupus nephritis, anti-CD154 treatment of murine lupus nephritis, 2541  
 lupus nephritis, cyclophosphamide in low-dose vs. high-dose, 1466  
 lupus nephritis, expression of urinary cytokine genes in, 1326  
 lupus nephritis, Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone mice, 486  
 lupus nephritis, IgG subclasses and C-reactive protein in, 460  
 lupus nephritis, intrinsic susceptibility to renal disease in NZW mice with SLE, 1080  
 lupus nephritis, nucleosomes in epidermal basement membrane in, 1355  
 RA, anti-glomerular basement membrane antibody-associated renal failure in leflunomide-treated patient, 1164  
 renal amyloidosis, infliximab treatment for, 3298, 3299  
 renal vasculitis ameliorated by monocyte chemoattractant protein 1 antagonist, mouse study, 2555  
 SLE, autoimmune glomerulonephritis in lupus-prone MRL/lpr mice, Fc receptor-independent development of, 486  
 SLE, intrinsic susceptibility to renal disease in NZW mice, 1080  
 SLE, LJP394 for prevention of renal flare, 442  
 SLE, polyreactive ANAs in lupus kidneys, mouse study, 2343  
 Knee  
 OA, association of BMI and, 1024  
 OA, asymmetric knee loading in advanced unilateral hip OA, 1556  
 OA, comparison of AP and Lyon schuss views to measure joint space width, 378  
 OA, deletion of IL-1 $\beta$ , IL-1 $\beta$ -converting enzyme, iNOS, or stromelysin 1 genes and development of in mice, 3452  
 OA, hyaluronan, acute adverse reaction to, 866  
 OA, MRI detection of periarticular lesions, 2836  
 OA, physical functioning over 3 years, 3359  
 OA, radiographic and symptomatic knee OA after meniscal tear, 2178  
 OA, radiography and MRI in defining knee OA, 682  
 OA, safety and efficacy of long-term intraarticular steroid injections, 370  
 OA-like changes in articular cartilage in mice with *cho* gene and, 2509  
 RA, synovial IL-18 expression in relation to proinflammatory responses in, 339  
 spinal cord injuries, cartilage atrophy in knee of patients with, 3377

## L

*La* gene, SS, gene expression in salivary gland in, 174  
 Large-artery stenosis  
 in GCA, incidence and predictors of, 3522  
 in GCA, mortality of, 3532  
 Laser-mediated microdissection, RA, analysis of gene expression in synovium, 97

LCK, ubiquitination of and expression in SLE T cells, 1343  
 Lectin, dendritic cell-associated C-type lectin DC-SIGN expression in RA synovium, 360  
 Leflunomide  
 RA, anti-glomerular basement membrane antibody-associated renal failure with, 1164  
 RA, efficacy and safety of, 1513  
 RA, leflunomide and MTX, 270, 271  
 RA, radiographic data from trials, 21, 2997  
 Leptin  
 OA, key role in, 3118  
 signaling of NO induction by in chondrocytes, in vitro study, 404  
 systemic and local regulation of articular cartilage metabolism, 3009  
 Leukocytes, splenectomy for streptococcal cell wall-induced arthritis alters activation of, 3557  
 Leukotrienes  
 in SSc-associated alveolitis, 1478  
 SSc, lung disease and, 1639  
 Liposomes, joint targeting of glucocorticoids with long-circulating liposomes, rat study, 2059  
*Listeria monocytogenes*, anti-TNF $\alpha$  therapy and infection with, 319, 1764, 3013  
 Loading, OA, asymmetric knee loading in advanced unilateral hip OA, 1556  
 Lumbar spine disc degeneration, risk factors for progression of, 3112  
 Lungs  
 pulmonary artery hypertension, diagnostic marker for in patients with SSc, effects of calcium-channel blockers, 3503  
 pulmonary rheumatoid nodules in etanercept-treated patient, 2077  
 SSc, CD8+ T cells in SSc lung disease, 2262  
 SSc, leukotrienes in bronchoalveolar lavage fluid, 1639  
 SSc, predictors of pulmonary hypertension in, 516  
 Lupus nephritis  
 ameliorated by monocyte chemoattractant protein 1 antagonist, mouse study, 2555  
 anti-CD40 ligand antibody treatment of, 719  
 anti-CD154 treatment of murine lupus nephritis, 2541  
 cyclophosphamide, efficacy of low-dose vs. high-dose, 1466  
 Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone mice, 486  
 IgG subclasses and C-reactive protein in, 460  
 nucleosomes in epidermal basement membrane in, 1355  
 SLE, intrinsic susceptibility to renal disease in NZW mice, 1080  
 urinary cytokine genes expressed in, 1326  
 Lyme arthritis, peptide binding to HLA-DR molecules in, 534  
 Lymphocytes  
 B lymphocyte depletion in RA, 2146  
 B lymphocyte stimulator protein and inflammation, 882  
 B lymphocyte stimulator protein local production in inflammatory arthritis, 982  
 Crk-associated substrate lymphocyte type RA pathophysiology in mice and humans, 1890  
 Lymphoma  
 RA, lymphoma subtypes, 1543  
 RA, risk of malignant lymphoma in RA patients and first-degree relatives, 963  
 rituximab for B cell lymphoma, 1484  
 SS, extrasalivary lymphoma development in, 3181  
 LymphoStat-B, human monoclonal antibody against B lymphocyte stimulator, 3253

## M

Macrophage migration inhibitory factor  
 incorporating disease outcome into definition of phenotype, 1171  
 inflammatory arthritis, p53 regulation by, 1881

#### Macrophage migration inhibitory factor (*cont'd*)

JIA, migration inhibitory factor promoter polymorphism in systemic-onset JIA, 1398

RA, fibroblast-like synoviocytes, control of proliferation by, 103

#### Macrophages

geldanamycin, effect on inflammatory cytokine production in, 541  
RA, dendritic cell-associated C-type lectin DC-SIGN expression by MMP macrophages in synovium, 360

RA, elimination of macrophages by Fcγ receptor-directed immunotoxin, 1229

RA, macrophage migration inhibitory factor as emerging therapeutic target, 291

RA, TNF-related apoptosis-inducing ligand expression in synovial fluid, 3096

serum amyloid P and phagocytosis of apoptotic cells, 248

Macrophagic myofasciitis (MMF), chronic fatigue syndrome in, 569

#### Maculopathy

hydroxychloroquine dosage based on ideal body weight, 763

new American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy, 1764

#### Magnetic resonance imaging (MRI)

APS, avascular necrosis in, 732

AS, scoring system for spinal inflammation, 1126

neocartilage analysis by, 1047

OA, periarticular lesions in knee OA, 2836

OA, radiography and MRI in defining knee OA, 682

OA, T and Z scoring of cartilage loss, 2829

positron emission tomography vs. MRI of proliferation of synovium, 3077

RA, bone damage evaluation by, 585

RA, computerized MRI erosion volumes in, 614

RA, Doppler ultrasound vs. MRI for synovial inflammation, 2434

RA, dynamic gadolinium-enhanced MRI discriminates active from inactive disease, 1207

RA, early use of MRI predicts future radiographic damage, 1814

RA, leflunomide and MTX, MRI comparison, 270, 271

RA, shoulder joint, comparison of imaging techniques, 3338

RA, synovitis and bone damage, 64

SLE, Jaccoud's arthropathy in, 147

SpA, MRI localization of sacroiliitis in, 1374

SpA, Second International Enthesitis Workshop, 896

#### Major histocompatibility complex (MHC)

Lyme arthritis, peptide binding to HLA-DR molecules in, 534

RA, inducible expression of class II MHC in inflammatory neutrophils, 2796

Malignant lymphoma, risk of in RA patients and first-degree relatives, 963

Marimastat, MMP-induced musculoskeletal side effects in rats, 1742

Masugi nephritis, SLE, intrinsic susceptibility to renal disease in NZW mice, 1080

#### Matrix metalloproteinase 1 (MMP-1)

OA, cartilage degradation promoted by endothelin 1 via MMP-1, 2855

OA, regulation of MMP-1 gene expression by SAF-1, 134

RA, expression of Fcγ receptors and production of, 1002

RA, IκB kinase 2 and MMP production in, 1901

Matrix metalloproteinase 2 (MMP-2), IκB kinase 2 and MMP production in RA, 1901

#### Matrix metalloproteinase 3 (MMP-3)

RA, IκB kinase 2 and MMP production in, 1901

RA, MMP-3 genotype and radiographic progression, 1162

RA, MMP-3 polymorphism and disease severity, 2695

#### Matrix metalloproteinase 13 (MMP-13)

OA, cartilage degradation promoted by endothelin 1 via MMP-1, 2855

RA, IκB kinase 2 and MMP production in, 1901

T cells and human osteoblast MMP-13 production, 993

#### Matrix metalloproteinases (MMPs)

CD44, in MMP induction by fibronectin fragment, 1271, 1763

cyclophilin B, release from chondrocyte cell surface by, 2197

IκB kinase 2 and MMP production in RA, 1901

marimastat-induced musculoskeletal side effects in rats, 1742

oncostatin M combined with TNFα induces expression of, 3404

SS, protein degradation by MMPs from labial salivary glands, 2573

McEwen, Currier, in memoriam, 2739

Measuring instruments, RA, development of an instrument to measure parenting disability in women with RA, 935

Mechanotransduction, tachykinin function in chondrocytes, 146

Medical costs, direct, and cost predictors in RA, 2750

MEFV gene, familial Mediterranean fever and, 1149, 2234

Menisectomy, impact of on radiographic and symptomatic knee OA, 2178

#### Mesenchymal cells

cartilage repair by cell-mediated gene therapy, rat study, 430

OA, chondrogenic differentiation of stem cells, 418

Metabolic cost, of adjuvant-induced arthritis in rats, 2979

Metacarpophalangeal joint (MCP joint), anatomic factors in early RA synovitis and bone erosion, 1214

#### Methotrexate (MTX)

adenosine receptors and inflammation inhibition by, 240

evidence-based monitoring guidelines for, 2706

GCA, MTX with corticosteroids, 1158, 1159

monitoring protocol for adverse effects, 2706, 2769

PsA, myeloid-related proteins in, 1676

RA, adalimumab concomitant with, 35, 855

RA, caffeine consumption and efficacy of treatment, 571

RA, dosage and mode of administration in clinical trials, 863

RA, etanercept plus MTX, 1493

RA, leflunomide and MTX, 270, 271

RA, tacrolimus concomitant with, 2763

Methylprednisolone, combination oral cyclophosphamide and prednisolone in early diffuse SSC, 2256

Mexican population, APS, valine/valine genotype at position 247 of β<sub>2</sub>GPI gene in, 471

Microarray analysis, guidelines for studies, 860, 861

#### Microchimerism

fetal loss and fetal cell microchimerism, 3237

HLA-DQA1 not correlated with, 2567

in SSC, 1109

Microdissection, RA, laser microdissection analysis of gene expression in synovium, 97

#### Migration inhibitory factor

incorporating disease outcome into definition of phenotype, 1171

inflammatory arthritis, p53 regulation by macrophage migration inhibitory factor in, 1881

JIA, polymorphism of macrophage migration inhibitory factor gene in systemic-onset JIA, 1398

RA, fibroblast-like synovocyte proliferation, control by, 103

RA, macrophage migration inhibitory factor as emerging therapeutic target, 291

Minodrinic acid, BMD and arthritis in rats with collagen-induced arthritis, 1732

Miscarriage. *See* Fetal loss

#### Mitochondria

NSAIDs and COX-2 inhibitors uncouple mitochondria in intact cells, 1438

OA, mitochondrial respiratory activity in human chondrocytes, 700

#### Mitogen-activated protein kinase (MAPK)

collagen-induced arthritis, FR167653 inhibition of p38 MAPK in rats, 2670

as regulators of JNK in RA, 2450

Mitogen-activated protein kinase kinase 1/2 (MAPK kinase 1/2), selective inhibition of in rabbit experimental OA, 1582

- Modified Disease Activity Score, RA, as indicator of disease status vs. radiologic progression, 272
- Molecular phenotyping, of human chondrocyte cell lines T/C-28a2, T/C-28a4, and C-28/I2, 3395
- Monitoring  
for adverse effects of MTX and biologic agents, 2769  
evidence-based MTX monitoring guidelines, 2706
- Monkey study, LymphoStat-B human monoclonal antibody against B lymphocyte stimulator, 3253
- Monoclonal antibodies. *See also names of individual drugs*  
LymphoStat-B against B lymphocyte stimulator, 3253  
RA, adalimumab treatment concomitant with MTX, 35, 855  
RA, osteoclastogenesis suppression by induction of apoptosis, 3350  
SLE, B cell depletion by rituximab, 455
- Monocyte chemoattractant protein  
lupus nephritis ameliorated by antagonist of, mouse study, 2555  
as mediator in SSc and type 1 tight-skin mouse, 1979
- Monocytes, peroxisome proliferator-activated receptor  $\gamma$  expression in acute gout, 231
- Monosodium urate monohydrate crystals  
acute gout, peroxisome proliferator-activated receptor  $\gamma$  expression induced by, 231  
inhibition of acute gouty arthritis by prostaglandin D synthase, mouse study, 2931  
neutrophil activation induced by, 1137  
S100 proteins in neutrophil recruitment in gouty arthritis, 2310
- Mortality. *See also Outcomes*  
body pain and reduced cancer survival, 1686  
GCA, large-artery complications of, 3532  
inflammatory polyarthritis, 1462  
RA, association with disease severity, 2425  
RA, due to leukemia/lymphoma, 2694  
RA, predicting, 1530  
RA, survival trends in, 54
- Mouse mammary tumor virus, not essential for pristane-induced lupus, 2900
- Mouse studies  
aggrecan, immunogenicity/arthritisogenicity of G3 domain of, 2959  
antigen-induced arthritis, p53 regulation by macrophage migration inhibitory factor in, 1881  
AS, *ANKH* role in, 2898  
atherosclerosis reduction by antiphospholipid antibody, 2974  
chondrocyte apoptosis induced by TNF $\alpha$ , 2845  
citrullinated peptide autoantibody production requires defects in regulation of B cell apoptosis, 2353  
collagen-induced arthritis, BMS-345541 I $\kappa$ B kinase inhibitor blocks inflammation and destruction in, 2652  
collagen-induced arthritis, CD25 $^{+}$  cell depletion and disease severity in, 1452  
collagen-induced arthritis, platelet endothelial cell adhesion molecule 1 and accelerated onset of, 3280  
collagen-induced arthritis, rosiglitazone treatment of, 3544  
collagen-induced arthritis, soluble IL-1 receptor accessory protein gene transfer for amelioration of, 2949  
collagen-induced arthritis, VEGF-B role in, 2660  
ecotropic murine leukemia viruses and exogenous mouse mammary tumor viruses and pristane-induced lupus, 2900  
fluvastatin, effects on antiphospholipid antibody-mediated activity, 3272  
gouty arthritis, prostaglandin D synthase in treatment of, 2931  
H-2 haplotype in *Fas*-intact lupus-prone mice, 2992  
high mobility group box chromosomal protein 1, arthritis induced by, 1693  
high mobility group box chromosomal protein 1, counteracting, 2052  
inflammatory arthritis, influence of DNA motifs on, 1701  
lupus nephritis, ameliorated by monocyte chemoattractant protein 1 antagonist, 2555
- Mouse studies (*cont'd*)  
lupus nephritis, anti-CD154 treatment in, 2541  
OA, deletion of IL-1 $\beta$ , IL-1 $\beta$ -converting enzyme, iNOS, or stromelysin 1 genes and development of, 3452  
OA, development of in  $\alpha$ 1 integrin-deficient mice, 2873  
OA-like changes in knee and temporomandibular joint articular cartilage, *cho* gene and, 2509  
oncostatin M-induced growth plate damage, 1750  
placental immunomodulator ferritin suppression of experimental arthritis, 846  
RA, citrullination of synovial proteins in murine RA models, 2489  
RA, Crk-associated substrate lymphocyte type, 1890  
RA, p16 induction at sites of cartilage invasion in SCID mouse coimplantation model of, 2069  
RA, sex-controlled clinical traits in, 1708  
renal vasculitis ameliorated by monocyte chemoattractant protein 1 antagonist, 2555  
SLE, anti-CD154 treatment on B cells, 495  
SLE, benzodiazepine treatment, 757  
SLE, delayed onset in mice expressing human C-reactive protein transgene, 1602  
SLE, Fc receptor-independent development of autoimmune glomerulonephritis, 486  
SLE, intrinsic susceptibility to renal disease in NZW mice, 1080  
SLE, polyreactive ANAs in lupus kidneys, 2343  
SLE, signaling activity of pathogenic T cells in, 1071  
SpA, immunity to versican and aggrecan in, 2903  
spontaneous arthritis in IFN $\gamma$  receptor-deficient mice, 2983  
SS, autoreactive CD4 $^{+}$  T cells and autoimmune exocrinopathy, 3603  
SSc, monocyte chemoattractant protein 3 as mediator of fibrosis in SSc and type 1 tight-skin mouse, 1979  
Th1-mediated pathology in arthritis, 839  
type I collagen gene expression in fibroblasts, 2275  
vasculitis, genetics of tissue specificity of, 1445
- Multicentric reticulohistiocytosis  
alendronate treatment, 3538  
anti-TNF treatment, 864
- Murine leukemia virus, not essential for pristane-induced lupus, 2900
- Muscle  
FM, expression and localization of opioid receptors in muscle satellite cells, 3291  
ultraviolet radiation and expression of autoimmune muscle disease, 2285
- Mutations. *See also Genetics; Polymorphism*  
CPPD crystal deposition disease, *ANKH* gene, 2627  
SLE, *DNASE1* gene A/T mutation in, 3297  
TRAPS, characterized by mutation affecting cleavage site of the receptor, 2386
- MX-68, adenosine receptors and inflammation inhibition by, 240
- Mycobacterium tuberculosis*, anti-TNF $\alpha$  therapy and infection with, 3013
- Mycophenylate mofetil, SLE-associated type B insulin resistance syndrome, 1067
- Myeloid-related proteins  
in JRA, 2622  
in PsA, 1676
- Myocardial perfusion scintigraphy, coronary artery angiography in SLE patients with abnormalities of, 3168

## N

- Naproxen, effect on arthritic cartilage, rat study, 1594
- Native American population, SSc, susceptibility genes in Choctaw Indians, 2585, 3295
- Neocartilage, MRI analysis of, 1047
- Nephritis, lupus. *See Lupus nephritis*
- Neurokinin 1 (NK1), OA, chondrocyte mechanotransduction and, 146

Neuronal damage, in neuropsychiatric lupus, 2881

Neuropsychiatric lupus

neuronal and astrocytic damage in, 2881

recent studies in, 2710

Neutrophils

apoptotic, in SLE, 2888

human apoptotic and necrotic neutrophils, effect of on dendritic cells, 2362

RA, inducible expression of class II MHC in inflammatory neutrophils, 2796

rapid prostaglandin E<sub>2</sub> synthesis in, 1137

S100 proteins in neutrophil recruitment in gouty arthritis, 2310

Nitric oxide

heat shock protein 70 prevents nitric oxide-induced apoptosis in articular chondrocytes, 1562

inhibition of hypochlorous acid-induced chondrocyte toxicity, 3140

Nitric oxide synthase (NOS)

eNOS gene polymorphisms in GCA, 3219

proinflammatory role of leptin and IFN $\gamma$  via NOS induction, in vitro study, 404

Nodules, cytokine profile of rheumatoid nodule, 334

Nonsteroidal antiinflammatory drugs (NSAIDs), uncoupling of mitochondria in intact cells, 1438

N-terminal pro-brain natriuretic peptide, as diagnostic marker for pulmonary artery hypertension in patients with SSC, effects of calcium-channel blockers, 3503

Nucleosomal antigens, in epidermal basement membrane in lupus nephritis, 1355

Nucleosomes, SLE and, 300

## O

Obesity. *See* Body weight

Older adults. *See also* Aging

hand OA, prevalence of in China vs. US, 1034

RA, prevalence in US population age 60 years and older, 917

Oncostatin M

growth plate damage induced by, mouse study, 1750

role in inflammatory response, 3301

TNF $\alpha$  combined with induces cartilage damage and MMP expression, 3404

ONO-5920, BMD and arthritis in rats with collagen-induced arthritis, 1732

Opioid receptors, expression and localization of in muscle satellite cells in FM, 3291

ORM2 gene, SS, gene expression in salivary gland in, 174

Osteoarthritis (OA)

aggrecanase 1 (ADAM-TS4), IL-1 induction of through activation of constitutively produced protein, 119

angiogenesis and inflammation in, 2173

AP-4 mediation of IL-1-stimulated TGF $\beta$ 1 expression in bovine articular chondrocyte cultures, 1569

bone morphogenetic protein 6 in articular cartilage, 2501

cartilage intermediate-layer protein as insulin-like growth factor 1 antagonist, 1302

cartilage oligomeric matrix protein, ethnic and sex differences in serum levels of, 675

cartilage repair by cell-mediated gene therapy, rat study, 430

cartilage tissue engineering and gene therapy approach, 709

chondrocyte apoptosis in, 1166

chondrocyte stimulation by combination of insulin-like growth factor 1 and osteogenic protein 1, 2188

clinical trials, evaluation of, 3001

concomitant RA and histopathologic changes, 1161

COX-2-specific inhibitors for, efficacy comparison, 3102

development of in  $\alpha$ 1 integrin-deficient mice, 2873

endothelin 1 and cartilage degradation, 2855

experimental, reduction of osteophyte formation and synovial thick-

ening by overexpression of TGF/bone morphogenetic protein inhibitors, 3442

extracellular nucleotide metabolism and signaling in, 2722

focal lesion development in cartilage and molecular matrix changes, 1261

hand, inheritance of in Iceland, 391

hand, prevalence of in China vs. US, 1034

hand, weight from birth to middle age and, 1030

hip, asymmetric knee loading in advanced unilateral hip OA, 1556

hip, genetic linkages of primary hip OA and restricted areas on chromosome 11q, 1461

hip joint space, age and sex differences in, 1041

hyaluronan, acute adverse reaction to, 866

hyaluronic acid plus phospholipid in experimental OA, rabbit study, 1923

immunologic intervention in pathogenesis, 602

insulin-like growth factor binding protein 3 synthesis in human articular cartilage cultures, 410

integrin-mediated human chondrocyte adhesion to cartilage, 110

interphalangeal hand joint involvement in men and women, 3371

knee, association of BMI and, 1024

knee, comparison of AP and Lyon schuss views to measure joint space width, 378

knee, deletion of IL-1 $\beta$ , IL-1 $\beta$ -converting enzyme, iNOS, or stromelysin 1 genes and development of in mice, 3452

knee, estrogen receptor  $\alpha$  gene and radiographic knee OA, 1913

knee, hyaluronan, acute adverse reaction to, 866

knee, joint space narrowing by standardized radiography, 385

knee, MRI detection of periarticular lesions, 2836

knee, physical functioning over 3 years, 3359

knee, radiographic and symptomatic knee OA after meniscal tear, 2178

knee, safety and efficacy of long-term intraarticular steroid injections, 370

leptin, key role in, 3118

leptin, systemic and local regulation of articular cartilage metabolism, 3009

lumbar spine disc degeneration, risk factors for progression of, 3112

mitochondrial respiratory activity in human chondrocytes, 700

MMP-1 gene expression, regulation by SAF-1, 134

MRI-based T and Z scoring of cartilage loss, 2829

pathogenesis of, 3304

proteoglycan degradation after injurious compression of cartilage, 129

RANTES production by articular chondrocytes, 278

selective inhibition of MAPK kinase 1/2 in rabbit experimental OA, 1582

stem cell therapy in caprine model of, 3464

substance P and neurokinin 1 (NK1) in chondrocyte mechanotransduction, 146

tachykinin expression in cartilage, 146

type II collagen fragments in synovial fluid, 3130

willow bark extract for, 278, 280

Osteoblasts, MMP-13 production regulated by T cells, 993

Osteoclastogenesis, RA, suppression of by induction of apoptosis in CD4<sup>+</sup> T cells, 3350

Osteogenic protein 1, chondrocyte stimulation by combination of insulin-like growth factor 1 and osteogenic protein 1, 2188

Osteoid osteoma, misdiagnosis of juxtaarticular osteoid osteoma, 776

Osteopenia, in adolescents with early-onset JIA, 2214

Osteophyte formation, reduction of and synovial thickening by overexpression of TGF/bone morphogenetic protein inhibitors in experimental OA, 3442

Osteoporosis

alendronate effects on BMD in glucocorticoid-treated patients, 1102

RA, premature aging in, 2713

vertebral compression fractures, intravertebral clefts in, 1414

- Osteoprotegerin  
in Paget's bone disease, 824  
TNF-mediated generalized bone loss and, mouse study, 2042  
Osteosclerosis, hepatitis C-associated, 268  
Outcomes. *See also* Mortality  
inflammatory arthritis, genetic variation in CCR5 and clinical outcome, 3615  
inflammatory polyarthritis, DMARDs and radiographic outcome, 46  
JIA, osteopenia in adolescents with early-onset JIA, 2214  
JIA, outcome in adults, 767  
knee OA, physical functioning over 3 years, 3359  
RA, comparison of clinical trial outcome measures, 3031  
RA, computerized MRI erosion volumes in, 614  
RA, employment outcomes and etanercept use, 3046  
RA, TNF gene polymorphism and infliximab therapy outcome, 1849  
relapsing polychondritis, urinary type II collagen neopeptide as outcome measure for, 2942  
undifferentiated arthritis of the hands, structured management protocol, 3039  
uveitis, etanercept therapy in children, 2079  
*See also* Mortality  
Outer surface protein A, peptide binding to HLA-DR molecules in treatment-resistant Lyme arthritis, 534  
Oxidative stress, of aging reduces chondrocyte survival, 3419
- P**
- Paget's disease  
resistance to bisphosphonates, 2097, 2321  
serum osteoprotegerin and RANKL in, 824  
Pain  
cancer risk and reduced cancer survival, association with body pain, 1686  
in children, widespread body pain, 2402, 2615  
in children with polyarticular arthritis, 1390  
FM, central sensitization in, 1420  
FM, expression and localization of opioid receptors in muscle satellite cells, 3291  
FM, subgrouping FM patients by neurobiologic and psychosocial factors, 2916  
Pamidronate  
AS, dose-response comparison, 583, 584  
resistance to in Paget's disease, 2321  
Pantropic retroviral transduction, OA, cartilage tissue engineering and gene therapy approach, 709  
Parathyroid hormone-related protein, streptococcal cell wall-induced inflammation and, 1721  
Parenting, measuring parenting disability in women with RA, 935  
Parotid gland, extrasalivary lymphoma development in SS, 3181  
Parvovirus B19  
antiphospholipid antibodies in pediatric and adult patients with rheumatic disease, 1939  
in juvenile chronic arthritis, 1631  
Pathogens. *See names of specific pathogens*  
Patient education, arthritis self-management education programs, 2207  
PD-1 gene, SS, expression in salivary gland, 174  
Pediatrics. *See* Children; *see also* Juvenile  
Peptides, APS, diagnostic peptide for disease-associated anticardiolipin antibodies, 737  
Peptidoglycans, synovial fibroblasts activated via Toll-like receptor signals, 642  
Periodic fever syndrome, etanercept in hyperimmunoglobulinemia D with, 2645  
Peroxisome proliferator-activated receptor  $\gamma$ , in acute gout, 231  
Phagocytosis  
of apoptotic neutrophils in SLE, 2888  
disposal of dying cells, 6  
Phagocytosis (*cont'd*)  
serum amyloid P (SAP) and apoptosis, 248  
Phospholipid, hyaluronic acid plus intraarticular phospholipid in experimental OA, rabbit study, 1923  
Phosphoribosylpyrophosphate synthetase, overactivity of as cause of uric acid overproduction, 2036  
Physiotherapy, adhesive capsulitis of the shoulder, 829  
Pituitary gland, influence of anti-TNF treatment in RA patients, 1504  
Placental immunomodulator, ferritin, suppression of experimental arthritis with, 846  
Plasticity, of clonal populations of dedifferentiated adult human articular chondrocytes, 1315  
Platelet endothelial cell adhesion molecule 1, accelerated onset of collagen-induced arthritis in mice, 3280  
Pleiotrophin, in RA, 660  
*Pneumocystis jiroveci* (formerly *P. carinii*), anti-TNF $\alpha$  therapy and infection with, 3013  
Poly(ADP-ribose) polymerase genes, RA, susceptibility and haplotypes, 638  
Polyarticular arthritis, pain in children with, 1390  
Polymerase chain reaction (PCR), RA, EBV quantitative assay using real-time PCR, 1223  
Polymorphism. *See also* Genetics; Mutations  
APS, Fc $\gamma$  receptor IIA polymorphism and, 1930  
APS, valine/valine genotype at position 247 of  $\beta_2$ -GPI gene in, 471  
AS, single-nucleotide polymorphism in 3' region of *IL1RN* gene, 2011  
Behçet's disease, TNF polymorphisms in, 807  
in Fc $\gamma$  receptor IIB (CD32HB) transmembrane region and receptor signaling, 3242  
GCA, endothelial NOS gene polymorphisms in, 3219  
JIA, macrophage migration inhibitory factor promoter polymorphism in systemic-onset JIA, 1398  
PSA, cytokine gene polymorphisms and susceptibility and severity, 1408  
RA, IFN $\gamma$ /IL-26 polymorphisms and sex bias in susceptibility to, 2773  
RA, IL-10 promoter polymorphisms with autoantibody production and joint destruction, 1841  
RA, stromelysin 1 (MMP-3) promoter gene and disease severity, 2695  
RA, susceptibility and poly(ADP-ribose) polymerase genes, 638  
RA, susceptibility to, effect of HLA-DR influenced by lymphotoxin  $\alpha$ -TNF haplotype, 90  
RA, TNF gene polymorphism and infliximab therapy outcome, 1849  
RA, TNF $\alpha$  -308 gene promoter polymorphism in, 3068  
RA, *TNFR2* polymorphism in Japanese patients, 273  
SS, humoral immunity to Ro52 not associated with Ro52 9571 C/T polymorphism, 3293  
SSc, *IL1A* polymorphisms in Japanese patients, 186  
Polymyositis (PM), global surface ultraviolet radiation intensity and, 2285  
Positron emission tomography, vs. MR imaging of proliferation of synovium, 3077  
Power Doppler ultrasonography  
for disease activity assessment, 285  
SpA, peripheral enthesitis by B-mode ultrasonography combined with power Doppler, 523  
Predictors  
cancer in patients with inflammatory myopathy, artificial neural network for, 1168  
GCA, large artery complications in, 3522  
inflammatory arthritis, genetic variation in CCR5 and clinical outcome, 3615  
JIA, radiographic progression, radiographic damage, and disability in, 3509  
onset of widespread body pain in children, 2615

- Predictors (*cont'd*)  
 RA, costs and cost predictors, 2750  
 RA, development in preclinical phase, 2701, 2741  
 RA, early use of MRI predicts future radiographic damage, 1814  
 RA, erosiveness in peripheral joints predicts atlantoaxial subluxations in, 1808  
 RA, mortality in, 1530  
 RA, synovial fluid exoglycosidases of, 2163  
 SSc, pulmonary hypertension in, 516  
 Prednisolone, SSc, oral combination cyclophosphamide and prednisolone in early diffuse SSc, 2256  
 Pregnancy  
 fetal loss and fetal cell microchimerism, 3237  
 hydroxychloroquine safety in pregnant patients, 3207  
 low molecular weight heparin plus aspirin vs. intravenous immunoglobulin for recurrent antiphospholipid antibody-associated fetal loss, 728  
 placental immunomodulator ferritin suppresses experimental arthritis, 846  
 prevention of congenital heart block with intravenous immunoglobulin and corticosteroid therapy, 280, 281  
 Pressure-pain thresholds, FM, subgrouping FM patients by neurobiologic and psychosocial factors, 2916  
 Prevalence  
 hand OA, in China vs. US, 1034  
 RA, in US population ages 60 years and older, 917  
 Raynaud's phenomenon in children ages 12-15 years, 3518  
 SSc, in large US population, 2246  
 SSc, susceptibility genes in Choctaw Indians with, 2585, 3295  
 Primate study, LymphoStat-B human monoclonal antibody against B lymphocyte stimulator, 3253  
 Pristane-induced arthritis  
 comparative genetic analysis between collagen-induced arthritis and pristane-induced arthritis, rat study, 2332  
 ecotropic murine leukemia viruses and exogenous mouse mammary tumor viruses not essential for, 2900  
 genetic control of RF production in, 3584  
 Pro-brain natriuretic peptide, as diagnostic marker for pulmonary artery hypertension in patients with SSc, effects of calcium-channel blockers, 3503  
 Progesterone, SLE, sex hormones and, 2100  
 Prostaglandin D synthase, for gouty arthritis in mice, 2931  
 Prostaglandin E<sub>2</sub>  
 as enhancer of membrane-associated prostaglandin E synthase expression in RA synovial fibroblasts, 2819  
 rapid synthesis in human neutrophils, 1137  
 selective inhibition of COX-2-generated prostaglandin E<sub>2</sub> synthesis in RA synoviocytes by taurine chloramine, 1551  
 Protein degradation, SS, protein degradation by MMPs from labial salivary glands, 2573  
 Proteoglycan-induced arthritis, RA, sex-controlled clinical traits in, mouse study, 1708  
 Proteoglycans  
 aggrecan G1 domain cointernalizes with hyaluronan in bovine articular chondrocytes, 3431  
 degradation of after injurious compression of cartilage, 1292  
 immunogenicity/arthritisogenicity of G3 domain of cartilage aggrecan, mouse study, 2959  
 inflammatory arthritis, type II collagen and aggrecan turnover at onset of, 3085  
 metabolism of in chondrocytes, hydrostatic pressure and, 2865  
 SpA, immunity to versican and aggrecan and, mouse study, 2903  
 Prothrombin, antiprothrombin antibodies, specificities, properties, and clinical significance of, 886  
 Pseudoleukocytosis, in cryoglobulinemia, 3000  
 Psoriatic arthritis (PsA)  
 cytokine gene polymorphisms and susceptibility and severity, 1408  
 Psoriatic arthritis (PsA) (*cont'd*)  
 etanercept, acute injection site reaction, 2078  
 myeloid-related proteins in, 1676  
 Psychobiology  
 subgrouping FM patients by neurobiologic and psychosocial factors, 2916  
 temperament and stress response in children with juvenile primary FM syndrome, 2923  
 Pulmonary function, leukotrienes in bronchoalveolar lavage fluid from SSc patients with lung disease, 1639  
 Pulmonary hypertension  
 diagnostic marker for in patients with SSc, effects of calcium-channel blockers, 3503  
 in SSc, predictors of, 516  
 Pulse wave analysis (PWA), in RA, 72  
 Pyramid approach  
 availability of drugs disclosed by manufacturers, 2389  
 RA, five-year followup of early DMARD vs. pyramid approach, 1797  
 Pyridostigmine, for FM, 277
- Q**
- Quality of care, improvement of in orthopedic surgery, 289  
 Quality of life, JIA, outcome in adults, 767  
 Questionnaires  
 Core Data Set distinguishes efficacy of active treatment vs. placebo, 625  
 RA, measuring parenting disability in women with, 935
- R**
- Rabbit studies  
 hyaluronic acid plus intraarticular phospholipid in experimental OA, 1923  
 selective inhibition of MAPK kinase 1/2 in experimental OA, 1582  
 Radiography  
 collagen-induced arthritis, CD25<sup>+</sup> cell depletion and disease severity in, 1452  
 CPPD deposition disease, neuropathic joint image, 1170  
 inflammatory polyarthritis, DMARDs and radiographic outcome, 46  
 JIA, predictors for radiographic progression, radiographic damage, and disability in, 3509  
 JIA, radiologic features in, 507  
 juvenile hemochromatosis, arthropathy in, 227  
 lumbar spine disc degeneration, progression of, 3112  
 OA, comparison of AP and Lyon schuss views to measure joint space width in knee, 378  
 OA, estrogen receptor  $\alpha$  gene and radiographic knee OA, 1913  
 OA, joint space narrowing by standardized knee radiography, 385  
 OA, meniscal tear impact on knee OA, 2178  
 OA, radiography and MRI in defining knee OA, 682  
 osteoporotic vertebral compression fractures, intravertebral clefts in, 1414  
 RA, early use of MRI predicts future radiographic damage, 1814  
 RA, MMP-3 genotype and radiographic progression, 1162  
 RA, modified Disease Activity Score vs. radiologic progression as indicator of disease status, 272  
 RA, randomized controlled trials, 21  
 RA, shoulder joint, comparison of imaging techniques, 3338  
 Randomized, controlled trials, RA, radiographic data from, 21  
 RANTES, OA, production by articular chondrocytes, 278  
 Ras, RA, Ras-mediated signaling pathways in synovial fibroblast-like cells and joint destruction, 2682  
 Rat studies  
 adjuvant-induced arthritis, chemokine receptor expression and in vivo signaling pathways in joints, 3568  
 adjuvant-induced arthritis, energy cost of, 2979

#### Rat studies (cont'd)

- adjuvant-induced arthritis, immune regulation in, 1788
  - antiinflammatory drugs, effects of on arthritis cartilage, 1594
  - cartilage repair by cell-mediated gene therapy, 430
  - collagen-induced arthritis and pristane-induced arthritis, comparative genetic analysis, 2332
  - collagen-induced arthritis, FR167653 inhibition of p38 MAPK in rats, 2670
  - collagen-induced arthritis, minodrinic acid treatment and BMD, 1732
  - counteracting high mobility group box chromosomal protein 1 as arthritis therapy, 2052
  - joint targeting of glucocorticoids with long-circulating liposomes, 2059
  - marimastat-induced musculoskeletal side effects, 1742
  - placental immunomodulator ferritin, suppression of experimental arthritis with, 846
  - quantitative trait loci (QTLs) and arthritis development, 551
  - RA, genetic control of RF production in RA rat model, 3584
  - RA, Ras-mediated signaling pathways in synovial fibroblast-like cells and joint destruction, 2682
  - streptococcal cell wall-induced arthritis attenuated by splenectomy, 3557
- Raynaud's phenomenon
- capillaroscopy and, 3023
  - in children ages 12-15 years, 3518
  - sildenafil citrate for, 282, 283
  - vasoconstrictive mechanisms in, 1992
- Reactive oxygen species, mechanical stress-induced depolymerization of hyaluronan and, bovine study, 3151
- Receptor activator of NF- $\kappa$ B ligand (RANKL), in Paget's bone disease, 824
- Recurrent fever syndromes. *See* Periodic fever syndrome
- Relapsing polychondritis, urinary type II collagen neopeptide as outcome measure for, 2942
- Renal disease. *See* Kidneys
- Renal flare, LJP394 for prevention of in SLE, 442
- Retinopathy
- hydroxychloroquine dosage based on ideal body weight, 763
  - new American Academy of Ophthalmology recommendations on screening, 1764
- Rheumatoid arthritis (RA). *See also* Juvenile rheumatoid arthritis
- activation-induced T cell-derived and chemokine-related cytokine/lymphotactin expression in, 1838
  - activin A in synovitis, 2442
  - adalimumab, concomitant MTX treatment, 35, 855
  - add-on or step-up trials for new drug development, 1481
  - adenosine deaminase 1 in, 668
  - adherent synovial fluid cells in, 1873
  - anakinra, large placebo-controlled safety study of, 927
  - anti-cyclic citrullinated peptide antibody in early RA, 857
  - anti-glomerular basement membrane antibody-associated renal failure in leflunomide-treated patient, 1164
  - anti-TNF therapy, long-term, favors adrenal androgen secretion, 1504
  - anti-TNF therapy, eligibility of patients for major clinical trials of, 313, 3611
  - anti-TNF therapy, paraplegia and, 269
  - antibodies against cyclic citrullinated peptide and IgA RF predict development, 2741
  - antibodies to glucose-6-phosphate isomerase, low prevalence of, 944
  - atherosclerosis, association with inflammation markers, 1833
  - atherosclerosis, screening for, 72
  - B lymphocyte depletion in, 2146
  - $\beta$ 1 integrin induces ICAM-1 and Fas on RA synoviocytes, 1239
  - bone morphogenetic proteins in arthritic synovium, 2807

#### Rheumatoid arthritis (RA) (cont'd)

- C48 and placental immunomodulator ferritin suppression of experimental arthritis, 846
- caffeine consumption and, 862
- case against haste in treatment of, 574, 575, 576
- CD34-selected vs. unmanipulated grafts for, 1463
- cervical spine disease in, 1775, 1808
- citrullination of synovial proteins in murine RA models, 2489
- coffee consumption and RA risk, 3055
- computerized MRI erosion volumes in, 614
- concomitant OA and histopathologic changes, 1161
- costs and cost predictors in, 2750
- Crk-associated substrate lymphocyte type and, 1890
- cytokine profile of rheumatoid nodule, 334
- dendritic cell-associated C-type lectin DC-SIGN expression in synovium, 360
- diabetes, hypertension, and RA, alternative perspective on treatment for, 575, 576
- diagnosis and prognosis of early arthritis, 856, 857
- disease status, modified Disease Activity Score vs. radiologic progression as indicator, 272
- Doppler sonography of bicipital tendon sheath in RA and degenerative shoulder disorders, 1828
- early DMARD vs. pyramid approach in, five-year followup study of, 1797
- early growth response 1 activity and expression of TIMP-1 in, 348
- early treatment of, 1, 2693
- EBV quantitative assay using real-time PCR, 1223
- elimination of macrophages by Fc $\gamma$  receptor-directed immunotoxin, 1229
- etanercept in JRA, long-term efficacy and safety, 218
- etanercept-induced lupus-like syndrome in, 1165
- etanercept plus MTX for, 1493
- etanercept use and employment outcomes, 3046
- Ets transcription factor ESE-1 in, 1249
- exercise and, 2393, 2415
- expression of Fc $\gamma$  receptors and production of TNF $\alpha$  and MMP, 1002
- fibroblast-like synoviocytes and FLICE-inhibitory protein, 858
- fibroblast-like synoviocytes, control of proliferation by macrophage migration inhibitory factor, 103
- finger and toe joints, interobserver agreement in assessing ultrasonography of, 955
- galectin 3 and its binding protein in, 2788
- gene expression profiles and RA heterogeneity, 2132
- genetic control of RF production in RA rat model, 3584
- genome-wide linkage studies, 1200
- hand, Doppler ultrasound vs. MRI for synovial inflammation, 2434
- hand and finger joint imaging with B-mode and Doppler sonography, 325
- high mobility group box chromosomal protein 1 and, 876, 971
- HLA class II genes and disease susceptibility and progression, 2779
- HLA-DRB1 alleles, sex differences in individuals with, 1762
- HLA-DRB1 genes and progression of joint damage, early treatment and, 579
- I $\kappa$ B kinase 2, role in cytokine and MMP production, 1901
- IFN $\gamma$ /IL-26 polymorphisms and sex bias in susceptibility to, 2773
- IL-6 receptor antagonist therapy for, 1471, 1521
- IL-10 promoter polymorphisms with autoantibody production and joint destruction, 1841
- IL-17 in, 594
- index, patient self-report questionnaire Core Data Set measures, for distinguishing efficacy, 625
- inducible expression of class II MHC in inflammatory neutrophils, 2796
- infliximab, ANAs in RA patients following treatment with, 1015
- infliximab, changes in bone metabolism and, 2996

## Rheumatoid arthritis (RA) (cont'd)

- innate immune system, contribution of, 590
- JAK/STAT pathway in, 2092
- joint targeting of glucocorticoids with long-circulating liposomes in experimental arthritis, rat study, 2059
- laser microdissection analysis of gene expression in synovium, 97
- leflunomide, efficacy and safety in, 1513
- leflunomide and MTX, MRI comparison, 270, 271
- long-term high-intensity exercise for, 2415
- lymphoma risk and, 963
- lymphoma subtypes in, 1543
- macrophage MIF as emerging therapeutic target in, 291
- malignant lymphoma, risk of in RA patients and first-degree relatives, 963
- MAPK as regulators of JNK in, 2450
- MCP joint anatomic factors in early RA synovitis and bone erosion, 1214
- MMP-3 genotype and radiographic progression, 1162
- mortality, survival trends, 54
- mortality associated with disease severity, 2425
- mortality due to leukemia/lymphoma with RA, 2694
- mortality, predicting, 1530
- MRI, early use and predicting future radiographic damage, 1814
- MTX, caffeine consumption and efficacy of, 571
- MTX, dosage and mode of administration in clinical trials, 863
- MTX, monitoring guidelines, 2706
- MTX concomitant with tacrolimus, 2763
- myeloid-related proteins in, 1676
- novel therapies for, 3308
- osteoblast MMP-13 production regulated by T cells, 993
- osteoclastogenesis suppression by induction of apoptosis, 3350
- osteoprotegerin and TNF-mediated generalized bone loss, mouse study, 2042
- p16 induction at sites of cartilage invasion in SCID mouse coimplantation model of, 2069
- p53 regulation by macrophage migration inhibitory factor, 1881
- parathyroid hormone-related protein in, 1721
- parenting disability in women, 935
- peptidoglycan activation of synovial fibroblasts via Toll-like receptor signals, 642
- pleiotrophin in, 660
- polymorphism in stromelysin 1 (MMP-3) promoter gene and disease severity, 2695
- prediction of development in preclinical phase, 2701, 2741
- premature aging in, 2713
- prevalence in US population 60 years and older, 917
- quantitative trait loci (QTLs) and arthritis development in rats, 551
- radiographic data from trials, 21, 2997
- Ras-mediated signaling pathways in synovial fibroblast-like cells and joint destruction, 2682
- reduced arterial elasticity in, 81
- rituximab therapy for, 1484
- Salmonella* septicemia, with anti-TNF antibody treatment, 1853
- screening the genome for RA susceptibility genes, 906
- sex-controlled clinical traits in, mouse study, 1708
- shoulder joint, comparison of imaging techniques, 3338
- stromal cell-derived factor 1 and CD4+ and CD8+ T cell migration, 2472
- stromal cell-derived factor 1 $\alpha$  in synovial fluid in early disease, 274, 275
- survival trends in, 54
- susceptibility to and HLA-DRB1-TNF haplotypes, 90
- susceptibility to and poly(ADP-ribose) polymerase gene promoter, 638
- susceptibility genes in multicase families, 906
- synovial fluid exoglycosidases and cartilage glycosaminoglycan depletion, 2163

## Rheumatoid arthritis (RA) (cont'd)

- synovial IL-18 expression in relation to proinflammatory responses in, 339
  - synovial IL-18 response, 631
  - synovitis and bone damage, MRI study, 64
  - T cell expansion in tonsil and synovium in patient with RA and tonsillitis, 2483
  - tacrolimus, efficacy and safety, 3328
  - taurine chloramine, selective inhibition of COX-2-generated prostaglandin E<sub>2</sub> synthesis in synoviocytes, 1551
  - Tie2 receptor tyrosine kinase regulates arthritis angiogenesis, 2461
  - tissue factor pathway in synovial inflammation, 651
  - TNF-related apoptosis-inducing ligand expression in synovial fluid, 3096
  - TNF $\alpha$ , soluble receptor I, and -308 gene promoter polymorphism in, 3068
  - TNF $\alpha$  blockade and synovial cell infiltrate, 2155
  - trial simulation study, 3031
  - tuberculosis, TNF-inhibitor therapy and, 2122
  - window of opportunity concept, 1771
  - wrist, dynamic gadolinium-enhanced MRI discriminates active from inactive disease, 1207
  - wrist, early use of MRI predicts future radiographic damage, 1814
- ## Rheumatic diseases
- antiphospholipid antibodies associated with parvovirus B19 infection, 1939
  - assessing efficacy and safety of treatments, 1781
  - extracellular nucleotide metabolism and signaling in, 2722
  - hydroxychloroquine safety in pregnant patients with connective tissue diseases, 3207
  - quantitative trait loci (QTLs) and arthritis development in rats, 551
  - spontaneous arthritis in IFN $\gamma$  receptor-deficient mice, 2983
  - systemic, endothelin and endothelin receptor antagonists in, 1190
  - vocational rehabilitation and reduction of job loss, 3212
- ## Rheumatoid factor (RF)
- IgA and development of RA, 2741
  - RA, genetic control of production in rat model, 3584
- ## Ribavirin, and IFN $\alpha$ treatment of hepatitis C-associated cryoglobulinemia and RF, 580
- ## Rituximab
- for autoimmune diseases, 1484
  - SLE, B cell depletion by, 455
- ## Ro52 gene
- SS, gene expression in salivary gland in, 174
  - SS, humoral immunity to, not associated with Ro52 9571 C/T polymorphism, 3293
- ## Rofecoxib, comparison of efficacy with celecoxib for OA, 3102
- ## Rosiglitazone, for collagen-induced arthritis, 3544

## S

- S100 proteins, in neutrophil recruitment in gouty arthritis, 2310
  - SAAI loci, familial Mediterranean fever, MEFV and SAA1 genotypes and, 1149
- ## Sacroiliitis
- SpA, immunity to versican and aggrecan and, mouse study, 2903
  - SpA, MRI localization of sacroiliitis in, 1374
- ## SAF-1, OA, regulation of MMP-1 gene expression by, 134
- ## Safety, assessing efficacy and safety of treatments, 1781
- ## Salivary glands
- SS, ectopic germinal center formation in, 3187
  - SS, gene expression in, 174
  - SS, IFN $\gamma$ -inducible protein and CXCR3 receptor 3 in, 2390
  - SS, protein degradation by MMPs from labial salivary glands, 2573
- ## *Salmonella* septicemia, with anti-TNF antibody treatment of RA, 1853
- ## SAPHO syndrome, TNF $\alpha$ blockade therapy in, 1467
- ## Sarcoidosis
- TNF $\alpha$  blockade in, 3542

- Sarcoidosis (*cont'd*)  
 tumoral calcinosis associated with, 1770
- Scleroderma. *See* Systemic sclerosis
- Self-management, arthritis education programs, 2207
- Senescence. *See* Aging
- Sepsis, infections and anti-TNF $\alpha$  therapy, 3013
- Septic arthritis, *Erysipelothrix rhusiopathiae* as cause of, 1156
- Septicemia, *Salmonella*, with anti-TNF antibody RA treatment, 1853
- Serum amyloid A, amyloid-enhancing factor mediates amyloid formation on fibroblasts, 1430
- Serum amyloid P (SAP)  
 disposal of dying cells and, 6  
 phagocytosis of apoptotic cells and, 248
- Sex hormones, SLE and, 2100
- Shared epitope  
 immunogenicity/arthritisogenicity of G3 domain of cartilage aggrecan, mouse study, 2959  
 RA, MMP-3 genotype and radiographic progression of, 1162
- Shoulder  
 adhesive capsulitis, intraarticular corticosteroids, supervised physiotherapy, or combined therapy for, 829  
 Doppler sonography of bicipital tendon sheath in RA and degenerative shoulder disorders, 1828  
 RA, comparison of imaging techniques, 3338
- Shrinking lung syndrome, in SSc, 2999
- Signaling  
 adjuvant-induced arthritis, in vivo signaling pathways in rat joints, 3568  
 autoantibodies inhibiting cholinergic neurotransmission neutralized by antiidiotypic antibodies, 3597  
 chondrocytes, NO induction by leptin and IFN $\gamma$ , in vitro study, 404  
 Fc $\gamma$  receptor IIB (CD32HB) polymorphism and receptor signaling, 3242  
 hydralazine inhibits extracellular signal-regulated kinase pathway, 746  
 RA,  $\beta$ 1 integrin induces ICAM-1 and Fas on RA synoviocytes, 1239  
 RA, JAK/STAT pathway, 2092  
 RA, Ras-mediated signaling pathways in synovial fibroblast-like cells and joint destruction, 2682  
 SLE, signaling activity of pathogenic T cells, mouse study, 1071  
 SLE, T cell receptor  $\zeta$  chain reconstitution restores T cell signaling in, 1948  
 SSc, altered regulation of TGF $\beta$  signaling in, 1779  
 SSc, epidermal growth factor up-regulates expression of TGF $\beta$  receptor in fibroblasts, 1652  
 SSc, SMAD signaling in fibroblasts, 1964  
 SSc, TNF receptor p55-mediated signaling in pathogenesis, 1117
- Sildenafil citrate, for Raynaud's phenomenon, 282, 283
- Silica, environmental factors in primary systemic vasculitis, 814
- Simulation, RA, comparison of clinical trial outcome measures, 3031
- Single-nucleotide polymorphism, AS, in 3' region of *IL1RN* gene, 2011
- Sjögren's syndrome (SS)  
 aquaporins in, 1167  
 autoantibodies inhibiting cholinergic neurotransmission neutralized by antiidiotypic antibodies, 3597  
 autoreactive CD4+ T cells and autoimmune exocrinopathy in mice, 3603  
 ectopic germinal center formation in, 3187  
 extrasalivary lymphoma development in, 3181  
 gene expression in salivary gland in, 174  
 HLA class II and primary SS, 2240  
 humoral immunity to Ro52 not associated with Ro52 9571 C/T polymorphism, 3293  
 protein degradation by MMPs from labial salivary glands, 2573  
 salivary gland, IFN $\gamma$ -inducible protein and CXCR3 receptor 3 expression in, 2390
- SMAD signaling  
 SSc, altered regulation of TGF $\beta$  signaling in, 1779  
 SSc, signaling in fibroblasts, 1964
- SmD1<sup>83-119</sup> reactive T cells, generation of anti-dsDNA antibodies, role in, 475
- SMURF2, in SSc, 1779
- Solvents, environmental factors in primary systemic vasculitis, 814
- Sonography. *See* Ultrasonography
- Spinal cord injuries, cartilage atrophy in knees of patients with, 3377
- Spine  
 AS, MRI scoring system for spinal inflammation, 1126  
 lumbar spine disc degeneration, risk factors for progression of, 3112  
 osteoporotic vertebral compression fractures, intravertebral clefts in, 1414  
 RA, cervical spine disease in, 1775, 1808  
 spinal cord injuries, cartilage atrophy in knees of patients with, 3377  
 vertebral fractures after therapy with glucocorticoid therapy, predictors of, 3224
- Splenectomy, streptococcal cell wall-induced arthritis attenuated by, 3557
- Spondylarthropathy (SpA)  
 bone morphogenetic proteins in arthritic synovium, 2807  
 fibrillin 1 as autoantigen, 3610  
 HLA-B\*2709 and, 866  
 immunity to versican and aggrecan and, mouse study, 2903  
 infliximab, ANAs in RA patients following treatment with, 1015  
 myeloid-related proteins in, 1676  
 peripheral enthesitis in, by B-mode ultrasonography combined with power Doppler, 523  
 sacroiliitis in, MRI localization of, 1374  
 Second International Enthesitis Workshop report, 896
- Spondylitis, immunity to versican and aggrecan and, mouse study, 2903
- Stem cells, chondrogenic differentiation of mesenchymal stem cells, 418
- Stem cell therapy, in caprine model of OA, 3464
- Stem cell transplantation  
 high-dose cyclophosphamide therapy without stem cell rescue, 1463  
 RA, CD34-selected vs. unmanipulated grafts for, 1463  
 for SLE, 2696
- Steroids  
 alendronate effects on BMD in glucocorticoid-treated patients, 1102  
 knee OA, safety and efficacy of long-term intraarticular steroid injections, 370
- Still's disease, expression of myeloid-related proteins in, 2622
- Streptococcal cell wall-induced inflammation  
 attenuated by splenectomy, 3557  
 parathyroid hormone-related protein and, 1721
- Streptococcus pneumoniae*, anti-TNF $\alpha$  therapy and infection with, 3013
- Stress response, in children with juvenile primary FM syndrome, 2923
- Stromal cell-derived factor 1 $\alpha$   
 RA, in synovial fluid in early RA, 274, 275  
 role in CD4+ and CD8+ T cell migration, 2472
- Stromal cells, cartilage-like gene expression in differentiated human stem cell spheroids, 418
- Stromelysin 1  
 OA, deletion of IL-1 $\beta$ , IL-1 $\beta$ -converting enzyme, iNOS, or stromelysin 1 genes and development of in mice, 3452  
 RA, MMP-3 polymorphism in and severity of, 2695
- Substance P, OA, chondrocyte mechanotransduction and, 146
- Superantigens, ecotropic murine leukemia viruses and exogenous mouse mammary tumor viruses and pristane-induced lupus, 2900
- Surgery, improving quality of care in orthopedic surgery, 289
- Survival  
 RA, disease severity associated with, independent of comorbidity, 2425  
 RA, survival trends, 54  
 SSc, in large US population, 2246

## Susceptibility

- AS, HLA haplotypes and B27 alleles, 1385
- inflammatory arthritis, stimulatory and suppressive DNA motifs and, mouse study, 1701
- JIA, -174G allele of the IL-6 gene and, 3202
- PsA, cytokine gene polymorphisms and, 1408
- RA, genome-wide linkage studies, 1200
- RA, HLA class II genes and, 2779
- RA, HLA-DRB1-TNF haplotypes and, 90
- RA, IFN $\gamma$ /IL-26 polymorphisms and sex bias in, 2773
- RA, poly(ADP-ribose) polymerase haplotype and, 638
- RA, screening the genome for RA susceptibility genes, 906
- RA, susceptibility genes in multicase families, 906
- SLE, intrinsic susceptibility to renal disease in NZW mice, 1080
- SSc, *IL1A* polymorphisms in Japanese patients, 186
- SSc, susceptibility genes in Choctaw, 2585, 3295

## Synovial fibroblasts. See Fibroblasts

## Synovial fluid

- OA, key role of leptin in, 3118
- OA, type II collagen fragments in synovial fluid, 3130
- RA, adenosine deaminase 1 activity in fibroblasts, 668
- RA, adherent synovial fluid cells in, 1873
- RA, early TNF $\alpha$  blockade and synovial cell infiltrate, 2155
- RA, exoglycosidases and cartilage glycosaminoglycan depletion, 2163
- RA, inducible expression of class II MHC in inflammatory neutrophils, 2796
- RA, stromal cell-derived factor 1 $\alpha$  in synovial fluid in early disease, 274, 275
- RA, TNF-related apoptosis-inducing ligand expression in, 3096

## Synovial tissue

- OA, inflammation and angiogenesis in, 2173
- RA, early growth response 1 activity and TIMP-1 in synovial fibroblasts, 348
- RA, ESE-1 in, 1249
- RA, gene expression profiles and RA heterogeneity, 2132
- RA, pleiotrophin in, 660
- RA, stromal cell-derived factor 1 and CD4+ and CD8+ T cell migration, 2472
- RA, synovial IL-18 expression in, 339, 631
- RA, tissue factor pathway in synovial inflammation, 651

## Synoviocytes

- JNK signaling in, 2450
- RA, activin A induces cell proliferation of fibroblast-like synoviocytes, 2442
- RA,  $\beta$ 1 integrin induces ICAM-1 and Fas on RA synoviocytes, 1239
- RA, fibroblast-like synoviocyte proliferation, control by macrophage migration inhibitory factor, 103
- RA, fibroblast-like synoviocytes and FLICE-inhibitory protein, 858
- RA, selective inhibition of COX-2-generated prostaglandin E<sub>2</sub> synthesis in RA synoviocytes by taurine chloramine, 1551

## Synovitis

- RA, activin A in RA synovitis, 2442
- RA, bone damage and, MRI study, 64
- RA, MCP joint anatomic factors in early RA synovitis and bone erosion, 1214
- undifferentiated arthritis of the hands, structured management protocol, 3039

## Synovium

- bone morphogenetic proteins in arthritic synovium, 2807
- positron emission tomography vs. MR imaging of proliferation, 3077
- RA, citrullination of synovial proteins in murine RA models, 2489
- RA, dendritic cells and macrophages in, 360
- RA, Doppler sonography vs. MRI for synovial inflammation, 2434
- RA, elimination of macrophages by Fc $\gamma$  receptor-directed immunotoxin, 1229
- RA, ESE-1 in, 1249

## Synovium (cont'd)

- RA, expression of Fc $\gamma$  receptors and production of TNF $\alpha$  and MMP, 1002
  - RA, galectin 3 and its binding protein in, 2788
  - RA, laser microdissection analysis of gene expression in synovium, 97
  - RA, Ras-mediated signaling pathways in synovial fibroblast-like cells and joint destruction, 2682
  - RA, T cell expansion in tonsil and synovium in patient with RA and tonsillitis, 2483
- ## Systemic lupus erythematosus (SLE)
- ACR revised classification criteria, 2067
  - anti-CD154 treatment on B cells, mouse study, 495
  - anti-dsDNA antibodies and, 300
  - apoptotic cell clearance in, 2888
  - autoimmune glomerulonephritis in lupus-prone MRL/lpr mice, Fc receptor-independent development of, 486
  - B cell depletion by rituximab in, 455
  - B lymphocyte stimulator expression in, 3475
  - BDCA-2 expression and IFN $\alpha$  production in, 2524
  - benzodiazepine treatment, mouse SLE, 757
  - blood lipids and TNF $\alpha$  activity in, 2533
  - CD22 ligand expression in murine SLE, 1612
  - CD27<sup>high</sup> plasma cells and disease activity, 1332
  - coronary risk factors in women, 3159
  - cyclophosphamide and mycophenolate mofetil for SLE-associated type B insulin resistance syndrome, 1067
  - delayed onset in mice expressing human C-reactive protein transgene, 1602
  - development of, in patient with congenital heart block, 2697
  - DNASE1* gene A/T mutation in, 3297
  - epitope spreading in, 582
  - etanercept-induced lupus-like syndrome in RA, 1165
  - flares, characterization of, 581, 582
  - H-2 haplotype in Fas-intact lupus-prone mice, 2992
  - hematopoietic stem cell transplantation for, 2696
  - high-dose cyclophosphamide without stem cell transplantation in, 166
  - hospitalization for coronary artery disease in SLE patients, 2519
  - hydralazine inhibits extracellular signal-regulated kinase pathway signaling, 746
  - IFN $\alpha$  as new target for therapy, 2396
  - intravenous immunoglobulin abrogates dendritic cell differentiation induced by IFN $\alpha$ , 3497
  - intrinsic susceptibility to renal disease in NZW mice, 1080
  - Jaccoud's arthropathy in, 147
  - LCK ubiquitination and expression in SLE T cells, 1343
  - LJP394 for prevention of renal flare, 442
  - lupus nephritis, ameliorated by monocyte chemoattractant protein 1 antagonist, 2555
  - lupus nephritis, anti-CD40 ligand antibody treatment of, 719
  - lupus nephritis, anti-CD154 treatment of murine lupus nephritis, 2541
  - lupus nephritis, cyclophosphamide, efficacy of low-dose vs. high-dose, 1466
  - lupus nephritis, expression of urinary cytokine genes in, 1326
  - lupus nephritis, IgG subclasses and C-reactive protein in, 460
  - lupus nephritis, nucleosomes in epidermal basement membrane in, 1355
  - neonatal. See Neonatal lupus
  - neuropsychiatric lupus, neuronal and astrocytic damage in, 2881
  - neuropsychiatric lupus, recent studies in, 2710
  - recurrent fetal loss, low molecular weight heparin plus aspirin vs. intravenous immunoglobulin for, 728
  - rituximab therapy for, 1484
  - sex hormones and, 2100
  - signaling activity of pathogenic T cells in, mouse study, 1071

# Systemic lupus erythematosus (SLE) (cont'd)

- SLE, CCR2 and CXCR3 in T cell-mediated response during disease flare, 3487
- SmD1<sup>83-119</sup>-reactive T cells, role in generation of anti-dsDNA antibodies, 475
- T cell receptor  $\zeta$  chain reconstitution restores T cell signaling and augments IL-2 production in, 1948
- triplets with, 3176
- Systemic sclerosis (SSc)
  - aberrant constitutive *IL1A* gene expression in, 193
  - AECAs and apoptosis in, 2605
  - amplification of SRY-positive cells in, 1109
  - anti-Th/To and anticentromere antibodies in SSc with limited cutaneous involvement, 203
  - anti-thrombopoietin receptor autoantibody-induced amegakaryocytic thrombocytopenia in, 1647
  - antibodies to U3 small nucleolar RNP complex in, 210
  - autoantibodies inhibiting cholinergic neurotransmission neutralized by antiidiotypic antibodies, 3597
  - capillaroscopy and Raynaud's phenomenon, 3023
  - CD8+ T cells in SSc lung disease, 2262
  - cellular microchimerism in, 1109
  - combination oral cyclophosphamide and prednisolone in early diffuse SSc, 2256
  - connective tissue growth factor/insulin stimulation of collagen synthesis in, 798
  - epidermal growth factor up-regulates expression of TGF $\beta$  receptor in fibroblasts, 1652
  - glutathione S-transferase gene variations and cardiovascular disease in, 854
  - HLA-DQA1 not correlated with microchimerism, 2567
  - IL1A* gene polymorphisms in Japanese SSc patients, 186
  - leukotrienes in SSc-associated alveolitis, 1478
  - monocyte chemoattractant protein 3 as mediator of fibrosis in, mouse study, 1979
  - prevalence, incidence and survival in large US population, 2246
  - pseudoscleroderma associated with TGF $\beta$ 1-producing advanced gastric carcinoma, 1766
  - pulmonary artery hypertension, diagnostic marker for and effects of calcium-channel blockers, 3503
  - pulmonary hypertension in, predictors of, 516
  - resistance to epidermal growth factor stimulation in, 1652
  - shrinking lung syndrome in, 2999
  - SMAD signaling in fibroblasts, 1964
  - SMURF2 involvement in, 1779
  - susceptibility genes in Choctaw, 2585, 3295
  - TGF $\beta$  signaling, altered regulation of in, 1779
  - Th2 cells inhibit collagen synthesis by dermal fibroblasts, 2593
  - TNF receptor p55-mediated signaling in pathogenesis, 1117
  - topoisomerase I antibody levels correlate with disease severity and activity, 1363
  - twin study, 1956
  - watermelon stomach, image, 2738

## T

### T cells

- AS, down-regulation of T cell cytokine response with infliximab, 780
- cytokines elicited by T cell epitopes from synovial autoantigen, 2375
- human osteoblast MMP-13 production and, 993
- JIA, T cell reactivity to heat shock protein 60 in, 2001
- RA, T cell expansion in tonsil and synovium in patient with RA and tonsillitis, 2483
- SLE, CCR2 and CXCR3 in T cell-mediated response during lupus flares, 3487
- SLE, LCK ubiquitination and expression in SLE T cells, 1343
- SLE, signaling activity of pathogenic T cells in, mouse study, 1071

### T cells (cont'd)

- SLE, T cell receptor  $\zeta$  chain reconstitution restores T cell signaling in, 1948
- SmD1<sup>83-119</sup>-reactive T cells and generation of anti-dsDNA antibodies, 475
- SS, autoreactive CD4+ T cells and autoimmune exocrinopathy in mice, 3603
- SSc, CD8+ T cells in SSc lung disease, 2262
- stromal cell-derived factor 1, role in CD4+ and CD8+ T cell migration, 2472
- T scores, OA, feasibility of MRI-based T and Z scoring of cartilage loss, 2829
- Tachykinins, OA, expression in cartilage, 146
- Tacrolimus
  - RA, efficacy and safety of in, 3328
  - RA, MTX concomitant with, 2763
- Takayasu arteritis, unresolved issues in, 2406
- Taurine chloramine, selective inhibition of COX-2-generated prostaglandin E<sub>2</sub> synthesis in RA synoviocytes by, 1551
- Temperament, in children with juvenile primary FM syndrome, 2923
- Temporal arteritis, unresolved issues in, 2406
- Temporomandibular joint, OA-like changes in articular cartilage in mice with *cho* gene and, 2509
- Testosterone, SLE, sex hormones and, 2100
- Th1 response, down-regulation of Th1-mediated pathology in arthritis, mouse study, 839
- Th2 cells, inhibit collagen synthesis by dermal fibroblasts in SSc, 2593
- Thrombocytopenia, SSc, anti-thrombopoietin receptor autoantibody-induced amegakaryocytic thrombocytopenia in, 1647
- Thrombosis, prevention of in APS, 3004
- Thrombotic thrombocytopenic purpura, in Behçet's disease, 1468
- Tibial cartilage volume, OA, radiography and MRI in defining knee OA, 682
- Tie2, arthritis angiogenesis regulated by, 2461
- Tissue engineering
  - neocartilage, MRI analysis of, 1047
  - OA, cartilage tissue engineering and gene therapy approach, 709
- Tissue factor, RA, synovial inflammation and, 651
- Tissue inhibitor of metalloproteinases 1 (TIMP-1), RA, early growth response 1 activity in synovial fibroblasts and, 348
- Tissue specificity, vasculitis, genetic basis of in mice, 1445
- TNF* gene, Behçet's disease, TNA polymorphisms in, 807
- TNFR2* polymorphism, in Japanese RA patients, 273
- TNFSF13A*, local production of in inflammatory arthritis, 982
- Toe joint, RA, ultrasonography and interobserver agreement in assessing, 955
- Toll-like receptor
  - RA, peptidoglycan activation of synovial fibroblasts via Toll-like receptor signals, 642
  - RA, *Salmonella* septicemia with anti-TNF antibody RA treatment, 1853
- Tonsillitis, RA, T cell expansion in tonsil and synovium in patient with RA and tonsillitis, 2483
- Topoisomerase I, SSc, anti-DNA topoisomerase I antibody levels correlate with disease severity and activity, 1363
- Total hip replacement, caseload and patient-reported results of, 560
- Transcription factors, OA, MMP-1 gene expression, regulation by SAF-1, 134
- Transforming growth factor (TGF)
  - AP-4 mediation of IL-1-stimulated TGF $\beta$ 1 expression in bovine articular chondrocyte cultures, 1569
  - experimental OA, reduction of osteophyte formation and synovial thickening by overexpression of TGF/bone morphogenetic protein inhibitors, 3442
  - pseudoscleroderma associated with TGF $\beta$ 1-producing advanced gastric carcinoma, 1766
  - SSc, altered regulation of TGF $\beta$  signaling in, 1779

Transforming growth factor  $\beta$  receptor type II, mechanism of up-regulation of, 1652

Trauma, proteoglycan degradation after injurious compression of cartilage, 1292

Treatment efficacy, problems and solutions in assessing, 1781

Triglycerides, as marker of disease activity in SLE, 2533

Triplets, with SLE, 3176

Tuberculosis

- anti-TNF $\alpha$  therapy and infection with, 2122, 3013
- what rheumatologists need to know, 2085

Tumor necrosis factor (TNF)

- AS, down-regulation of T cell cytokine response in infliximab-treated AS, 780
- gene, polymorphism and infliximab therapy outcome in RA, 1849
- osteoprotegerin and TNF-mediated generalized bone loss, mouse study, 2042
- RA, expression of Fc $\gamma$  receptors and production of, 1002
- RA, *TNFR2* polymorphism in Japanese patients, 273

Tumor necrosis factor  $\alpha$  (TNF $\alpha$ )

- antagonists, distributions of clinical responses to, 1500
- chondrocyte apoptosis induced by in mice, 2845
- combined with oncostatin, induces cartilage damage and MMP expression, 3404
- RA, ESE-1 and, 1249
- in RA with or without amyloidosis, 3068
- in SAPHO syndrome, 1467
- SLE, disease activity and, 2533
- SSc, Th2 cells inhibit collagen synthesis by dermal fibroblasts via membrane-associated TNF $\alpha$ , 2593

Tumor necrosis factor receptor. *See also* Etanercept

- in RA with or without amyloidosis, 3068
- SSc, TNF receptor p55-mediated signaling in pathogenesis, 1117

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS)

- clinical spectrum of, 1768
- genetic background in patients with TRAPS features, 2632, 2995
- mutation affecting cleavage site of the receptor, 2386

Tumor necrosis factor-related apoptosis-inducing ligand, expression of in RA synovial fluid, 3096

Twin studies

- OA, BMI association with knee OA, 1024
- SSc, 1956

## U

U3 small nucleolar RNP complex, antibodies to in SSc, 210

Ultrasonography

- antiinflammatory drugs and arthritis cartilage, rat study, 1594
- Doppler sonography of bicipital tendon sheath in RA and degenerative shoulder disorders, 1828
- power Doppler sonography for disease activity assessment, 285
- RA, Doppler ultrasound vs. MRI for synovial inflammation, 2434
- RA, hand and finger joint imaging with B-mode and Doppler sonography, 325
- RA, interobserver agreement in assessing finger and toe joints, 955
- RA, shoulder joint, comparison of imaging techniques, 3338
- SpA, peripheral enthesitis in by B-mode ultrasonography combined with power Doppler, 523

## Ultrasonography (cont'd)

- SS, protein degradation by MMPs from labial salivary glands, 2573
- Ultraviolet radiation, autoimmune muscle disease and, 2285
- Urate crystals. *See* Monosodium urate monohydrate crystals
- Urea-based elution, polyreactive ANAs in lupus kidneys, mouse study, 2343
- Uric acid overproduction, phosphoribosylpyrophosphate synthetase overactivity as cause of, 2036
- Urinary sediment, lupus nephritis, expression of urinary cytokine genes in, 1326
- Urinary type II collagen neopeptide, as outcome measure for relapsing polychondritis, 2942
- Uveitis, long-term outcome of etanercept therapy in children, 2079

## V

Vascular disease. *See* Atherosclerosis; Cardiovascular disease

Vascular endothelial growth factor (VEGF)

- IL-6 receptor antagonist therapy for RA and, 1471, 1521
- VEGF-B in mouse models of arthritis, 2660

Vasculitis

- environmental factors in primary systemic vasculitis, 814
- genetics of tissue specificity of, mouse studies, 1445
- human apoptotic and necrotic neutrophils, effect of on dendritic cells, 2362
- large-vessel vasculitis, unresolved issues in, 2406
- Veriscan, SpA, immunity to and, mouse study, 2903

Vertebral fractures

- following glucocorticoid therapy, predictors of, 3224
- osteoporotic vertebral compression fractures, intravertebral clefts in, 1414

Viral load, RA, EBV quantitative assay using real-time PCR, 1223

Vocational rehabilitation, reduction in job loss with, 3212

## W

Web tools, FCP: bioinformatic tool assisting in PubMed searches, 2083

Wegener's granulomatosis (WG)

- artificial neural network to predict cancer in patients with inflammatory myopathy, 1168
- baseline data on WG Etanercept Trial patients, 2299

Weight. *See* Body weight

Willow bark extract, for OA, 278, 280

Wrist

- RA, dynamic gadolinium-enhanced MRI discriminates active from inactive disease, 1207
- RA, early use of MRI predicts future radiographic damage, 1814

## X

X-ray absorptiometry, BMD in juvenile DM, 2294

## Z

Z scores, OA, feasibility of MRI-based T and Z scoring of cartilage loss, 2829

Zymosan-induced arthritis

- antiinflammatory drugs and arthritis cartilage, rat study, 1594
- placental immunomodulator ferritin suppression of, 846